07:00 – 08:15 SUNRISE SYMPOSIA

Session SUN01 ROTRF Symposium: Antibody-Mediated Rejection - an Ounce of Prevention is Worth a Pound of Cure

Monday, August 16, 2010 07:00 AM - 08:15 AM
Room: MR 220 - 222

Moderators: Andrew Bradley, Allan Kirk

SUN01.1 Humoral Immunity: Mechanisms of Graft Injury and Relationship to Cellular Immunity
W.M. Baldwin III
Cleveland/UNITED STATES OF AMERICA

SUN01.2 Detection and Identification of Alloantibodies circa 2010: Myths and Realities
H. Gebel
Atlanta/UNITED STATES OF AMERICA

SUN01.3 The 2 Key Questions for Desensitization: Who and How?
D. Glotz
Paris/FRANCE

SUN01.4 Giving the Incompatible Patient Hope with Kidney Paired Donation
A. Bingaman
San Antonio/UNITED STATES OF AMERICA

SUN01 - DISCUSSION
Session SUN02 Non-HLA antibodies in transplantation (Absorber)

Monday, August 16, 2010 07:00 AM - 08:15 AM
Room: MR 212 - 214

Moderators: Ron J. Shapiro

Introduction

R. Shapiro
Pittsburgh/UNITED STATES OF AMERICA

SUN02.1 Predictors of graft failure in kidney transplant recipients

J.M. Grinyó
Barcelona/SPAIN

SUN02.2 The role of non-HLA antibodies on acute rejection

K.J. Wood
Oxford/UNITED KINGDOM

SUN02.3 Testing for non-HLA antibodies, a clinical approach

A. Tambur
Chicago/UNITED STATES OF AMERICA

SUN02.4 Summary & Closing Remarks

R. Shapiro
Pittsburgh/UNITED STATES OF AMERICA

Session SUN03 Optimal screening of donors and recipients

Monday, August 16, 2010 07:00 AM - 08:15 AM
Room: MR 211

Moderators: Elmi J. Muller, Jutta J. Preiksaitis
TTS 2010 SCIENTIFIC PROGRAM

SUN03.1 Tuberculosis

M. Sester
Homburg/GERMANY

SUN03.2 Chagas Disease and Strongyloides

R. Bestetti
/?/BRAZIL

SUN03.3 Use of NAT in Screening

A. Humar
Edmonton/CANADA

SUN03.4 Tricky Screening Cases and Expanding the Organ Pool

M.G. Ison
Chicago/UNITED STATES OF AMERICA

SUN03 - DISCUSSION

Session SUN04 Formation, detection and characterization of antibodies to transplantation antigens

Monday, August 16, 2010 07:00 AM - 08:15 AM
Room: MR 202 - 204

Moderators: Susan . Fuggle, Noureddine . Berka

SUN04.1 The immunogenicity of HLA

I. Doxiadis
Leiden/NETHERLANDS

SUN04.2 Generation and determinants of cellular and humoral responses

A. Zeevi
Pittsburgh/UNITED STATES OF AMERICA

SUN04.3 Solid phase immunoassays for antibody detection and quantitation
TTS 2010 SCIENTIFIC PROGRAM

P.M. Campbell
Edmonton/CANADA

SUN04.4 From antibody specificity to epitope matching

R.J. Duquesnoy
Pittsburgh/UNITED STATES OF AMERICA

SUN04 - DISCUSSION

Session SUN05 The Art of Patient Care

Monday, August 16, 2010 07:00 AM - 08:15 AM
Room: MR 205 - 207

Moderators: Susan . Chernenko, Clare . Whittaker

SUN05.1 Nurse led health promotion clinics: A paradigm shift to patient centered care

J. Routledge
London/UNITED KINGDOM

SUN05 - DISCUSSION

SUN05.2 Fairytale or nightmare? A patient's story on adherence

P. Harden
Oxford/UNITED KINGDOM

SUN05 - DISCUSSION

08:30 – 08:30 PLENARY SESSION

Session PL01 The Genome and Beyond

Monday, August 16, 2010 08:30 AM - 10:00 AM
Room: Ballroom A/B

Moderators: Jeremy . Chapman, Marcelo . Cantarovich
TTS 2010 SCIENTIFIC PROGRAM

PL01.1 Vision and Future of Systems Biology
L. Hood
Seattle/UNITED STATES OF AMERICA

PL01.2 Beyond the Genome
J. Greenblatt

PL01.3 Monitoring Allograft Status in the 21st Century: A Noninvasive Molecular Approach
M. Suthanthiran
New York/UNITED STATES OF AMERICA

10:30 – 12:00 CONCURRENT MORNING SYMPOSIA

Session O01 Experimental Immunobiology

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 202 - 204

Moderators: Caigan . Du, Philip . Acott

O01.01 Ganciclovir attenuates murine cytomegalovirus associated renal allograft inflammation.
U. Saunders, B. Rha, L.L. Guo, J.F. George, W.J. Britt, M. Shimamura
Birmingham/UNITED STATES OF AMERICA

O01.02 Separating Antiviral Response from Heterologous Alloreactivity: Vβ4 CD8 T Cells May Not Directly Cause Allograft Rejection In Latent MHV68 Infection
Atlanta/UNITED STATES OF AMERICA

O01.03 Modulation of the Wnt signaling pathway by WISE antibody improves long-term kidney transplant outcome in a rat renal transplant model
X. Yuan¹, S. Vonderfecht², X. Ge¹, J. Lee², A. Jurisch¹, E. Valente², J. Pretorius², B. Tipton², A.G. Winters², L.C. Harriss¹, L. Zhang², A. You², Y. Gao², C. Paszty², W.G. Richards², W.S. Simonet², X. Qian², S.G. Tullius¹
¹Boston/UNITED STATES OF AMERICA, ²Thousand Oaks/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

001.04 NK cells mediate chronic kidney allograft injury in tolerant parent to F1 transplants

London/CANADA

001.05 Renal tubular cell (TEC) expression of SPI-6 (Serpin Protease Inhibitor-6) is required for protection from Granzyme B mediated effector cell injury following transplantation

London/CANADA

001.06 BK virus high level replication in vitro reduced by cyclosporine A, proximal tubule cell type and culture environment (polarity) but not by Tacrolimus

P.D. Acott, P.A. O'Regan, A.O. Skotnicki, J.F.S. Crocker
Halifax/CANADA

001.07 Adenovirus-mediated antisense ERK2 gene therapy down-regulates expression of TβRI and TGF-β, decreases infiltrates, and ameliorates chronic renal allograft fibrosis in a rat model

N. Gong, Z. Chen, X. Chen
Wuhan/CHINA

001.08 Significant Prolongation of Renal Allograft Survival By Applying A Novel NF-kappa B Inhibitor, Dehydroxymethylepoxyquinomicin, In A Rat Acute Rejection model

K. Shinoda, K. Nakagawa, H. Kono, E. Kikuchi, A. Miyajima, M. Oya
Tokyo/JAPAN

001.09 Ischemia reperfusion injury therapy: inhibitor of coagulation during preservation rescues chronic kidney inflammation, fibrosis and graft loss.

R. Thuillier, S. Giraud, O. Page, T. hauet
Poitiers Cedex/FRANCE

Session O02 T Cell Diversity and Functional Biology

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 205 - 207

Moderators: Leslie Brent, David White
O02.01 Regulatory T cell therapy prolongs human skin allograft survival in a humanised mouse model

F. Issa, J. Wieckiewicz, R. Goto, T. Goodacre, K.J. Wood
Oxford/UNITED KINGDOM

O02.02 CD4+CD25+Tregs activated in vitro with IL-2 and IL-12p70 suppress rejection of fully allogeneic grafts in animals with no other immunosuppression.

B.M. Hall¹, N.D. Verma¹, R. Boyd¹, C.M. Robinson¹, G.T. Tran¹, C. Wang², G.A. Bishop², S.J. Hodgkinson¹
¹Eveleigh/AUSTRALIA, ²Sydney/AUSTRALIA

O02.03 Combined administration of a novel mutant TGF-β1/Fc and rapamycin modulates the immune balance between Treg and Th17 and promotes allograft tolerance

Pittsburgh/UNITED STATES OF AMERICA

O02.04 CD4CD25 Positive Mast Cells in Long-Term Surviving Grafts Followed by T-Regulatory Therapy: MC-regs?

A. Andakyan, S. Burruss, L.-S. Hong, X. Shen, S. Romanov, F. Gao, M. Fishbein, N. Semiletova
Los Angeles/UNITED STATES OF AMERICA

O02.05 Inducing Islet Allograft Tolerance by Combining Regulatory T Cell Therapy with Donor-specific T Cell Deletion

K. Lee¹, G. Miao¹, V. Nguyen¹, H. Scholz², T.V. Brennan¹, S.-M. Kang¹, Q. Tang¹
¹San Francisco/UNITED STATES OF AMERICA, ²Oslo/NORWAY

O02.06 Allogeneic Treg generated in vitro with retinoic acid and TGF-β control cytokine production and allograft rejection.

C. Moore¹, C. Fuentes¹, V. Ramirez¹, M.R. Bono¹, J.A. Fierro¹, K.J. Wood², A. Bushell², M. Rosemblatt¹
¹Santiago/CHILE, ²Oxford/UNITED KINGDOM

O02.07 Generation of human T regulatory cells with the capacity to suppress islet allograft rejection in a xenogeneic mouse model.

A. McMurchy, D. Dai, J. Gillies, C.B. Verchere, M.K. Levings
Vancouver/Canada

O02.08 Contribution of regulatory T cells combined with low-dose Sirolimus, but not Tacrolimus, to delay acute rejection of renal allografts in cynomolgus monkeys
TTS 2010 SCIENTIFIC PROGRAM

A. Ma, L. Song, S. Qi, Y. Hu, H. Dun, Z. Xiong, P. Daloze, H. Chen
Montreal/CANADA

002.09 Up regulation of FOXP3 expression in CD4+CD25+ IL-7R α low regulatory T cells in operational tolerance after pediatric living donor liver transplantation

H.A. Nafady Hego, Y. Li, S. Sakaguchi, S. Uemoto, T. Koshiba
Kyoto/JAPAN

Session 003 Genomics and Biomarkers

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 211

Moderators: Daniel . Salomon, Thomas . Mueller

003.08 A Highly Specific Novel 3 Gene-set Can Non-invasively Predict Operational Renal Allograft Tolerance

L. Li1, S. Heish1, J.D. Scandling2, T. Sigdel1, M. Sarwal1
1Stanford/UNITED STATES OF AMERICA, 2Palo Alto/UNITED STATES OF AMERICA

003.01 Over-expression of human CD39 in mouse liver protects against ischemia reperfusion injury in a model of liver transplantation

B. LU1, S. Pommey1, S. Robson2, A. d'Apice1, P. Cowan1, K. Dwyer1
1Fitzroy/australia, 202115/UNITED STATES OF AMERICA

003.02 Assigning a probability of TCMR to kidney transplant biopsies.

J. Reeve, J. Sellarés, M. Mengel, B. Sis, L.G. Hidalgo, K.S. Famulski, P. Halloran
Edmonton/CANADA

003.03 Structural aspects of HLA class I epitopes recognized by human monoclonal antibodies

R.J. Duquesnoy1, M. Marrari1, A. Mulder2
1Pittsburgh/UNITED STATES OF AMERICA, 2Leiden/NETHERLANDS

003.04 Acute Rejection of Cardiac Allografts results in a Unique Signature of MicroRNAs

L. Wei, M. Wang, A. Harris, O.M. Martinez, S.M. Krams
Stanford/UNITED STATES OF AMERICA
O03.05 Oncostatin M is the key acute phase response gene in the renal epithelial and vascular compartment

T.F. Mueller¹, W.L. Phan¹, C. Compston¹, S. Rose-John², D. Perkins³, V.A. Luyckx⁴
¹Edmonton/CANADA, ²Kiel/GERMANY, ³San Diego/UNITED STATES OF AMERICA

O03.06 Genetic polymorphisms of adhesion molecules and kidney transplant survival

A. Heinold, G. Opelz, B. Döhler, S. Scherer, A. Ruhenstroth, T.H. Tran
Heidelberg/GERMANY

O03.07 Transcriptional profiling of liver grafts in spontaneous operational tolerance.

F. Bohne¹, M. Martinez-Llordella¹, J.J. Lozano¹, M. Lopez¹, C. Benitez¹, R. Miquel¹, G. Tisone², A. Rimola¹, A. Sanchez-Fueyo¹
¹Barcelona/SPAIN, ²Rome/ITALY

O03.09 Discerning gene expression profiles involved in loss of graft function with IF/TA: utility in diagnosis and disease progression.

Richmond/UNITED STATES OF AMERICA

Session O04 Organ Donation and Allocation I

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 109 - 110

Moderators: Bernard Cohen, Valter Garcia

O04.01 Impact of the 2006 UK National Kidney Allocation Scheme

R.J. Johnson¹, S.V. Fuggle¹, L.L. Mumford¹, J.A. Bradley², J.L.R. Forsythe³, C. Rudge⁴
¹Bristol/UNITED KINGDOM, ²Cambridge/UNITED KINGDOM, ³Edinburgh/UNITED KINGDOM, ⁴London/UNITED KINGDOM

O04.02 Comparison of Model for End-Stage liver disease (MELD) & United Kingdom End-Stage Liver Disease (UKELD) scores as a predictor for death on the liver transplant waiting list and as a predictor of mortality following liver transplantation

Birmingham/UNITED KINGDOM
O04.03 Outcomes and Distributional Efficacy of Kidneys rejected by local and regional centers in the United States

L.K. Kayler, J. Sokolich, J. Magliocca, J. Schold
Gainesville/UNITED STATES OF AMERICA

O04.04 Primum non nocere: can living donation be justified as long as deceased donation is not optimally exploited?

L. Roels¹, J. Smits², B. Cohen¹
¹Linden/BELGIUM, ²Leiden/NETHERLANDS

O04.05 Tools to compare organ procurement process

R. Deulofeu, J. Twose, M. Sanroma
Barcelone/SPAIN

O04.06 Family approach – retrospective analysis of family refusals

F. Schaub¹, D. Norba², G.R. Kirste²
¹Frankfurt Am Main/GERMANY, ²Frankfurt/GERMANY

O04.07 Organ scarcity, restriction of non-residents to European transplant wait lists and the prohibition of discrimination under EU Law

F. Ambagtsheer¹, A. Rahmel², W. Weimar¹
¹Rotterdam/NETHERLANDS, ²Leiden/NETHERLANDS

O04.08 Paired living kidney donation in the UK

R.J. Johnson¹, J. Allen¹, S.V. Fuggle¹, J.A. Bradley²
¹Bristol/UNITED KINGDOM, ²Cambridge/UNITED KINGDOM

O04.09 An assessment of the work required to evaluate living donors

C. Rose, P. Blezinski, L. Sills, R. McCarrell, W. Gourlay, J. Gill, J. Gill
Vancouver/Canada

Session O05 Induction Immunosuppression

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: Ballroom A/B
TTS 2010 SCIENTIFIC PROGRAM


O05.01 Final 36 Month Results Of A Multicenter, Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) With Tacrolimus, Mycophenolate Mofetil and a Rapid Steroid Withdrawal in Renal Transplantation

M. Hanaway¹, E.S. Woodle², S. Mulgaonkar³, R. Peddi⁴, G. Harrison⁵, K. Vandeputte⁵, W. Fitzsimmons⁵, R. First⁵, J. Holman⁵
¹Birmingham/UNITED STATES OF AMERICA, ²Cincinnati/UNITED STATES OF AMERICA, ³Livingston/UNITED STATES OF AMERICA, ⁴San Francisco/UNITED STATES OF AMERICA, ⁵Deerfield/UNITED STATES OF AMERICA

O05.02 Kidney transplantation with campath 1H and infliximab induction followed by either tacrolimus or sirolimus monotherapy: 12-months follow-up

O. Viklicky¹, J. Slatinska¹, H.-D. Volk², B. Sawitzki², M. Burgelova¹, P. Reinke²
¹Prague 4/CZECH REPUBLIC, ²Berlin/GERMANY

O05.03 To Wean or Not to Wean Tacrolimus Monotherapy After Alemtuzumab Pretreatment in Living Donor Kidney Transplant Recipients: A Comparative Study.

Pittsburgh/UNITED STATES OF AMERICA

O05.04 Induction immunosuppression improves graft survival in organ transplantation: a report of 15 years UNOS registry data

J. CAI, P.I. Terasaki
Los Angeles/UNITED STATES OF AMERICA

O05.05 Induction Immunosuppression in the Elderly Kidney Transplant Recipient: An analysis of OPTN/UNOS data informing a risk stratified approach

J. Gill¹, M. Sampaio², Y.W. Cho², J. Gill³, S. Bunnappadist²
¹Vancovouver/CANADA, ²Los Angeles/UNITED STATES OF AMERICA, ³Vancouver/CANADA

O05.06 Short- and long term kidney graft survival: the impact of intra-operative high-dose ATG-Fresenius induction and identification of important predictors

J. Kaden¹, G. May¹, A. Völz², C. Wesslau¹, D.K. Abendroth³
¹Berlin/GERMANY, ²Frankfurt/GERMANY, ³Ulm/GERMANY
TTS 2010 SCIENTIFIC PROGRAM

O05.07 Interleukin-2 receptor antagonists versus ATG for kidney transplant recipients; an updated Cochrane systematic review.

A. Webster, L.P. Ruster, R. Mc Gee, S.L. Matheson, G.Y. Higgins, N.S. Willis, J.R. Chapman, J. Craig
Sydney/AUSTRALIA

O05.08 Impact of IL2-RA Induction Therapy in the Prevention of Acute Rejection with TAC/MMF-Based Immunosuppression

J. Gralla, A. Wiseman
Denver/UNITED STATES OF AMERICA

O05.09 One year follow up efficacy and safety of induction therapy comparison of anti-interleukin-2 receptor antibodies and thymoglobulin

L. Li, A. Chaudhuri, A. Chen, X. Zhao, M. Bezchinsky, M. Sarwal
Stanford/UNITED STATES OF AMERICA

Session O06 CMV Infection

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 220 - 222

Moderators: Petra . Reinke, William . Rawlinson

O06.01 The IMPACT STUDY: Extending Valganciclovir Prophylaxis in Kidney Transplant High Risk (D+/R) Recipients is Associated with Long-term Benefits.

A. Humar¹, Y. LEBRANCHU², F. Vincenti³, E. Blumberg⁴, J.D. Punch⁵, A.P. Limaye⁶, D. Abramowicz⁷, A.G. Jardine⁸, I.A. Hauser⁹, M. Farhan¹⁰, P. Peeters¹¹
¹Edmonton/CANADA, ²Tours/FRANCE, ³San Francisco/UNITED STATES OF AMERICA, ⁴Philadelphia/UNITED STATES OF AMERICA, ⁵Ann Arbor/UNITED STATES OF AMERICA, ⁶Seattle/UNITED STATES OF AMERICA, ⁷Anderlecht/BELGIUM, ⁸Glasgow/UNITED KINGDOM, ⁹Frankfurt/M/GERMANY, ¹⁰Welwyn Garden City/UNITED KINGDOM, ¹¹Ghent/BELGIUM

O06.02 The IMPACT Study: Phenotypic Analysis of Previously Uncharacterized Cytomegalovirus UL54 and UL97 Amino Acid Substitutions Detected in Virus from Patients Receiving 200 or 100 Days of Valganciclovir (Valcyte®) Prophylaxis

S. Chou¹, G. Marousek¹, V. Wong¹, G. Boivin², N. Goyette², M. Farhan³, R. Elston³
¹Portland/UNITED STATES OF AMERICA, ²Sainte-Foy/CANADA, ³Welwyn Garden City/UNITED KINGDOM
TTS 2010 SCIENTIFIC PROGRAM

O06.03 The IMPACT study: 100-day vs 200-day prophylaxis with valganciclovir (Valcyte®) to reduce CMV disease post-transplant is cost-effective within US health care setting

A.G. Jardine¹, I.A. Hauser², C. Gahlemann³, K. Berenson⁴, E. Blumberg⁵, A. Humar⁶
¹Glasgow/UNITED KINGDOM, ²Frankfurt/M/GERMANY, ³Basel/SWITZERLAND, ⁴New York/UNITED STATES OF AMERICA, ⁵Philadelphia/UNITED STATES OF AMERICA, ⁶Edmonton/CANADA

O06.04 Association of Cytomegalovirus (CMV) Infection and Disease with Death and with Graft Loss or Death after Liver Transplant in High Risk Recipients

W. Bosch, M.G. Heckman, N.N. Diehl, J.A. Shalev, W.C. Hellinger
Jacksonville/UNITED STATES OF AMERICA

O06.05 Primary CMV Infections Are Common in Kidney Transplant Recipients after 6 Months Valganciclovir Prophylaxis

I. Helanterä, L. Kyllönen, I. Lautenschlager, K. Salmela, P. Koskinen
Helsinki/FINLAND

O06.06 Monitoring with or without Pre-emptive Therapy versus Prophylaxis for Cytomegalovirus (CMV) in Renal Transplant Patients

T.A.K. Rana, J. Taylor, J.A. Akoh
Plymouth/UNITED KINGDOM

O06.07 Development of primary CMV-specific T-cell responses in D+/R- transplant recipients during valganciclovir prophylaxis

C. La Rosa¹, A.P. Limaye², A. Krishnan¹, G. Blumstein¹, D.J. Diamond¹
¹Duarte/UNITED STATES OF AMERICA, ²Seattle/UNITED STATES OF AMERICA

O06.08 In vivo viral microRNA profiling in a large cohort of transplant patients with CMV disease

L.F. Lisboa¹, D. Kumar¹, X. Pang¹, L. Tyrrell¹, J. Huang¹, A. Åsberg², A. Hartmann², A. Humar¹
¹Edmonton/CANADA, ²Oslo/NORWAY

O06.09 The IMPACT Study: Valganciclovir Pharmacokinetic Parameters Do Not Change When Extending Prophylaxis from 100 to 200 Days.

C. Washington¹, H. Welker², M. Farhan³, A. Humar⁴
¹South San Francisco/UNITED STATES OF AMERICA, ²Basel/SWITZERLAND, ³Welwyn Garden City/UNITED KINGDOM, ⁴Edmonton/CANADA

Session O07 A New Century of Pediatric Transplantation?
TTS 2010 SCIENTIFIC PROGRAM

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 217 - 219

Moderators: Susan . Samuel, Anne . Dipchand

O07.01 Can We Ignore HLA-DR Matching in Pediatric Kidney Transplantations?: an Analysis of OPTN/UNOS data
J. Cicciarelli, T. Shah, B. Hardy, I.V. Hutchinson, Y.W. Cho
Los Angeles/UNITED STATES OF AMERICA

O07.02 The association between cytomegalovirus immune globulin (CMVIG) use and long-term recipient and graft survival in pediatric heart transplantation recipients
D.R. Snydman¹, K. Kistler², J. Morris², P. Ulsh³
¹Boston/UNITED STATES OF AMERICA, ²Harrisburg/UNITED STATES OF AMERICA, ³King Of Prussia/UNITED STATES OF AMERICA

O07.03 Two Decade Experience with Pediatric Intestinal Failure and Transplantation; Evolution and Future Progress
G.J. Bond, K. Soltys, R. Sindhi, K.M. Abu-Elmagd, G. Mazariogos
Pittsburgh/UNITED STATES OF AMERICA

O07.04 Post-Transplant Lymphoproliferative Disorder in Australian and New Zealand Pediatric Renal Transplant Recipients
S. McTaggart¹, D. Longmore¹, L. Conwell¹, S.P. McDonald², J. Burke¹
¹Brisbane/AUSTRALIA, ²Adelaide/AUSTRALIA

O07.05 63 Pediatric Living Donor Kidney Transplantations Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 6 Year Experience
Pittsburgh/UNITED STATES OF AMERICA

O07.06 Are liver transplanted children more impulsive? Attention and executive functioning after pediatric liver transplantation
T. Kaller, N. Langguth, B. Nashan, R. Ganschow, K.-H. Schulz
Hamburg/GERMANY

O07.07 The Outcome of Corneal Transplantation in Infants, Children and Adolescents
O07.08 Pharmacokinetic Profile of Valganciclovir in Pediatric Transplant Recipients

Montreal/CANADA

O07.09 Role of the liver transplantation in the management of hepatoblastoma in children

H. Ismail, D. Broniszczak, P. Kalicinski, P. Kluge, B. Dembowska-Baginska, A. Kosciesza, A. Lembas
Warsaw/POLAND

Session O08 Immunosuppression for Liver Transplantation

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 118 - 120

Moderators: Douglas Hanto, Hans Schlitt

O08.01 Early steroid-free immunosuppressive therapy with FK 506 after liver transplantation - 5-year results of a prospective randomized double-blinded placebo-controlled study

N. Weiler, M. Hoppe-Lotichius, T. Zimmermann, I. Kraemer, G. Otto
Mainz/GERMANY

O08.02 Long term follow up of 22 operational tolerant liver transplant recipients.

Miami/UNITED STATES OF AMERICA

O08.03 Predicting "operational tolerance" after liver transplantation

T.M. Manzia, R. Angelico, L. Toti, M. Manuelli, I. Bellini, D. Sforza, L. Perrone, G. Tisone
Rome/ITALY

O08.04 Campath-1H induction immunosuppression in adult non-HCV liver transplant recipients. Eight year experience of a single Center.
O08.05 Single centre experience in conversion of calcineurin inhibitor to sirolimus-based immunosuppression following liver transplantation.

Cambridge/UNITED KINGDOM

O08.06 Sirolimus improves renal function but does not negatively influence outcomes in liver transplant recipients

J. Campsen, M. Zimmerman, S. Mandell, M. Kaplan, I. Kam
Aurora/UNITED STATES OF AMERICA

O08.07 No immunologic graft failure in consecutive 17 cases of ABO-incompatible living donor liver transplantation under rituximab prophylaxis

Seoul/KOREA

O08.08 Short-term, low-dose thymoglobuline: the best option to spare calcineurin inhibitors in liver transplant recipients with renal failure?

P.C. Casciato, S. Marciano, O.A. Galdame, A.G. Villamil, J.C. Bandi, E. de Santibañes, A.C. Gadano
Buenos Aires/ARGENTINA

O08.09 Donor specific antibodies found in nearly all patients who chronically rejected their liver transplant.

J.G. O’Leary¹, H. Kaneku², B. Susskind¹, L. Jennings¹, J.E. Baker¹, G. Klintmalm¹, P.I. Terasaki²
¹Dallas/UNITED STATES OF AMERICA, ²Los Angeles/UNITED STATES OF AMERICA

Session O09 Optimizing Immediate Graft Function in Kidney Transplantation

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: Ballroom C

TTS 2010 SCIENTIFIC PROGRAM

O09.01 N-Octanoyl-Dopamine reduces inflammation and compared to Dopamine improves renal function in acute renal failure

C. Tsagogiorgas, M. Schneider, G. Lueg, M. Hottenrott, P. Schnuelle, B. Yard, S. Hoeger
Mannheim/GERMANY

O09.02 CD73 deficiency and inhibition protect in kidney ischaemia reperfusion injury (IRI)

S. Rajakumar¹, B. Lu¹, S. Crikis¹, S. Robson², A. d'Apice³, P. Cowan¹, K. Dwyer³
¹Melbourne/AUSTRALIA, ²02115/UNITED STATES OF AMERICA, ³Fitzroy/AUSTRALIA

O09.03 Renal Perfusion Pump vs. Cold Storage for Donation After Cardiac Death Kidneys: A Systematic Review

T.B. McGregor, V. Bathini, V. McAllister, P. Luke, A. Sener
London/CANADA

O09.04 Curcumin treatment during preservation improves long term graft outcome

R. Thuiller¹, H. Lathelize¹, J. Paarkkinen², L. Vaahtera², T. hauet¹
¹Poitiers Cedex/FRANCE, ²Helsinki/FINLAND

O09.05 Improving kidney preservation: HEMO2Life® supplementation rescues ischemia reperfusion injury

R. Thuiller¹, T.M.T. ngo¹, D. Dutheil², F. zai², T. hauet¹
¹Poitiers Cedex/FRANCE, ²Morlaix/FRANCE

O09.06 Tetrahydrobiopterin (BH4) Inhibits SAMPK and Reduces DGF Following Renal Ischemia

R. Sucher, P. Gehwolf, G. Rumberg, I. Kronberger, C. Margreiter, R. Öllinger, S. Schneeberger, E. Werner, B. Zeiger, J. Pratschke, G. Brandacher
Innsbruck/AUSTRIA

O09.07 Remote ischemic preconditioning using the hind limb as remote organ reduces ischemia-reperfusion injury of the kidney in rats.

M.C. Warlé, K. Wever, L. te Riet, G.A. Rongen, J.A. van der Vliet
Nijmegen/NETHERLANDS

O09.08 Gingko biloba extract (EGb 761) ameliorates kidney injury and promotes renal function recovery in a rat model of ischemia-reperfusion injury.
O09.09 Liposomal curcumin ameliorates renal ischaemia-reperfusion injury via NFkB inhibition and antioxidant pathways.

N. Rogers, M. Stephenson, S. Kireta, P.T. Coates
Adelaide/AUSTRALIA

Session O10 Mesenchymal Stem Cells and Cellular Transplantation

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 212 - 214

Moderators: Mario . Abbud-Filho, Michael . Breimer

O10.01 Heme oxygenase-1 induction improves the survival of human embryonic stem cell-derived cardiomyocyte grafts in vitro and in vivo

J. Luo, B.P.J. Van Biber, M.A. Laflamme, M.D. Allen
Seattle/UNITED STATES OF AMERICA

O10.03 Hybrid islet transplantation with marginal islet mass and adipose tissue-derived stem cells can elicit long-term islet graft survival and support normoglycemia in diabetic mice.

Osaka/JAPAN

O10.04 Transplantation of fetal membrane-derived mesenchymal stem cells protect against renal ischemia reperfusion injury.

Suita/JAPAN

O10.05 Biomaterial seeded with bone marrow derived cells did retard progression and impact differently distinct stages of chronic kidney disease

Sao Jose Do Rio Preto/BRAZIL
TTS 2010 SCIENTIFIC PROGRAM

O10.06 Bone Marrow Derived Stromal Cells (BMSC) Therapy in Peripheral Nerve Regeneration: new surgical and therapeutic approach.

M. Madajka, A. Mendiola, B. Przybyla, M. Siemionow
Cleveland/UNITED STATES OF AMERICA

O10.07 Allogenic Epineural Tube Nerve Gap Repair with Bone Marrow Stromal Cells (BMSC) Supportive Therapy Yields Comparable Outcomes to Autograft Repair

G. Brzezicki, A. Jundzill, A. Mendiola, A. Klimczak, J. Gatherwright, M. Siemionow
Cleveland/UNITED STATES OF AMERICA

O10.08 Comparison of In-vivo Created Donor-Recipient Chimeric Cell Therapy and Bone Marrow Cell Therapy as a Supportive Treatments in Face Allograft Model

J. Cwykiel, F. Zor, A. Klimczak, M. Siemionow, M. Madajka
Cleveland/UNITED STATES OF AMERICA

Session O11 Late Breaking I

Monday, August 16, 2010 10:30 AM - 12:00 PM
Room: MR 121 - 122

Moderators: Pierre . Daloze

O11.01 Longterm clinical recovery in Parkinsonian monkey recipients of CTLA4-Ig transgenic porcine neural precursors

R. Aron Badin¹, A. Padoan², M. Vadori³, M. Boldrin³, L. Cavicchioli², G.M. De Benedictis², F. Fante³, M. Seveso³, D. Sgarabotto², C. Jan¹, V. Daguin⁴, P. Naveilhan⁴, I. Neveu⁴, J.-P. Soulillou⁴, B. Vanhove⁴, M. Plat⁵, F. Bottè⁵, V. Eric⁵, L. Denaro², R. Manara², P. Zampieri², D. D'avella², D. Rubello⁴, E. Ancona², P. Hantraye¹, E. Cozzi²
¹Fontenay-aux-Roses/FRANCE, ²Padua/ITALY, ³Legnaro, Padova/ITALY, ⁴Nantes/FRANCE, ⁵Nouzilly/FRANCE, ⁶Rovigo/ITALY

O11.02 A Novel Device for Longer Term LVAD Support – Single Centre Experience with HeartWare

F. Özalp, T. Butt, N. Wrightson, T. Pillay, D. O'Leary, G. MacGowan, S. Schueler
Newcastle Upon Tyne/UNITED KINGDOM

O11.03 Hypothermic Ex Vivo Perfusion Prevents Ischemia Reperfusion Injury in Rat Lungs from Non-Heart-Beating Donors

F. Özalp, T. Butt, N. Wrightson, T. Pillay, D. O'Leary, G. MacGowan, S. Schueler
Newcastle Upon Tyne/UNITED KINGDOM
O11.04 Protective effect of ventilation before organ procurement on graft lungs donated after cardiac death in a canine lung transplantation model

Kyoto/JAPAN

O11.05 Nonhuman Primates May Fail to Serve as an Adequate Model for Studying Extracorporeal Porcine Liver Perfusions

J.P. Waldman, M. Rees
Toledo/UNITED STATES OF AMERICA

O11.06 Perfusion by oxygenated buffer containing prostaglandin E1 prior to cold preservation prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donors

Y. Hara, Y. Akamatsu, Y. Kobayashi, T. Iwane, S. Satomi
Sendai/JAPAN

O11.07 IL-15 reconstituted humanized mice - a cutting-edge model to study human NK cells in transplantation

Regensburg/GERMANY

O11.08 Pre-transplant maternal-fetal immune status predicts allograft outcome

P. Dutta, M. Dart, A. David, S.M. Schumacher, W.J. Burlingham
Madison/UNITED STATES OF AMERICA

12:15 – 13:15 MINI ORAL SESSIONS

Session MO01 Immune Regulation and Tolerance I

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 202 - 204

Moderators: Johann . Pratschke, Leslie . Brent
MO01.01 Induced CD4+CD25+Foxp3+ regulatory T cells and impaired development of CD8+CD44+CD62L+ memory T cells promote specific tolerance to cardiac allografts following Rapamycin treatment

P. Urbanellis, J. Wang, I. Shalev, W. He, O.A. Adeyi, M.J. Phillips, A. Bartczak, R. Khattar, D.R. Grant, G.A. Levy
Toronto/CANADA

MO01.02 Increased Treg Stability upon Graft Tolerance Induction in Lymphopenic Hosts

D. Hanidziar¹, T.B. Strom², M. Koulmanda³
¹02215/UNITED STATES OF AMERICA, ²5491/UNITED STATES OF AMERICA

MO01.03 Tribbles-1 is expressed by regulatory T cells and interacts with FOXP3

E. DUGAST¹, L. Docherty², E. Kiss-Toth², S. Pettré¹, R. Danger¹, J.-P. Souillou¹, S. Brouard¹, J. Ashton-Chess³
¹Nantes Cedex 1/FRANCE, ²Sheffield/UNITED KINGDOM, ³Nantes/FRANCE

MO01.04 Mechanistic insight into Induction of Mediating Generation of Myeloid-Derived Suppressor Cells by Liver Stromal Cells

Cleveland/UNITED STATES OF AMERICA

MO01.05 Pretransplant treatment with donor-derived regulatory macrophages prolongs survival of fully mismatched allografts in unconditioned, non-immunosuppressed recipients

P. Riquelme, J.A. Hutchinson, E.K. Geissler
Regensburg/GERMANY

MO01.06 De Novo expression of CD8 on CD4+CD8-CD25+Foxp3+ T regulatory cells, activated by alloantigen and IL-2, identifies alloantigen specific T regulatory cells.

B.M. Hall¹, N.D. Verma², R. Boyd¹, C.M. Robinson¹, G.T. Tran¹, C. Wang³, G.A. Bishop³, S.J. Hodgkinson¹
¹Eveleigh/AUSTRALIA, ²Kensington/AUSTRALIA, ³Sydney/AUSTRALIA

MO01.07 The direct alloreactivity pathway is more susceptible to regulation by nTreg than the indirect pathway.

G. Noël, C. Daniel
Laval/CANADA
TTS 2010 SCIENTIFIC PROGRAM

MO01.08 The Janus kinase inhibitor CP-690,550 preserves the suppressive activity of human CD4+CD25brightFoxP3+ regulatory T cells and strongly inhibits effector T cells

C. Baan¹, V. Sewgobind¹, M. Quaedackers¹, L.V.D. Laan¹, G. Chan², W. Weimar¹
¹Rotterdam/NETHERLANDS, ²New London/UNITED STATES OF AMERICA

MO01.09 Rapamycin Conditioned Dendritic Cells for In Vitro Differentiation of Donor-Specific CD4+CD25+Foxp3+ Regulatory T cells for Islet Transplantation

K.L. Pothoven, T. Kheradmand, J.L. Houlihan, X. Luo
Chicago/UNITED STATES OF AMERICA

MO01.10 Adoptive Transfer of Ex vivo Donor Alloantigen-stimulated Regulatory T Cells Combined with Low Dose Tacrolimus Ameliorates Rejection of Lung Transplantation Between Fully Mismatched Miniature Swines

N. Satoda, Y. Li, H. Ohe, S. Sakaguchi, S. Uemoto, H. Date, T. Koshiba
Kyoto/JAPAN

MO01.11 Human CD4+FOXP3+ T regulatory cells produce CXCL8 and recruit inflammatory immune cells

M. Himmel, S. Crome, S. Ivison, T. Steiner, M.K. Levings
Vancouver/CANADA

MO01.12 CTLA4-Ig Mediated Tolerance Induction Relies on Interrelated Mechanisms Involving the Immunomodulatory Enzyme IDO and Treg

R. Sucher¹, R. Oberhuber¹, N. Fischler¹, I. Kronberger¹, R. Öllinger¹, S. Schneeberger¹, D. Fuchs¹, E. Werner¹, B. Zelger¹, G. Tellides², N. Pilat³, T. Wekerle³, R. Margreiter¹, J. Pratschke¹, G. Brandacher¹
¹Innsbruck/AUSTRIA, ²New Haven/UNITED STATES OF AMERICA, ³Vienna/AUSTRIA

Session MO02 Clinical and Ethical Aspects of Living Donor Transplantation

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 109 - 110

Moderators: Francis . Delmonico, Jean . Shapiro

MO02.01 Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?
MO02.02 Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

J.M. Söfteland1, N. Kvarnström1, A. Lennerling1, M. Rizell1, A. Odén2, I. Fehrman-Ekholm1
1Göteborg/SWEDEN, 2Romelanda/SWEDEN

MO02.03 Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

1Toledo/UNITED STATES OF AMERICA, 2Maumee/UNITED STATES OF AMERICA, 3Columbus/UNITED STATES OF AMERICA, 4Baltimore/UNITED STATES OF AMERICA, 5Phoenix/UNITED STATES OF AMERICA, 6Winston-Salem/UNITED STATES OF AMERICA, 7Buffalo/UNITED STATES OF AMERICA, 8Cambridge/UGANDA, 9Indianapolis/UNITED STATES OF AMERICA, 10Chestnut Hill/UNITED STATES OF AMERICA, 11Orlando/UNITED STATES OF AMERICA, 12Ann Arbor/UNITED STATES OF AMERICA, 13Houston/UNITED STATES OF AMERICA, 14Birmingham/UNITED STATES OF AMERICA, 15Sacramento/UNITED STATES OF AMERICA

MO02.04 Long-term outcomes of living kidney donors – a single centre experience of 29 years

Hong Kong/CHINA

MO02.05 Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

E. van Hardeveld, B. Bennett, S. Cohney, J. Pickering, T. Furlong
Parkville/AUSTRALIA

MO02.06 100 Kidney Transplants Performed Via Kidney Paired Donation at the Johns Hopkins Hospital

Baltimore/UNITED STATES OF AMERICA

MO02.07 Age does not affect survival of kidneys from elderly living donors

Rotterdam/NETHERLANDS
TTS 2010 SCIENTIFIC PROGRAM

MO02.08 Living Kidney Donor Relationships in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs

M. Cooper, M. Phelan, R.N. Barth, S. Fayek, S.T. Bartlett, B. Philosophe
Baltimore/UNITED STATES OF AMERICA

MO02.09 Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

M.D. Rizzari, T.M. Suszynski, K.J. Gillingham, H.N. Ibrahim, A.J. Matas
Minneapolis/UNITED STATES OF AMERICA

Session MO03 Induction Immunosuppression

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 211

Moderators: John . Najarian, Diego . Cantarovich

MO03.01 Low Dose Rabbit Anti-Thymocyte Globulin Induction Therapy Results in Prolonged Selective CD4 T Cell Depletion Irrespective of Maintenance Immunosuppression

Buffalo/UNITED STATES OF AMERICA

MO03.02 Low dose ATG induction for older kidney transplant recipients (old for old); single centre experience over 4 years.

G. Block, M. Meier, J. Steinhoff, C.B. Buerk, M. Nitschke
Lübeck/GERMANY

MO03.03 Low dose rabbit anti-thymocyte globulin induction in low risk renal transplant recipients: 8 years follow up.

Buffalo/UNITED STATES OF AMERICA

MO03.04 Safety of rituximab as induction therapy in renal transplantation; results of an interim analysis

M.W.F. van den Hoogen, A.J. Hoitsma, L.B. Hilbrands
Nijmegen/NETHERLANDS
TTS 2010 SCIENTIFIC PROGRAM

MO03.05 Alemtuzumab (Campath-1H) induction and prednisone – free maintenance immunotherapy in kidney transplant Hispanic patients

Y.A. Baez, F.A. Giron
Bogota/COLOMBIA

MO03.06 Basiliximab Induction versus Alemtuzumab Induction with Steroid Free Maintenance in Kidney Transplantation: Two-Year Outcomes

Toledo/UNITED STATES OF AMERICA

MO03.07 Alemtuzumab Induction and Tacrolimus Maintenance Immunosuppression with and without Mycophenolic Acid in Kidney Transplantation

Toledo/UNITED STATES OF AMERICA

MO03.08 Relationship Between Rejection and Infection after T-Cell Depleting Induction Therapy

Winston-Salem/UNITED STATES OF AMERICA

MO03.09 Effect of Induction Therapy on Acute Rejection risk and Severity, Infection and Malignancy-related mortality in Renal Transplant recipients

R.M. Croke
Perth/AUSTRALIA

MO03.10 Campath Induction Does Not Predispose to Cytomegalovirus Disease

C. Gurk-Turner, J. Deyo, R. Munivenkatappa, B. Philosophe, R.N. Barth
Baltimore/UNITED STATES OF AMERICA

MO03.11 IL2 Blocker Induction in Living Related Renal Transplantation

Vellore/INDIA

MO03.12 Interleukin-2 Receptor Antagonist Induction Therapy Leads To Increased Tacrolimus Levels After Kidney Transplantation
Session MO04 Epidemiology and Clinical Outcomes

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 205 - 207


MO04.01 Hemodialysis versus peritoneal dialysis – what is the best bridging to renal transplantation

U. Ott, C. Ruester, M. Busch, H. Wunderlich, G. Wolf
Jena/GERMANY

MO04.02 Spousal Donor Renal Transplants - a viable option

T.A. Sarguroh, R.R. Sen, R.R. Jagdale, J.P. Kothari, R.A. Sirsat, A. Almeida
Mumbai/INDIA

MO04.03 The impact of pre-transplant phosphate levels on outcomes after kidney transplantation

R. Sapir-Pichhadze, S.J. Kim, K. Parmar
Toronto/CANADA

MO04.04 The long-term outcomes of kidney transplants with multiple renal arteries

I.S. Moon, J.K. Hwang, J.I. Kim, S.C. Park, C.W. Yang, S.N. Kim, Y.-B. Koh
Seoul/KOREA

MO04.05 Older Patients Who Are Transplanted Have An Excellent Outcome Provided They Are Cardiologically Tested

A. Asderakis, M. Stephens, M.A. Ilham
4xw/UNITED KINGDOM

MO04.06 Kidney transplantation decreases rates of hospital separation for acute cardiac events but not cardiac failure compared to dialysis

S. Sen, S.P. McDonald
Adelaide/AUSTRALIA
TTS 2010 SCIENTIFIC PROGRAM

MO04.07 The Evolving Outcomes of Kidney Transplant Recipients Over 70 Years of Age

Cleveland/UNITED STATES OF AMERICA

MO04.08 Trends in Estimated Glomerular Filtration Rate During Years 1 to 5 Post-Transplant, Data from the Predicting Outcomes in Renal Transplant (PORT) International Data Collaboration

J. Snyder1, J. Liu1, M. Skeans1, A. Israni1, G. L'Italian2, B. Kasiske1
1Minneapolis/UNITED STATES OF AMERICA, 2Wallingford/UNITED STATES OF AMERICA

MO04.09 African American Race as a Risk Factor in Outcomes After Second and Third Kidney Transplantation

J. McGee, L.-C.P. Chou, A. Harbin, Y.-H. Hsueh, C.L. Yau, D.P. Slakey
New Orleans/UNITED STATES OF AMERICA

MO04.10 The influence of Different Erythropoietin Regimes on Hemoglobin at 1 month post transplant

Y. Reddy, Y. Reddy, N. Fathima, G. Abraham
Chennai/INDIA

MO04.11 Statistical Assessment of a Rate of Post-Transplant Lymphoproliferative Disorder among EBV-positive Kidney Recipients

L. Tracy1, L. Tracy1, P. Archdeacon1, E. Messersmith2
1Silver Spring/UNITED STATES OF AMERICA, 2Ann Arbor/UNITED STATES OF AMERICA

MO04.12 A Mixed Treatment Comparison of Efficacy and Cardiometabolic Safety of Belatacept, Cyclosporine and Tacrolimus for Immunosuppression Therapy in Adult Renal Transplant Recipients

S. Goring1, O. Eyawo1, E.J. Mills2, A. Levy3, G.J. L'Italien4, D. Trivedi5, B. Kasiske6
1Vancouver/CANADA, 2Ottawa/CANADA, 3Halifax, Ns/CANADA, 4Wallingford/UNITED STATES OF AMERICA, 5Plainsboro/UNITED STATES OF AMERICA, 6Minneapolis/UNITED STATES OF AMERICA

Session MO05 Living Liver Donors and Techniques

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 217 - 219

Moderators: David Grant, Chung Mau Lo
TTS 2010 SCIENTIFIC PROGRAM

MO05.02 Effects of Ischemic Preconditioning of the Graft in Adult Living Related Right Liver Transplantation

D. Azoulay, P. Andreani, S. De La Serna, E. Vibert, C. Salloum, R. Adam, D. Castaing
Villejuif/FRANCE

MO05.03 Donor morbidity in right lobe living donor liver transplantation: 91 consecutive cases in a European centre

Villejuif/FRANCE

MO05.04 The caval anastomosis technique does not influence renal function after orthotopic liver transplantation – a German single center experience

F. Rauchfuß, M. Druschlak, R. Voigt, M. Heise, U. Settmacher
Jena/GERMANY

MO05.05 Cavo-portal and reno-portal anastomosis for liver transplantation in patients with diffuse portal vein thrombosis: long-term results in 20 consecutive patients from a single centre

C. Lim, C. Salloum, S. De La Serna, P. Bhangui, R. Adam, D. Castaing, D. Azoulay
Villejuif/FRANCE

MO05.06 Contemporaneous portal and arterial reperfusion versus portal reperfusion first during liver transplantation: a prospective randomized study

U. Baccarani, A. Rossetto, D. Lorenzin, C. Musolino, C. Comuzzi, V. Bresadola, G.L. Adani
Udine/ITALY

MO05.07 Long term outcome of ex situ right lobe split grafts in Liver Transplantation

London/UNITED KINGDOM

MO05.08 Prevention of ischemic type biliary lesions by arterial first reperfusion in orthotopic liver transplantation

Frankfurt/GERMANY

MO05.09 The Pattern of Graft Volume Change After Living Donor Liver Transplantation
TTS 2010 SCIENTIFIC PROGRAM
M.K. Ju, K.H. Huh, D.J. Joo, J.S. Choi, M.S. Kim, S.I. Kim
Seoul/KOREA

MO05.10 Liver transplantation in the presence of diffuse portal vein thrombosis: A 10 year experience with cavoportal hemitransposition.
J.M. Söfteland, N. Kvarnström, S. Friman, M. Olausson
Göteborg/SWEDEN

MO05.11 Importance of Liver Biopsy in the Selection of Living-Donors for Liver Transplantation
S. Sevmis, S. Aktas, H. Karakayali, B. Demirhan, H. Selcuk, M. Haberal
Ankara/TURKEY

Session MO06 Laboratory Immunology and Kidney Transplantation

Monday, August 16, 2010 12:15 PM - 01:15 PM
Room: MR 220 - 222

Moderators: Ronald . Kerman, Ian . Hutchinson

MO06.01 Creatinine and Cystatin C-based Equations for the Estimation of Glomerular Filtration Rate in Kidney Transplantation: Correlation with Histopathology
Izmir/TURKEY

MO06.02 Predicting Outcomes in Kidney Transplantation: A Comparison of Three Semi-Quantitative Proteinuria Tests
B. Kiberd
Halifax/CANADA

MO06.03 Glomerulitis during Acute Cellular Rejection May be a Surrogate Marker of Vasculitis in Renal Allografts (Better Index for Diagnosis of Vasculitis)
Royal Oak/UNITED STATES OF AMERICA

MO06.04 Expression of E-cadherin, HSP(Heat Shock Protein)47, TGF-β1 and C4d in Chronic Allograft Nephropathy
TTS 2010 SCIENTIFIC PROGRAM

S. Lee, Y. Chung, J. Park, D. Kim, S. Park, J. Kim, S. Hyun, E. Nam
Seoul/KOREA

MO06.05 Donor-Specific HLA Antibodies Detected by Single Antigen Beads in Renal Transplant Patients: Impact on Clinical Outcome

J.P. Peräsaari, L. Kyllönen, K. Salmela, J. Merenmies
Helsinki/FINLAND

MO06.06 A Banff cv2 lesion in a pre-implantation biopsy is the best predictor of delayed graft function following renal transplantation.

Baltimore/UNITED STATES OF AMERICA, Philadelphia/UNITED STATES OF AMERICA

MO06.07 Biochemical markers of bone turnover and genotyping of polymorphisms and bone densitometry as standard test in the study of bone disease in renal transplant patients.

Murcia/SPAIN

MO06.08 Bortezomib Therapy for Antibody-Mediated Rejection: Effect on graft function and HLA Donor-Specific Antibody level.

L.E. Morales-Buenrostro, S.A. Leyva, L.A. Marino-Vazquez, O. Vega-Vega, G. Cantu
Mexico City/MEXICO

MO06.09 A Graded Desensitization Treatment Protocol for Management of Living Donor Recipients with Donor Specific Antibody

Houston/UNITED STATES OF AMERICA

MO06.10 C4d binding correlated with strong HLA antibodies can cause graft failure

K. Mizutani, M. Gotoh, P.I. Terasaki
Nagoya/JAPAN, Los Angeles/UNITED STATES OF AMERICA

Session MO07 Islet and Pancreas Transplantation I
MO07.01 Human Islet Isolation Utilizing a Novel Mammalian Tissue Free Enzyme

Edmonton/CANADA

MO07.02 Factors affecting early graft function in Islet Transplantation

Vancouver/CANADA

MO07.03 HLA Class I Sensitization in Islet Transplant Recipients – Report from the Collaborative Islet Transplant Registry

B. Naziruddin¹, S. Wease², D. Stablein², F. Barton², T. Berney³, M.R. Rickels⁴, R. Alejandro⁵
¹Dallas/UNITED STATES OF AMERICA, ²Rockville, Md/UNITED STATES OF AMERICA, ³Geneva/SWITZERLAND, ⁴Philadelphia, Pa/UNITED STATES OF AMERICA, ⁵Miami/UNITED STATES OF AMERICA

MO07.04 Combination Therapy with B7-H4 and CTLA-4.Ig Prolongs Islet Allograft Survival

X. Wang¹, J. Hao¹, D. METZGER¹, A. Mui¹, Z. Ao¹, C.B. Verchere¹, L. chen², D. OU¹, G.L. Warnock¹
¹Vancouver/CANADA, ²Baltimore/UNITED STATES OF AMERICA

MO07.05 A novel approach to prevent early loss of transplanted islets by targeting donor islets with a PPARγ agonist prior to transplantation

T. Mera¹, D. Kojima¹, T. Itoh², N. Matsuoka¹, J. Ono¹, S. Kodama¹, Y. Yasunami¹
¹Fukuoka/JAPAN, ²Dallas/UNITED STATES OF AMERICA

MO07.06 Stimulating Mouse and Human Beta Cell Replication by GPR 119 Endogenous Ligand and Synthetic Agonist

Minneapolis/UNITED STATES OF AMERICA

MO07.07 Macrophage recruitment and activation by human islet amyloid polypeptide: a role for amyloid-induced inflammation in islet transplant failure?
TTS 2010 SCIENTIFIC PROGRAM

C. Westwell-Roper, D. Dai, K.J. Potter, C.B. Verchere
Vancouver/CANADA

MO07.08 Rapamycin impairs proliferation of transplanted islet beta cells

G. Parnaud, N. Niclauss, D. Bosco, T. Berney
Geneva/SWITZERLAND

MO07.09 Early loss of transplanted islets in the liver of mice triggered by HMGB1 is prevented by antithrombin III

D. Kojima¹, T. Mera¹, T. Itoh², N. Matsuoka¹, S. Kodama¹, Y. Yasunami¹
¹Fukuoka/JAPAN, ²Dallas/UNITED STATES OF AMERICA

MO07.10 Cotransplantation with Liver Stromal Cells Protects Islet Allografts via Induction of Myeloid Derived Suppressor Cells (MDSC)

H.S. Chou, H.-R. Yang, L. Wang, J.J. Fung, S. Qian, L. Lu
Cleveland/UNITED STATES OF AMERICA

13:30 – 15:00 STATE OF THE ART SYMPOSIA

Session SOTA01 Global strategies to improve deceased organ donation

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: MR 109 - 110

Moderators: Guenter . Kirste, John . Fung

SOTA01.1 Strategic donation intitiatives through DOPKI and the WHO

B. Dominguez-Gil
Madrid/SPAIN

SOTA01.2 Improvement in organ donation in Australia

G. O’Callaghan
Canberra/AUSTRALIA

SOTA01.3 Improving organ donation in Brasil and Latin America
TTS 2010 SCIENTIFIC PROGRAM

E. Rocha
Rio De Janeiro/BRAZIL

SOTA01.4 Increasing utilization of deceased donor kidneys

K. O'Connor
Bellevue/UNITED STATES OF AMERICA

SOTA01 - DISCUSSION

Session SOTA02 Hematopoietic Stem Cell Transplantation

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: MR 220 - 222


SOTA02.1 Genetic networks in stem cell biology and function

G. Sauvageau
Montreal/CANADA

SOTA02.2 Hematopoietic stem self renewal, differentiation and cord blood transplantation

C. Smith
Vancouver/CANADA

SOTA02.3 Innovations in stem cell expansion and transplantation

J. Deeg
Seattle/UNITED STATES OF AMERICA

SOTA02 - DISCUSSION

Session SOTA03 Induction immunosuppression

Monday, August 16, 2010 01:30 PM - 03:00 PM
TTS 2010 SCIENTIFIC PROGRAM

Room: Ballroom A/B

Moderators: Gabriel . Danovitch, Denis . Glotz

SOTA03.1 New molecular targets for biological therapy
F. Vincenti
San Francisco/UNITED STATES OF AMERICA

SOTA03.2 Immunological consequences of different induction strategies
N. Najafian
Boston/UNITED STATES OF AMERICA

SOTA03.3 Induction therapy in renal transplant patients
D. Abramowicz
Anderlecht/BELGIUM

SOTA03.4 Induction therapy in non-renal transplant patients
L. Rostaing
Toulouse/FRANCE

SOTA03 - DISCUSSION

Session SOTA04 Allorecognition and response

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: MR 211

Moderators: Terry . Strom, Anthony . Jevnikar

SOTA04.1 Complementary roles of innate and adaptive immunity
F. Lakkis
Pittsburgh/UNITED STATES OF AMERICA

SOTA04.2 B cell selection and anergy in humans
P. Wilson
TTS 2010 SCIENTIFIC PROGRAM

SOTA04.3 B cells in rejection and tolerance
A.S. Chong
Chicago/UNITED STATES OF AMERICA

SOTA04 - DISCUSSION

Session SOTA05 Antibody-mediated rejection (AMR) The changing face of rejection in heart transplantation

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: Ballroom C

Moderators: Mario . Deng, Stephan . Schueler

SOTA05.1 Pretransplant sensitization
J. Kobashigawa
Beverly Hills/UNITED STATES OF AMERICA

SOTA05.2 Clinical spectrum/presentation of AMR
A. Kfoury
Murray/UNITED STATES OF AMERICA

SOTA05.3 Current therapies for AMR
A. Zuckermann
Vienna/AUSTRIA

SOTA05 - DISCUSSION

Session SOTA06 Living Donor Liver Transplantation

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: MR 118 - 120
TTS 2010 SCIENTIFIC PROGRAM

Moderators: Roy . Calne, Peter . Neuhaus

SOTA06.1 Right and Left grafts and the small-for-size syndrome
C.-M. Lo
Hong Kong/HONG KONG

SOTA06.2 Recipient outcomes in the A2ALL study
A. Shaked
Philadelphia/UNITED STATES OF AMERICA

SOTA06.3 Analysis of worldwide donor morbidity and mortality
D.R. Grant
Toronto/CANADA

SOTA06 - DISCUSSION

Session SOTA07 Islet transplantation: immunology and physiology

Monday, August 16, 2010 01:30 PM - 03:00 PM
Room: MR 212 - 214

Moderators: David . Thompson

SOTA07.1 Significance of Autoimmunity in Clinical Islet Transplantation
R.G. Gill
Edmonton/CANADA

SOTA07.2 Significance of Alloimmunity in Clinical Islet Transplantation
B. Roep
NETHERLANDS

SOTA07.3 Results and Clinical Impact of Islet Autotransplantation: Lessons for Islet Allo-transplantation

SOTA07.4 Impact on Hypoglycemia and Metabolic Effect on Glucose/Insulin/Counter-regulation
TTS 2010 SCIENTIFIC PROGRAM

SOTA07 - DISCUSSION

15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA

Session O12 Experimental Ischemia and Reperfusion Injury

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 220 - 222

Moderators: Matthew . Cooper, Ian . Alwayn

O12.01 Development of Hepatic Ischemia and Reperfusion Injury is Independent of Myeloid Cell-Derived COX-2

Los Angeles/UNITED STATES OF AMERICA

O12.02 TIM-3 Signaling in Innate Immunity-Dominated Liver Injury Induced by Ischemia and Reperfusion (IRI)

Y. Uchida1, B. Ke1, M.C.S. Freitas1, N. Najafian2, R.W. Busuttil1, J.W. Kupiec-Weglinski1
1Los Angeles/UNITED STATES OF AMERICA, 2Boston/UNITED STATES OF AMERICA

O12.03 Treatment with Diannexin post-reperfusion decreases DGF and improves GFR in renal transplant recipients of marginal kidney donors

M. Cooper1, S. Kapur2, R. Stratta3, A. D'Alessandro4, S. Mulgaonkar5, A. Allison6, M. Russell6, S. Knechtle7
1Baltimore/UNITED STATES OF AMERICA, 2New York/UNITED STATES OF AMERICA, 3Winston-Salem/UNITED STATES OF AMERICA, 4Madison/UNITED STATES OF AMERICA, 5Livingston/UNITED STATES OF AMERICA, 6Mountain View/UNITED STATES OF AMERICA, 7Atlanta/UNITED STATES OF AMERICA

O12.04 Augmentation of hepatic ischemia/reperfusion (I/R) injury in liver grafts lacking PD-L1 expression

Pittsburgh/UNITED STATES OF AMERICA
O12.05 Double deficiency of C5aR/C3aR significantly prevents mice from renal ischemia/reperfusion injury

Q. Peng, G. Xing, K. Li, N. Wang, S.H. Sacks, W. Zhou
London/UNITED KINGDOM

O12.06 Tenascin-C: A Critical Player in Hepatic Ischemia and Reperfusion Injury

N. Kuriyama¹, S. Duarte¹, T. Hamada², R.W. Busuttil¹, A.J. Coito¹
¹Los Angeles/UNITED STATES OF AMERICA, ²Tsu/JAPAN

O12.07 Pretransplant Kidney-Specific Treatment to Eliminate the Need for Systemic Immunosuppression

P. Glowacki¹, L. Brasile¹, B. Stubenitsky²
¹Albany/UNITED STATES OF AMERICA, ²Utrecht/NETHERLANDS

O12.08 Repeated-dose, lentiviral-mediated IL-10 airway gene delivery targeting chronic transplanted airway allograft obliteration

Toronto/CANADA

O12.09 A novel role of Phosphoinositide-3 kinase gamma inhibition in suppressing heart allograft rejection

T. Akiyoshi, J. Azzi, S. Yang, R. Moore, R. Abdi
Boston/UNITED STATES OF AMERICA

Session O13 Assays to Predict Allograft Rejection

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 217 - 219

Moderators: Josep M. Campistol, David Rush

O13.01 Anti-Angiotensin Type 1 Receptor (AT1R) Antibody Associated with C4d+ Antibody Mediated Rejection (AMR) in Patients with No Donor HLA Specific Antibody (DHSA)

N. Reinsmoen¹, C.-H. Lai¹, H. Heidecke², K. Cao¹, G. Ong¹, M. Naim¹, Q. Wang¹, J. Mirocha¹, A. Vo¹, S. Jordan¹, D. Dragun²
¹Los Angeles/UNITED STATES OF AMERICA, ²Berlin/GERMANY
O13.02 Effect of Desensitization on DSA Strength and C4d Deposition

D.P. Lucas, M.S. Leffell, R.A. Montgomery, D.S. Warren, A.A. Zachary
Baltimore/UNITED STATES OF AMERICA

O13.03 The immunogenicity of HLA determined at the structural and physiochemical level predicts the occurrence and magnitude of humoral immune responses to alloantigen and correlates with outcome following deceased donor kidney transplantation

V. Kosmoliaptis¹, L. Sharples¹, A.N. Chaudhry¹, R.J. Johnson², S.V. Fuggle², T.R. Dafforn³, D.J. Halsall¹, J.A. Bradley¹, C.J. Taylor¹
¹Cambridge/UNITED KINGDOM, ²Bristol/UNITED KINGDOM, ³Birmingham/UNITED KINGDOM

O13.04 Early Post Transplant DeNovo HLA Antibodies Predict Decline in Lung Allograft Function at 18 months Post Transplant

Toronto/CANADA

O13.05 Clinical Relevance of Pre- and Post- Transplant Alloantibodies Detected by Complement-Dependent Cytotoxicity and Luminex Methodologies in Liver Transplantation

F. Monteiro¹, H. Rodrigues¹, J.E. Kalil-Filho¹, P. Adams², M. Paredes¹, P. Massarolo¹, S. Mies¹, M.C. Ribeiro de Castro¹
¹Sao Paulo/BRAZIL, ²Columbus/UNITED STATES OF AMERICA

O13.06 Recipient C5 Haplotype and Allograft Outcome in Living Donor Kidney Transplantation

J.C. Jeong¹, Y.-H. Hwang¹, S. Hurh¹, H.-S. Kim¹, H. Lee², Y.J. Kim¹, M.-G. Kim¹, N.-I. Byeon¹, M.H. Park¹, J. Yang¹, C. Ahn¹
¹Seoul/KOREA, ²Daejon/KOREA

O13.07 Pre-transplant evaluation of donor-specific alloreactivity and FoxP3 expression: Association with acute graft rejection after kidney transplantation

Hannover/Germany

O13.08 Predicting late interstitial fibrosis/tubular atrophy in kidney allografts: a role for CD44 expression on renal tubuli
O13.09 Levels of sMICA, as detected by a highly sensitive Luminex assay, highly associate with Graft Rejection

D. Fuerst¹, M. Sadeghi², I. LAHDOU², K. Recker¹, H. Schrezenmeier¹, J. Mytilineos³
¹GERMANY, ²Heidelberg/GERMANY, ³Ulm/GERMANY

Session O14 Molecular Mechanisms of Delayed Kidney Graft Function

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 211

Moderators: Christophe . Legendre, Shiro . Takahara

O14.01 High-mobility group box1 (HMGB1) contributes to kidney ischemia reperfusion injury through TLR4 signaling

J. Ma, H. Wu, P. Wang, K.R. WYBURN, S. Chadban
Sydney/AUSTRALIA

O14.02 Hypoxia induced tubular cell (TEC) release of HMGB1 propagates renal injury by effects on TEC viability and NK cell activation

A. Lau, Z.-X. Zhang, S. Wang, A.M. Jevnikar
London/CANADA

O14.03 Association between ICAM-1 and VCAM-1 gene polymorphisms and graft function in early period after kidney transplantation.

Stettin/POLAND


D. Kentrup, S. Reuter, B. Edemir, A. Grabner, H. Pavenstädt, E. Schlatter, E. Büssemaker
Münster/GERMANY

O14.05 HMGB-1 Mediates Injury In Renal Transplantation
TTS 2010 SCIENTIFIC PROGRAM

D.K. Abendroth¹, M. Marzinzig¹, J. Kaden²
¹Ulm/GERMANY, ²Berlin/GERMANY

O14.06 MiRNA and mRNA regulation of delayed graft function in zero-hour deceased organ donor kidney biopsies

J. Wilflingseder¹, P. Perco¹, A. Kainz¹, B. Mayer¹, R. Oberbauer²
¹Vienna/AUSTRIA, ²Linz/AUSTRIA

O14.07 Multivariate Analysis of Causative Factors of Non-Function Kidney in 1856 Kidney Transplants from Non-heart-beating Deceased Donors.

S. Teraoka¹, A. Aikawa¹, K. Takahashi², K. Uchida³, S. Satomi⁴, S. Takahara⁵, S. Oshima⁶, J. Ashikari¹, K. Nomoto¹
¹Tokyo/JAPAN, ²Niigata/JAPAN, ³Nagoya/JAPAN, ⁴Sendai/JAPAN, ⁵Suita/JAPAN, ⁶Aichi/JAPAN

O14.08 High-dose antithrombin can not improve kidney function despite improved graft perfusion in human kidney transplantation – Final results of a prospective, controlled trial

Munich/GERMANY

O14.09 Diagnosing ischemia reperfusion injury: analysis of severity markers in a pig model of kidney transplantation

L. rossard, F. favreau, C. nadeau, R. Thuillier, T. hauet
Poitiers Cedex/FRANCE

Session O15 Access to Treatment and Quality of Life

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 109 - 110

Moderators: Elias . David-Neto, Jeffrey . Zaltzman

O15.01 Disparities in living donor kidney transplantation- The potential role of social networks

K. Ladin, E. Langnas, J.R. Rodrigue, M. Pavlakis, D. Mandelbrot, D.W. Hanto
Boston/UNITED STATES OF AMERICA

O15.02 The Follow Up of Renal Transplant Recipients by Telephone Consultation: Three Years Experience from a Single UK Renal Unit.
TTS 2010 SCIENTIFIC PROGRAM

A. Connor\textsuperscript{1}, S. Fletcher\textsuperscript{2}, R. Higgins\textsuperscript{2}
\textsuperscript{1}Oxford/UNITED KINGDOM, \textsuperscript{2}Coventry/UNITED KINGDOM

O15.03 What Are My Chances? Age-based Disparities In Living Donor Kidney Transplantation

K. Ladin\textsuperscript{1}, Y. Chretriens\textsuperscript{2}, E. Langnas\textsuperscript{1}, J.R. Rodrigue\textsuperscript{1}, M. Pavlakis\textsuperscript{1}, D. Mandelbrot\textsuperscript{1}, D.W. Hanto\textsuperscript{1}
\textsuperscript{1}Boston/UNITED STATES OF AMERICA, \textsuperscript{2}Cambridge/UNITED STATES OF AMERICA

O15.04 Ten Concepts For Ethical Practice and Psychiatric Care Of Transplant Recipients and Living Organ Donors

O.S. Surman
Boston/UNITED STATES OF AMERICA

O15.05 Nonresident Alien Transplantation in the United States

F. Delmonico\textsuperscript{1}, V. Ghimire\textsuperscript{1}, G. Danovitch\textsuperscript{2}
\textsuperscript{1}Newton/UNITED STATES OF AMERICA, \textsuperscript{2}Los Angeles/UNITED STATES OF AMERICA

O15.06 Clinical and socio-demographic determinants of utility among patients with renal transplantation

B. Herczeg\textsuperscript{1}, M. Polgarne Hoschek\textsuperscript{2}, I. mucsi\textsuperscript{1}, M.Z. Molnar\textsuperscript{1}, Z. Kalo\textsuperscript{1}
\textsuperscript{1}Budapest/HUNGARY, \textsuperscript{2}Sopron/HUNGARY

O15.07 Interactive Model of Peer Support of Young Adult Transplant Recipients : The Starbucks Factor

P. Harden, D. Lonsdale, N. Bandler, K. Davies
Oxford/UNITED KINGDOM

O15.08 Qualitative studies better reflect patient distress versus standardized quality of life questionnaires

S. Abbey\textsuperscript{1}, E. De Luca\textsuperscript{1}, M. Shildrick\textsuperscript{2}, P. McKeever\textsuperscript{1}, J. Poole\textsuperscript{1}, O. Mauthner\textsuperscript{1}, H. Ross\textsuperscript{1}
\textsuperscript{1}Toronto/CANADA, \textsuperscript{2}Belfast/IRELAND

O15.09 The quality of life of live related donor in India

New Delhi/INDIA

Session O16 Use of mTOR inhibitors and MPA I
TTS 2010 SCIENTIFIC PROGRAM
Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: Ballroom A/B

Moderators: Klemens . Budde, Josep . Grinyo

O16.01 Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen After Calcineurin Inhibitor Withdrawal in de novo Renal Transplant Patients: 2 Years Follow-Up of the ZEUS Trial

T. Becker¹, W. Arns², K. Budde³, F. Pietruck⁴, U. Eisenberger⁵, W. Fischer⁶, S. Kramer⁶, C. Sommerer⁷, P. Reinke³
¹Hanover/GERMANY, ²Koeln-Merheim/GERMANY, ³Berlin/GERMANY, ⁴Essen/GERMANY, ⁵Bern/SWITZERLAND, ⁶Nuremberg/GERMANY, ⁷Heidelberg/GERMANY

O16.02 Efficacy Benefit With Everolimus and Very Low Tacrolimus Exposure in De novo Renal Transplant Recipients: 12 Month Results of the ASSET Study

R. Hené¹, R.M. Langer², S. Vitko³, M. Christiaans⁴, K. Ciechanowski⁵, E. Cassuto⁶, J. Dominguez⁷, J. Wyzga⁸, A.C. Henriques⁹, J. Pascual¹⁰
¹Utrecht/NETHERLANDS, ²Budapest/HUNGARY, ³Prague/CZECH REPUBLIC, ⁴Maastricht/NETHERLANDS, ⁵Szczecin/POLAND, ⁶Nice/FRANCE, ⁷Santiago/CHILE, ⁸Warszawa/POLAND, ⁹Porto/PORTUGAL, ¹⁰Barcelona/SPAIN

O16.03 De novo Everolimus Combined with Reduced Cyclosporine Exposure - Analysis of renal function at 12 Months in Renal Transplant Recipients

¹Salt Lake City/UNITED STATES OF AMERICA, ²Ann Arbor/UNITED STATES OF AMERICA, ³Seoul/KOREA, ⁴Lexington/UNITED STATES OF AMERICA, ⁵Melbourne/ AUSTRALIA, ⁶Kosice/SLOVAK REPUBLIC, ⁷Shreveport,/UNITED STATES OF AMERICA, ⁸East Hanover/UNITED STATES OF AMERICA, ⁹Sao Paulo/BRAZIL

O16.04 Everolimus With Reduced Exposure of Cyclosporine: Efficacy Results From a Randomized Prospective Study in 833 De novo Renal Transplant Recipients

H. Tedesco-Silva¹, Y.S. Kim², T. Johnston³, R. Walker⁴, G. Tufvesson⁵, G. Zibari⁶, K. Mange⁷, C. Panis⁷, Z. Wang⁷, D. Cibrik⁸
¹Sao Paulo/BRAZIL, ²Seoul/KOREA, ³Lexington/UNITED STATES OF AMERICA, ⁴Melbourne/ AUSTRALIA, ⁵Uppsala/SWEDEN, ⁶Shreveport,/UNITED STATES OF AMERICA, ⁷East Hanover/UNITED STATES OF AMERICA, ⁸Ann Arbor/UNITED STATES OF AMERICA

O16.05 Correlation of Everolimus Exposure With Efficacy and Safety Outcomes: Results From a Multicenter Study in Renal Transplantation Using Reduced CsA Exposure
O16.06 Intensified dose of enteric-coated mycophenolate sodium (EC-MPS) for 6 weeks, in combination with anti-IL2R induction, cyclosporine micro-emulsion (CsA-ME) with or without steroids, in adult de novo low immunological risk kidney transplant recipients: Final efficacy and safety results of a prospective multicenter randomized open-label study: DOMINOS Study.

G. TOUCHARD1, Y. LEBRANCHU2, G. MOURAD2, L. Rostaing2, S. QUERE2, K. CHAOUCHE-TEYARA2, F. VILLEMAIN2
1Poitiers/France, 2On Behalf Of Dominos French Group/France

O16.07 Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium (EC-MPS) offers Early Adequate Mycophenolic Acid (MPA) Exposure in De Novo Renal Transplant Recipients

H. Tedesco-Silva1, C. Sommerer2, W. Arns3, F. Contieri4, D.M. Kuypers5, S. Vaidya6, K. Budde7
1Sao Paulo/Brazil, 2Heidelberg/Germany, 3Cologne/Germany, 4Curitiba/Brazil, 5Leuven/Belgium, 6East Hanover/United States of America, 7Berlin/Germany

O16.08 How delayed graft function impacts exposure to mycophenolic acid in patients following renal transplantation.

T. van Gelder
Rotterdam/Netherlands

O16.09 Immunosuppressive regimen for first kidney or kidney/pancreas transplant significantly impacts sensitization at the time of second transplantation.

K.L. Dawson, S.J. Patel, R.J. Knight, A.O. Gaber
Houston/United States of America

Session O17 Non-Viral Infections in Transplantation

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 202 - 204

Moderators: Rainaldo . Bestetti, Michael . Ison
TTS 2010 SCIENTIFIC PROGRAM

O17.01 Randomized Prospective Trial of Depleting Antibody Induction in Kidney and Pancreas Transplantation: Infectious Complications

R.J. Stratta, W. Doares, A.C. Farney, J. Rogers, L. Hart
Winston-Salem/UNITED STATES OF AMERICA

O17.02 Reactivation of Chagas disease after renal transplantation

J. de la Fuente, C. Chiurchiu, J. Bittar, T. Alvarellos, W. Douthat, J. de Arteaga, P.U. Massari
Córdoba/ARGENTINA

O17.03 Invasive aspergillosis after liver transplantation: Risk factors, morbidity and prophylaxis

F. Saliba, V. Delvart, P. Ichai, N. Kassissi, F. Botterel-Chartier, D. Azoulay, M. Kouassi, R. Adam, D. Castaing, D. Samuel
1Villejuif/FRANCE, 2Creteil/FRANCE

O17.04 Pretransplant Infectious Disease Screening of Donors and Recipients from Endemic Regions

A.A. Dowton, C.N. Kotton
Boston/UNITED STATES OF AMERICA

O17.05 Immunity to pneumococcal antigens in kidney transplant recipients

M. Lindemann, F.M. Heinemann, P.A. Horn, O. Witzke
Essen/GERMANY

O17.06 Donor-Derived Disease Transmission Events in the United States 2006 - 2009: A Report from the OPTN Ad Hoc Diseases Transmission Advisory Committee (DTAC)

Richmond/UNITED STATES OF AMERICA

O17.07 Efficacy and Long-term Outcome of Amphotericin B Lipid Complex (ABLC) Prophylaxis in High Risk Liver Transplant Recipients in the current practice

F. Saliba, V. Delvart, P. Ichai, N. Kassissi, F. Botterel-Chartier, M. Kouassi, D. Azoulay, R. Adam, D. Castaing, S. Brettegne, D. Samuel
1Villejuif/FRANCE, 2Creteil/FRANCE

O17.08 The Impact of Post Operative Sepsis on Outcomes in Liver Transplantation
Session O18 Biologic and Therapeutic Advances in Heart Transplantation I

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 205 - 207


O18.01 Effects of Donor Pretreatment with Dopamine on Graft Function after Heart Transplantation: Data from a randomized controlled trial.

U.T. Benck, S. Hoeger, U. Goettmann, D. Doenmez, B. Yard, P. Schnuelle
Mannheim/GERMANY

O18.02 Initiation of Everolimus with Calcineurin Inhibitor (CNI) Minimization in Thoracic Transplant Patients with Impaired Renal Function: 24 Months Follow-up of a Multicenter, Randomized Study

L. Gullestad¹, H. Eiskjaer², G.C. Riise³, V. Sigurdardottir³, S.-A. Mortensen⁴, L. Mared⁵, B. Ekmehag⁵, S. Simonsen⁶, Ø. Bjørtuft⁶, B. Rundqvist³, K. Jansson⁷, E. Gude⁶, D. Solbu⁶, M. Iversen⁴
¹0027/NORWAY, ²Aarhus/DENMARK, ³Gothenburg/SWEDEN, ⁴Copenhagen/DENMARK, ⁵Lund/SWEDEN, ⁶Oslo/NORWAY, ⁷Linköping/SWEDEN

O18.03 Cardiac Transplant Candidates with LVAD may have Circulating Level of HLA-Specific Natural Antibodies

A. Nikaein¹, N. El-Awar², J. Hunt¹
¹Dallas/UNITED STATES OF AMERICA, ²Los Angeles/UNITED STATES OF AMERICA

O18.04 Donor Selection by Virtual Crossmatching for Sensitized Heart Transplant Patients

D.-F. Chen¹, N.L. Reinsmoen⁷, B.O. Burgess¹, G.F. Egnaczyk¹, C.B. Patel¹, C.A. Milano¹, J.G. Rogers¹
¹Durham/UNITED STATES OF AMERICA, ²Los Angelos/UNITED STATES OF AMERICA
O18.05 Patients on long-term betaceptor-antagonist treatment with peak oxygen consumption above the cut-off point for heart transplantation listing have worse survival if a restrictive pattern in lung function tests occurs

M.K. Lizak, M. Zakliczynski, A. Jarosz, M. Zembala
Zabrze/POLAND

O18.06 Incidence and Management of Surgical Wound Complications in De Novo Heart Transplant Recipients Treated with Everolimus

M.J. Barten¹, J.M. Arizon², G. Dong³, H. Eisen⁴, J. Kobashigawa⁵, H.B. Lehmkuhl⁶, C. Pellegrini⁷, H. Ross⁸, A. Zuckermann⁹
¹Leipzig/GERMANY, ²Cordoba/SPAIN, ³East Hanover/UNITED STATES OF AMERICA, ⁴Philadelphia/UNITED STATES OF AMERICA, ⁵Los Angeles/UNITED STATES OF AMERICA, ⁶Berlin/GERMANY, ⁷Pavia/ITALY, ⁸Toronto/CANADA, ⁹Vienna/AUSTRIA

O18.07 Incidence of ventricular arrhythmias in patients with continuous-flow left ventricular assist devices as a bridge to cardiac transplantation: HeartMate XVE versus HeartMate II

A.S. Nagji, D.J. Lapar, C.C. Ballew, J.D. Bergin, J.A. Kern
Charlottesville/UNITED STATES OF AMERICA

O18.08 Emergency Heart Transplantation Outcome: the Italian Experience

C. De Cillia, S. Venettoni, A. Ricci, M. Caprio, F. Lolli, L. Rizzato, A. Tancredi, A. Nanni Costa
Roma/ITALY

O18.09 Effect of Conversion From Calcineurin Inhibitors (CNIs) to Sirolimus on Renal Function in Cardiac Transplant Recipients With Mild to Moderate Renal Insufficiency: Interim Safety and Efficacy Results

M.G. Crespo-Leiro¹, A. Zuckermann², A. Keogh³, D. Mancini⁴, F. González-Vilchez⁵, L. Almenar⁶, S. Brozena⁷, H. Eisen⁷, S. See Tai⁸, S. Kushwaha⁹
¹La Coruña/SPAIN, ²Vienna/AUSTRIA, ³Sydney/AUSTRALIA, ⁴New York/UNITED STATES OF AMERICA, ⁵Santander/SPAIN, ⁶Valencia/SPAIN, ⁷Philadelphia/UNITED STATES OF AMERICA, ⁸Collegeville/UNITED STATES OF AMERICA, ⁹Rochester/UNITED STATES OF AMERICA

Session O19 The Problem of Viral Hepatitis in Liver Transplantation
Moderators: Sheung Tat . Fan, Norman . Kneteman

O19.01 The impact of Sirolimus based immunosuppression on response to anti-HCV therapy after liver transplantation
S. Asthana¹, K. Burak², V. Bain¹, G. Meeberg¹, D. Bigam¹, A.M..J. Shapiro¹, N.M. Kneteman¹
¹Edmonton/CANADA, ²Calgary/CANADA

O19.02 Hepatitis C (HCV)-3 Study: Lessons Learned From a Multicenter Liver Transplantation (OLT) Trial.
G. Klintmalm¹, C.G. Fasola², G. Netto³, L. Jennings¹, H..C..V...3. Study Group¹
¹Dallas/UNITED STATES OF AMERICA, ²Temple/UNITED STATES OF AMERICA, ³Baltimore/UNITED STATES OF AMERICA

O19.03 Elevated CXCR3 Content on Lymphocytes from HIV/HCV Infected Patients May Facilitate T-Cell Recruitment To The Liver
P.M. Kimball, C. Glover, R. Stirling
Richmond/UNITED STATES OF AMERICA

O19.04 Antiviral treatment of HCV recurrence after liver transplantation: impact on costs and quality of life.
C. Logge, E. Vettorazzi, L. Fischer, B. Nashan, M. Sterneck
Hamburg/GERMANY

O19.05 Limiting HCV Progression in Transplant Recipients Through Conversion to Sirolimus Based Immunosuppression
Dallas/UNITED STATES OF AMERICA

O19.06 Donor Risk Index and Associated Donor Variables May Influence Serum Hepatitis C Viral Load
T.R. Flohr¹, T. Hranjec¹, S.C. Kumer¹, J.B. Stokes¹, H. Bonatti¹, R.G. Sawyer¹, K. Brayman¹, T.L. Pruett², T.M. Schmitt¹
¹Charlottesville/UNITED STATES OF AMERICA, ²Minneapolis/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

O19.07 Factors Affecting Recurrence of Hepatitis C after Liver Transplantation—Correlation with Histology on Protocol Liver Biopsies.

Dallas/UNITED STATES OF AMERICA

O19.08 Risk factors and long-term prognosis of hepatitis B virus recurrence after liver transplantation under prophylaxis of combined low dosed hepatitis B immunoglobulin and nucleoside analogues after liver transplantation

L. Minru
Guangzhou/CHINA

O19.09 Effect of MDR1 and ABCG8 polymorphisms on hepatitis C recurrence following liver transplantation

S.M. Iacob¹, V.R. Cicinnati¹, A. Dechene¹, C.G. Klein¹, M. Lindemann¹, G.C. Sotiropoulos¹, A. Radtke², I. Popescu³, G. Gerken¹, A. Paul¹, S. Beckebaum¹
¹Essen/GERMANY, ²Kiel/GERMANY, ³Bucharest/ROMANIA

Session O20 Options and Outcomes in the Sensitized Kidney Recipient

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: Ballroom C

Moderators: Mark . Stegall, E Steve . Woodle

O20.01 Terminal Complement Inhibition Decreases Early Acute Humoral Rejection in Sensitized Renal Transplant Recipients.

Rochester/UNITED STATES OF AMERICA

O20.02 Proteasome Inhibition Depletes Alloantibody-Secreting Plasma Cells and Improves Efficacy of Plasma Exchange in Highly Sensitized Renal Allograft Candidates

S. Raghavaiah, T.S. Diwan, M.D. Stegall, J.M. Burns, J.M. Gloor
Rochester/UNITED STATES OF AMERICA
O20.03 Outcomes of Patients Desensitized For a Positive Crossmatch Compared To Patients Who Are Not Offered This Option

Baltimore/UNITED STATES OF AMERICA

O20.04 Long-term outcome according to levels of preformed donor-specific HLA-antibodies in kidney transplantation

Paris/FRANCE

O20.05 Combined Liver-Kidney Transplants: Do Livers Always Protect Kidneys in Allosensitized Recipients?

M. Askar¹, J.D. Schold¹, B. Eghtesad¹, S.M. Flechner¹, B. Kaplan², L. Klingman¹, N. Zein¹, J.J. Fung¹, T. Srinivas¹
¹Cleveland/UNITED STATES OF AMERICA, ²Tucson/UNITED STATES OF AMERICA

O20.06 Report from an 80 Transplant Center Multi-regional Kidney Paired Donation Program

M. Rees¹, J. Kopke², R. Pelletier³, L. Chan⁴, L. Melton⁵, J. Rogers⁶, O. Pankewycz⁷, T. Taber⁸, B. Nibhanupudy⁹, C. Young¹⁰, A.B. Leichtman¹¹, C. Smith¹², S. Rees¹², L. Reece¹²
¹Toledo/UNITED STATES OF AMERICA, ²Cincinnati/UNITED STATES OF AMERICA, ³Columbus/UNITED STATES OF AMERICA, ⁴Denver/UNITED STATES OF AMERICA, ⁵Dallas/UNITED STATES OF AMERICA, ⁶Winston-Salem/UNITED STATES OF AMERICA, ⁷Buffalo/UNITED STATES OF AMERICA, ⁸Indianapolis/UNITED STATES OF AMERICA, ⁹Orlando/UNITED STATES OF AMERICA, ¹⁰Birmingham/UNITED STATES OF AMERICA, ¹¹Ann Arbor/UNITED STATES OF AMERICA, ¹²Maumee/UNITED STATES OF AMERICA

O20.07 Rapid Expansion of Live Donor Kidney Transplantation at a Single Center Using Kidney Paired Donation

A. Bingaman, F. Wright, M. Kapturczak, C. Murphey
San Antonio/UNITED STATES OF AMERICA

O20.08 Proteasome Inhibitor-Based Antihumoral Therapy Associated Peripheral Neuropathy: A Prospective Analysis in Renal Transplant Candidates and Recipients

Cincinnati/UNITED STATES OF AMERICA
O20.09 Prospective, Staged Trial Of A Proteasome Inhibitor-Based Desensitization Protocol for Kidney Transplant Candidates

Cincinnati/UNITED STATES OF AMERICA

Session 021 Clinical Islet Transplantation

Monday, August 16, 2010 03:30 PM - 05:00 PM
Room: MR 212 - 214

Moderators: Thierry . Berney, Annika . Tibell

O21.01 Effect of ASKP1240 (4D11), a Fully Human Anti-CD40 Monoclonal Antibody, on a Single Donor-derived Allogeneic Islet Transplantation in Cynomolgus Monkeys

M. Watanabe¹, K. Yamashita¹, D. Fukumori¹, T. Suzuki¹, H. Kamachi¹, D. Kuraya¹, Y. Koshizuka¹, M. Ogura¹, T. Yoshida¹, F. Sakai², T. Miura³, M. Matsushita¹, S. Todo¹
¹Sapporo/JAPAN, ²Tsukuba/JAPAN, ³Shizuoka/JAPAN

O21.02 A comparison of islet transplantation with medical therapy on the progression of diabetic complications

Vancouver/Canada

O21.03 Alemtuzumab induction and Tac/MMF maintenance substantially improves long term insulin independence rates after clinical islet transplantation, and strongly suppresses both auto and alloreactivity

A.M. Shapiro¹, C. Toso², A. Koh¹, S.R. Calne³, T. Kin¹, D. O'Gorman¹, A. Malcolm¹, P. Dinyari¹, S. Imes¹, R. Owen¹, N.M. Kneteman¹, D. Bigam¹, P. Senior¹, B. Roep⁴
¹Edmonton/CANADA, ²Geneva/SWITZERLAND, ³Cb2 2as/UNITED KINGDOM, ⁴NI-233za/NETHERLANDS

O21.04 Islet Allograft Survival in Type 1 Diabetic Patients Using Calcineurin Inhibitor-free Protocols Based on T-Cell Adhesion or Costimulation Blockade

A.M. Posselt, G. Szot, L. Frassetto, U. Masharani, M. Tavakol, F. Vincenti, L. Fong, J. Bluestone, P. Stock
San Francisco/UNITED STATES OF AMERICA

O21.05 Double blockage of IL-1beta and TNF-alpha facilitated single donor islet transplantation
O21.06 Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans

Praha/CZECH REPUBLIC

O21.07 Influence of donor age on islet isolation and transplantation outcome

N. Niclauss1, D. Bosco1, P. Morel1, S. Demuyllder-Mischler1, C. Brault2, G. Parnaud1, L. Giovannoni1, L. Badet2, P.-Y. Benhamou2, T. Berney1
1Geneva/SWITZERLAND, 2Lyon/FRANCE, 3Grenoble/SWITZERLAND

O21.08 Measuring of HMGB1 is a new useful potency assay to predict outcome of islet transplantation in mice.

T. Itoh1, H. Noguchi1, M. Takita1, K. Sugimoto1, M. Shimoda2, B. Naziruddin2, M.F. Levy2, Y. Yasunami3, S. Matsumoto1
1Fort Worth/UNITED STATES OF AMERICA, 2Dallas/UNITED STATES OF AMERICA, 3Fukuoka/JAPAN

O21.09 Viable Islet Dose Based on Oxygen Consumption Rate Predicts Clinical Islet Autotransplant Outcome

K.K. Papas1, M. Bellin1, D.E. Sutherland1, K. Mueller1, E.S. Avgoustiniatos1, A.N. Balamurugan1, P.R. Rozak1, G. Loganathan1, D. Qian2, J.C. Niland2, B.J. Hering1
1Minneapolis/UNITED STATES OF AMERICA, 2Duarte/UNITED STATES OF AMERICA
TUESDAY, AUGUST 17

07:00 – 08:15 SUNRISE SYMPOSIA

Session SUN06 ELPAT: Altruistic Organ Donation to a Stranger

Tuesday, August 17, 2010 07:00 AM - 08:15 AM
Room: MR 211

Moderators: Willem . Weimar, Bryce . Kiberd

SUN06.1 Altruistic kidney and liver donors

L. Wright
Toronto/CANADA

SUN06.2 "The calculating Altruist"

L. De Castro
?/SINGAPORE

SUN06.3 Should health professionals encourage Samaritan donation?

M.T. Hilhorst
Rotterdam/NETHERLANDS

SUN06 - DISCUSSION

Session SUN07 Genetically Modified Pigs For Xenotransplantation

Tuesday, August 17, 2010 07:00 AM - 08:15 AM
Room: MR 212 - 214

Moderators: Peter . Cowan, Jean-Paul . Soulillou

SUN07.1 Gal KO and complement regulators: how far have they taken us?

D.K.C. Cooper
Pittsburgh/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

SUN07.2 Promoters and transgenes: what works and what doesn’t

P. Cowan
Melbourne/AUSTRALIA

SUN07.3 Genetic modification of islets: the case for and against

B.J. Hering
Minneapolis/UNITED STATES OF AMERICA

SUN07 - DISCUSSION

Session SUN08 What's new in transplant ID

Tuesday, August 17, 2010 07:00 AM - 08:15 AM
Room: MR 205 - 207


SUN08.1 H1N1: Impact in solid organ transplantation

D. Kumar
Edmonton/CANADA

SUN08.2 PML: role of rituximab and MMF

E. Major
/.UNITED STATES OF AMERICA

SUN08.3 Resistant Bacteria in Solid Organ Transplant

S. Huprikar
New York/UNITED STATES OF AMERICA

SUN08.4 HHV-8 and solid organ transplantation

R. Razonable
Rochester/UNITED STATES OF AMERICA

SUN08 - DISCUSSION
Session SUN09 "How can we reduce the 30 day mortality after heart transplantation?"

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**
**Room: MR 220 - 222**

**Moderators:** Finn . Gustafsson, Heather . Ross

SUN09.1 Optimizing Donation and Donor Organs: Managing the Extended Donor

M. Zembala
Zabrze/POLAND

SUN09.2 Ischemia-reperfusion injury and use of VAD

D.H. Freed
Winnipeg/CANADA

SUN09.3 Perioperative CVICU management in the heart transplant recipient

P. Murphy
Toronto/CANADA

SUN09 - DISCUSSION

---

Session SUN10 Proteomics in Transplantation - a BC Proteomics Network Symposium

**Tuesday, August 17, 2010 07:00 AM - 08:15 AM**
**Room: MR 202 - 204**

**Moderators:** Christoph . Borchers, Juergen . Kast

SUN10.1 Innovations and applications of proteomics to transplantation biology and medicine

L. Anderson
Washington/UNITED STATES OF AMERICA

SUN10.2 Biomarkers in Transplantation
C. Borchers  
Victoria/CANADA

SUN10.3 From Targets to Therapies

B. Verchere  
Vancouver/CANADA

SUN10 - DISCUSSION

Session SUN11 The Road To Tolerance (One Lambda Symposium)

Tuesday, August 17, 2010 07:00 AM - 08:15 AM  
Room: Hall A

Moderators: Carl Groth

SUN11.1 Tolerance: From Animal Models to the Clinic

D.H. Sachs  
Boston/UNITED STATES OF AMERICA

SUN11.2 Inducing Immune Tolerance and Chimerism after Kidney Transplantation

S. Strober  
Stanford/UNITED STATES OF AMERICA

SUN11.3 New Simplified Clonal Deletion Protocol with Bortezomib

H.L. Trivedi  
Ahmedabad/INDIA

SUN11.4 Paving the Road to Tolerance: DAWN versus Weaners

P. Terasaki  
Los Angeles/UNITED STATES OF AMERICA

SUN11 - DISCUSSION
08:30 – 08:30 PLENARY SESSION

Session PL02 Allorecognition and Tolerance

Tuesday, August 17, 2010 08:30 AM - 10:00 AM
Room: Ballroom A/B

Moderators: Gerhard . Opelz, Lori . West

PL02.1 Why is the Alloresponse so Strong?
P. Marrack
Denver/UNITED STATES OF AMERICA

PL02.2 Inducing Transplantation Tolerance
C. Larsen
Atlanta/UNITED STATES OF AMERICA

PL02.3 Tolerance in Clinical Transplantation
D.H. Sachs
Boston/UNITED STATES OF AMERICA

10:30 – 12:00 CONCURRENT MORNING SYMPOSIA

Session O22 B Cells and Antibody Response

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 202 - 204

Moderators: William . Baldwin, Mark . Pescovitz

O22.01 Lack of memory-B-cells facilitates development of donor-specific blood group tolerance after ABO-incompatible heart transplantation in early childhood

Edmonton/CANADA
O22.02 Is blood group antigen expression on vascular endothelium required for B cell tolerance induction following ABO-incompatible transplant during immunological immaturity?

M. Jeyakanthan, X. Zhou, K. Tao, R.V. Rajotte, M. Mengel, L.J. West
Edmonton/CANADA

O22.03 Liver Sinusoidal Endothelial Cells expressing Carbohydrates Render Reactive B cells Tolerant

Y. Igarashi, T. Irei, H. Ohdan
Hiroshima/JAPAN

O22.04 Blocking the Formation of Intra-graft Lymphoid Tissue Influences Effector Humoral Responses

1Cambridge/UNITED KINGDOM, 2New Haven/UNITED STATES OF AMERICA

O22.05 A Novel Mechanism for Alloantibody Production.

Cambridge/UNITED KINGDOM

O22.06 Impaired Alloreactive CD8 T Cell Memory Response and Prolonged Allograft Survival in Sensitized Recipients in the Absence of Humoral Immunity

H. Ji, X. Shen, F. Gao, Y. Zhai, R.W. Busuttil, J.W. Kupiec-Weglinski
Los Angeles/UNITED STATES OF AMERICA

O22.07 A New Method To Prevent Humoral Response In Skin Allografts

L. Brasile, P. Glowacki, B. Stubenitsky
1Albany/UNITED STATES OF AMERICA, 2Utrecht/NETHERLANDS

O22.08 Allospecific B cells can receive effective help for generating anti-MHC class I alloantibody through the acquisition and presentation of additional graft antigens.

Cambridge/UNITED KINGDOM

O22.09 The reduction of Raf/MEK/ERK pathway by anti-ABO association may be the identity of accommodation in ABO-incompatible transplantation.
TTS 2010 SCIENTIFIC PROGRAM

K. Iwasaki¹, Y. Miwa¹, M. Haneda¹, H. Ogawa², K. Uchida¹, A. Takeda¹, A. Nakao¹, T. Kobayashi¹
¹Nagoya/JAPAN, ²Obihiro/JAPAN

Session O23 Activation and Role of T Regulatory Cells

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 205 - 207

Moderators: Megan . Levings, Nader . Najafian

O23.01 Blockade of OX40 costimulation reduces the alloreactive effector T cell pool and prevents CD8+ T cell mediated skin allograft rejection.

G. Kinnear¹, K.J. Wood¹, D. Marshall², N.D. Jones¹
¹Oxford/UNITED KINGDOM, ²Slough/UNITED KINGDOM

O23.02 Cytotoxic CD8 T Cells Receive Help From Indirect Pathway CD4 T Cells by Presenting Processed Alloantigen on Acquired MHCII

Cambridge/UNITED KINGDOM

O23.03 Heterologously primed T cells are required to initiate CD4-dependent skin and islet graft rejection

B. Fazekas de St Groth¹, Y.W. Loh², D. Gracey³, B. Roediger¹, S.I. Alexander⁴
¹Newtown/AUSTRALIA, ²Locked Bag #6/AUSTRALIA, ³Camperdown/AUSTRALIA, ⁴Westmead/AUSTRALIA

O23.04 A strategy to inhibit effector T cell infiltration of allograft tissues by stimulation of the chemokine receptor CXCR3

G. O'Boyle, P. Newton, Y. Jenkins, S. Ali, J.A. Kirby
Newcastle Upone Tyne/UNITED KINGDOM

O23.05 Memory T cells migrate to and reject vascularized cardiac allografts independent of CXCR3 and CCR5

M. Oberbarscheidt, J. Walch, Q. Li, J. Walters, A. Williams, G. Camirand, F. Lakkus
Pittsburgh/UNITED STATES OF AMERICA

O23.06 Interleukin-33 prolongs allograft survival during chronic cardiac rejection
O23.07 Lymphocyte subpopulations including FoxP3+ regulatory T-cells and BAFF/BAFF-R in pediatric kidney transplantation

A. Lehnhardt, F. Dunst, M. van Husen, D.E. Müller-Wiefel, M. Koch, M.J. Kemper
Hamburg/GERMANY

O23.08 Donor-derived Influenza-specific Memory T cells Dominate the Immune Response in Recipients Following Mouse Liver Transplantation

I. Klein¹, N.K. Polakos¹, D.J. Topham², N.I. Crispe³
¹San Francisco/UNITED STATES OF AMERICA, ²Rochester/UNITED STATES OF AMERICA, ³Seattle/UNITED STATES OF AMERICA

O23.09 Regulatory T cells and Th17 T cell responses in the control of autoantibody-mediated allograft vasculopathy.

Cambridge/UNITED KINGDOM

Session O24 Molecular Mechanisms of Chronic Kidney Graft Injury

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 211

Moderators: Sundaram, Hariharan, Dietmar, Abendroth

O24.01 Molecular markers of short and long term outcomes post kidney transplantation

Richmond/UNITED STATES OF AMERICA

O24.02 Kidney transplant injury is associated with a significant endoplasmic reticulum stress response

T.F. Mueller, T. Simmen, C. Compston, V.A. Luyckx
Edmonton/CANADA

O24.03 Impact of polymorphisms of the renin-angiotensin-aldosterone system on long-term outcome in renal transplantation
O24.04 Intra-graft Expression of Immune/inflammatory Genes on 1-Yr Biopsies is Associated with Subsequent Decline in GFR in Living Donor Kidney Transplantation

W. Park¹, M. Griffin², M.D. Stegall¹, F. Cosio¹
¹Rochester/UNITED STATES OF AMERICA, ²Galway/IRELAND

O24.05 MicroRNA Expression Signatures Distinguish Human Renal Allografts with Interstitial Fibrosis/Tubular atrophy from Normal

T. Muthukumar, F. Mueller, D. Anglicheau, V. Sharma, R. Ding, D. Dadhana, M. Suthanthiran
New York/UNITED STATES OF AMERICA

O24.06 Genetic heterogeneity of chronic rejection of kidney allografts

P. Hribova, I. Brabcova, R. Zachoval, J. Slatinska, E. Honsova, O. Viklicky
Prague 4/CZECH REPUBLIC

O24.07 Patients with endstage renal disease have dysfunctional HDL which recovers after successful renal transplantation

M. van der Giet, M. Schuchardt, T. Huang, M. Tölle
Berlin/GERMANY

O24.08 Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection

O. Thaunat, C. Deteix, B. McGregor, V. Dubois, E. Morelon
Lyon/FRANCE

O24.09 Increased number of glomerular (G) CD68 + cells is the single most sensitive predictor of transplant glomerulopathy (TG) and graft loss

J.C. Papadimitriou, C. Drachenberg, A. Haririan, R. Munivenkatappa
Baltimore/UNITED STATES OF AMERICA

Session O25 Organ Donation and Allocation II

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 109 - 110
O25.01 Identification of a combined clinico-histological score for the allocation of kidneys from expanded criteria donors (ECD)

M. Rossini, M. Fiorentino, A. Schena, G. Lucarelli, F.P. Selvaggi, F.P. Schena, P. Ditonno, G. Grandaliano
Bari/ITALY

O25.02 Kidneys Retrieved from Donors with Prolonged Time to Asystole Increase the Organ Pool Without Compromising DCD Outcome

Cambridge/UNITED KINGDOM

O25.03 A large-scale survey of the Singapore public on the awareness of the Human Organ Transplant Act and its relationship to altruistic behaviour.

T. Kee, V. Joshi, K.V.D. Erf, W.L. Chow, T.S. Swah, P. Goh, G. Tan, S. Yeo, R. Tan, C. Lim, J. Lim, C.M. Chan
Singapore/SINGAPORE

O25.04 Global Survey Assessing Muslim Attitudes To Organ Donation

A. Sharif, P. Cockwell, G. Lipkin, S. Ball, R. Borrows
Birmingham/UNITED KINGDOM

O25.05 Use of N-Acetylcyestein during liver procurement: final report of a prospective randomized controlled trial.

Padova/ITALY

O25.06 Normothermic Perfusion Induces Ischaemic Preconditioning In Livers From Donors After Cardiac Death And Protects Them From Extended Preservation and Reperfusion Injury

Oxford/UNITED KINGDOM

O25.07 Continuous Improvement of Pulsatile Perfusion Parameters Over 12 Hours in Marginal Kidney Graft Preservation.

Miami/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

O25.08 Prolonged Cold Ischemia Time Before Double Kidney Transplantation Does Not Negatively Impact on Outcomes When Preserved by Pulsatile Machine Perfusion.

Miami/UNITED STATES OF AMERICA

O25.09 Is the increase in DCD organ donors in the UK contributing to a decline in DBD donors?

D.M. Summers1, C. Counter2, J.A. Bradley1, J. Neuberger2
1Cambridge/UNITED KINGDOM, 2Bristol/UNITED KINGDOM

Session O26 New Immunosuppressive Agents

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: Ballroom A/B


O26.01 Safety Profile of Belatacept in Kidney Transplant Recipients from a Pooled Analysis of Phase II and Phase III Studies

J. Grinyo1, B. Charpentier2, J.O.M. Pestana3, H. de Jonge4, F. Vincenti5, R. Shi6, M. Agarwal7, D. Thomas5, C. Larsen8
1Barcelona/SPAIN, 2Paris/FRANCE, 3São Paulo/BRAZIL, 4Leuven/BELGIUM, 5San Francisco/UNITED STATES OF AMERICA, 6Hopewell/UNITED STATES OF AMERICA, 7Princeton/UNITED STATES OF AMERICA, 8Atlanta/UNITED STATES OF AMERICA

O26.02 Immunosuppression with Belatacept-based, CNI-Avoiding and Steroid-Avoiding Regimens vs a Tacrolimus-based, Steroid-avoiding Regimen in Kidney Transplant Patients: Results of a 1-year, Randomized Study

R. Ferguson1, F. Vincenti2, D. Kaufman3, E.S. Woodle4, B. Marder5, F. Citterio6, W.H. Marks7, Y. Dong8, M. Agarwal9, P. Garg9, J.M. Grinyó10
1Columbus/UNITED STATES OF AMERICA, 2San Francisco/UNITED STATES OF AMERICA, 3Chicago/UNITED STATES OF AMERICA, 4Cincinnati/UNITED STATES OF AMERICA, 5Denver/UNITED STATES OF AMERICA, 6Rome/ITALY, 7Seattle/UNITED STATES OF AMERICA, 8Hopewell/UNITED STATES OF AMERICA, 9Princeton/UNITED STATES OF AMERICA, 10Barcelona/SPAIN

O26.03 Switch From a CNI- to a Belatacept-Based Immunosuppressive Regimen in Kidney Transplant Recipients is Safe and Results in Better Renal Function: 12 Month Results from a Phase II Study
O26.04 Belatacept vs Cyclosporine in ECD Kidney Transplants: Two-Year Outcomes from the BENEFIT-EXT Study

1Le Kremlin-Bicêtre/FRANCE, 2Atlanta/UNITED STATES OF AMERICA, 3Sâo Paulo/BRAZIL, 4Leuven/BELGIUM, 5San Francisco/UNITED STATES OF AMERICA, 6New York/UNITED STATES OF AMERICA, 7Hopewell/UNITED STATES OF AMERICA, 8Princeton/UNITED STATES OF AMERICA, 9Barcelona/SPAIN

O26.05 Belatacept vs Cyclosporine in Kidney Transplant Recipients: Two-Year Outcomes from the BENEFIT Study

1Atlanta/UNITED STATES OF AMERICA, 2Barcelona/SPAIN, 3Paris/FRANCE, 4Sâo Paulo/BRAZIL, 5Toulouse/FRANCE, 6Leuven/BELGIUM, 7Hopewell/UNITED STATES OF AMERICA, 8Princeton/UNITED STATES OF AMERICA, 9San Francisco/UNITED STATES OF AMERICA

O26.06 The Effect Of Tasocitinib (CP-690,550) On The Incidence Of Acute Rejection And Renal Function In De Novo Kidney Transplant Patients: 6-Month Interim Analysis Of A Phase 2B Study

S. Busque1, J. Eris2, D. Abramowicz3, B. Nashan4, C. Legendre5, S. Vitko6, A. Mota7, N. Lawendy8, G. Chan8, F. Vincenti9
1Palo Alto/UNITED STATES OF AMERICA, 2Sydney/AUSTRALIA, 3Anderlecht/BELGIUM, 4Hamburg/GERMANY, 5Paris/FRANCE, 6Prague/CZECH REPUBLIC, 7Coimbra/PORTUGAL, 8New London/UNITED STATES OF AMERICA, 9San Francisco/UNITED STATES OF AMERICA

O26.07 Effect of terminal complement inhibition by Eculizumab on T-cell and natural killer cell depletion in living donor kidney transplant recipients induced with polyclonal rabbit antithymocyte globulin.

B.K.P. Goh, P.G. Dean, S. Raghavaiah, M.D. Stegall
Rochester/UNITED STATES OF AMERICA

O26.08 The Excellent Results of High-Dose Mizoribine combined with Cyclosporine,Corticosteroid and Basiliximab in Renal Transplant recipients-A Japanese muticenter study-

N. Yoshimura1, K. Uchida2, K. Yuzawa3, Y. Fukuda4, Y. Ichikawa5, K. Akioka6, M. Fujisawa7, A. Sugitani8, S. Ito9, T. Nakatani10, T. Horimi11

1Toulouse/FRANCE, 2Cochin/INDIA, 3Buenos Aires/ARGENTINA, 4San Diego/UNITED STATES OF AMERICA, 5San Francisco/UNITED STATES OF AMERICA, 6Hopewell/UNITED STATES OF AMERICA, 7Princeton/UNITED STATES OF AMERICA, 8Barcelona/SPAIN
O26.09 Bortezomib effectiveness in 69 patients treated in 29 centers worldwide

M.J. Everly¹, P.I. Terasaki²
¹Canoga Park/UNITED STATES OF AMERICA, ²Los Angeles/UNITED STATES OF AMERICA

Session O27 BK Virus Infection

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 220 - 222

Moderators: Henrik . Ekberg, Serdar . Yilmaz

O27.01 New protocol of BKV-specific T cell analysis allows for improved assessment of phenotypic and functional characteristics of BKV-specific immunity

Berlin/GERMANY

O27.02 Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Towards a New Therapy for BK Virus infection

A. LIACINI, L.A. Tibbles
Calgary/CANADA

O27.03 Pilot Study of Sirolimus/Leflunomide Therapy for BK Viremia

L.A. Tibbles, M. Maric Viskovic, C.M. Rodriguez Velez, A. Sar, S. Yilmaz
Calgary/CANADA

O27.04 Modification of immunosuppression can enhance the reconstitution of BKV-specific immunity preventing graft failure due to BKV-associated nephropathy in renal transplant patients

Berlin/GERMANY

O27.05 Pre-transplant BK-virus infection in dialyzed renal transplant candidates
O27.06 Alemtuzumab does not increase the risk of BK viruria or viremia following kidney, simultaneous kidney-pancreas, or pancreas after kidney transplantation.

Madison/UNITED STATES OF AMERICA

O27.07 Multivariate Analysis of Risk Factors for Polyoma Virus Infection after Kidney Transplantation

Minneapolis/UNITED STATES OF AMERICA

O27.08 Ureteral stent placement is associated with the development of polyoma viremia

D.J. Conti¹, L. Kushnir², K. Chambers², M.H. Gallichio²
¹Albany, New York/UNITED STATES OF AMERICA, ²Albany, New York/UNITED STATES OF AMERICA

O27.09 Risk factors of polyomavirus BKV high-level viruria and viremia in de novo renal transplantation: a multivariate analysis from the DIRECT Study comparing cyclosporine and tacrolimus

H.H. Hirsch¹, F. Vincenti², S. Friman³, A. Wiecek⁴, M.D. Pescovitz⁵, T. Jenssen⁶, L. Rostaing⁷, F. Citterio⁸, E. Scheuermann⁹, H. Prestele¹
¹Basel/SWITZERLAND, ²San Francisco/UNITED STATES OF AMERICA, ³Gothenburg/SWEDEN, ⁴Katowice/Poland, ⁵Indianapolis/UNITED STATES OF AMERICA, ⁶Oslo/NORWAY, ⁷Toulouse/FRANCE, ⁸Rome/ITALY, ⁹Frankfurt/GERMANY

Session O28 Innovation in Composite Tissue Transplantation

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 217 - 219

Moderators: Jean Michel Dubernard, David Cooper

O28.01 Early Outcomes of Cell Based Immunomodulation in Upper Limb Allotransplantation – The Pittsburgh Experience
O28.02 Hand Transplantation in Innsbruck: Update at 10 Years After the First Transplant

Innsbruck/AUSTRIA

O28.03 Results of the first pilot study on bilateral hand allotransplantation

P. Petruzzo¹, E. Morelon¹, A. Gazarian¹, J. Kanitakis¹, M. Brunet¹, M. Lanzetta², X. Martin¹, J.M. Dubernard³, L. Badet⁴
¹Lyon/FRANCE, ²Monza/ITALY

O28.04 Mouse Hind Limb Transplantation – a Novel Composite Tissue Allotransplantation (CTA) Model Utilizing a Nono-suture Cuff Technique For Revascularisation

R. Sucher¹, C.-H. Lin¹, R. Zanoun¹, I. Kronberger², R. Jindal¹, B.J. Pulikkottil³, M. Weinstock¹, V.S. Gorantla¹, S. Schneeberger¹, J. Pratschke², W.P.A. Lee¹, G. Brandacher²
¹Pittsburgh/UNITED STATES OF AMERICA, ²Innsbruck/AUSTRIA

O28.05 What are the hallmarks of chronic rejection in composite tissue allotransplantation

Lyon/FRANCE

O28.06 International Registry on Hand and Composite Tissue Transplantation

P. Petruzzo¹, M. Lanzetta², J.M. Dubernard¹, P. Cavadas³, R. Margreiter⁴, F. Schuind⁵, W. Breidenbach⁶, J. Jableki⁶, S. Schneeberger⁴, C. Kaufman⁶, L. Landin³
¹Lyon/FRANCE, ²Monza/ITALY, ³Valencia/SPAIN, ⁴Innsbruck/AUSTRIA, ⁵Bruxelles/BELGIUM, ⁶Louisville/UNITED STATES OF AMERICA, ⁷Tzbenica/POLAND

O28.07 The Influence of Rejection Episodes in Recipients of Bilateral Corneal Grafts

K.A. Williams, T.-L. Kelly, M. Lowe, D.J. Coster
Bedford Park/AUSTRALIA

O28.08 Face Transplantation Outcomes: feasibility reproducibility and efficacy
TTS 2010 SCIENTIFIC PROGRAM

Creteil/FRANCE

O28.09 Regulation of Composite Tissue Allotransplantation with CD200

R. Jindal, R. Sucher, Y. Wang, M. Weinstock, R. Zanoun, T.W. Ng, K.K. Atsina, S. Schneebaeger, G.
Brandacher, X.X. Zheng, V.S. Gorantla, W.P.A. Lee
Pittsburgh/UNITED STATES OF AMERICA

Session O29 Outcomes of Liver Transplantation I

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 118 - 120

Moderators: John . O’Grady, Stephen . Chung

O29.01 Long term follow-up and outcome of liver transplantation from HCV positive donors: a European
multicentric case-control study

R. BALLARIN1, G. TARANTINO1, A. CUCCHETTI2, M. SPAGGIARI1, R. MONTALTI1, F. DI BENEDETTO1, M.
VALMASONI1, C. LONGO3, N. DE RUVO1, N. CAUTERO1, G.P. GUERRINI1, S. NADALIN4, R. TROISI5, U.
CILLO3, A.D. PINNA2, P. BURRA3, G.E. GERUNDA1
1Modena/ITALY, 2Bologna/ITALY, 3Padova/ITALY, 4Tübingen/GERMANY, 5Ghent/BELGIUM

O29.02 A novel RNAi-based therapy for liver ischemia reperfusion injury through gene silencing of TLR4
using targeted shRNA-liposomes

N. Jiang1, X. Zhang2, X. Zheng2, D. Chen2, L.K. Siu2, A. Shunnar2, Y. Zhang2, D. Quan2, A.M. Jevnikar2,
G. Chen1, W. Min2
1Guangzhou/CHINA, 2London/CANADA

O29.03 The use of livers with metabolic disorders for transplantation - current status: The Domino Liver
World Transplant Register (DLTR) viewpoint

H.E. Wilczek1, M. Larsson1, A.J. Stangou2, O. Suhr3, B.-G. Ericzon1
1Stockholm/SWEDEN, 2London/UNITED KINGDOM, 3Umeå/SWEDEN

O29.04 IGL-1 versus UW preservation solution in liver transplantation: a randomized comparative study.

Clichy/FRANCE
O29.05 D-MELD prediction of graft survival after deceased donor Liver Transplantation. Results of the Italian retrospective multicenter Donor-Recipient match study.

A.W. Avolio¹, U. Cillo², M. Rossi¹, M. Colledan³, G. Tisone¹, G. Gerunda⁴, G. Rossi⁵, U. Valente⁶, L. Lupo⁷, G.M. Ettorre¹, A. Risaliti⁸, V. Bresadola⁹, B. Gridelli¹⁰, M. Donataccio¹¹, O. Cuomo¹², F. Calise¹², A.D. Pinna¹³, L. De Carlis⁵, F. Zamboni¹⁴, V. Mazzaferrro⁵, N. Nicolotti¹, E. Nure¹, A. Vitale², Q. Lai¹, D. Pinelli³, D. Sforza¹, R. Montalti¹⁴, L. Caccamo², M. Gelli⁶, M. Rendina⁷, G. Vennarecci¹, D. Nicolini⁸, U. Baccarani⁹, S. Gruttadauria¹⁰, A. Perrella¹², A. Cucchetti¹³, J. Mangoni¹³, V. Tondolo¹⁴, E. Regalia⁵, A. Gasbarrini¹, M. Angelico¹, S. Agnes¹

¹Rome/ITALY, ²Padua/ITALY, ³Bergamo/ITALY, ⁴Modena/ITALY, ⁵Milan/ITALY, ⁶Genua/ITALY, ⁷Bari/ITALY, ⁸Ancona/ITALY, ⁹Udine/ITALY, ¹⁰Palermo/ITALY, ¹¹Verona/ITALY, ¹²Naples/ITALY, ¹³Bologna/ITALY, ¹⁴Cagliari/ITALY

O29.06 Liver transplantation for transthyretin systemic amyloidosis disorders: An updated review from The Familial Amyloidotic Polyneuropathy World Transplant Register (FAPWTR)

H.E. Wilczek¹, M. Larsson¹, A.J. Stangou², O. Suhr³, B.-G. Ericzon¹

¹Stockholm/SWEDEN, ²London/UNITED KINGDOM, ³Umeå/SWEDEN

O29.07 Survival after liver transplant in patients who develop renal insufficiency

H. Patel, A. Patel, G. Divine, D. Moonka

Detroit/UNITED STATES OF AMERICA

O29.08 Post-Transplant Stage Progression in Liver Transplant Recipients with Chronic Kidney Disease (CKD): Single Center Analysis with 10 Years of Follow-Up


Madison/UNITED STATES OF AMERICA

O29.09 Over-Expression of Inducible Nitric Oxide Synthase in Ethanol-Induced Fatty Livers after Transplantation: Its Relation to Mitochondrial Dysfunction and Graft Injury


Charleston/UNITED STATES OF AMERICA

Session O30 Therapeutic Strategies for Kidney Transplantation

Tuesday, August 17, 2010 10:30 AM - 12:00 PM

Room: Ballroom C

Moderators: Anantharaman. Vathsala
O30.01 Rejection Characteristics of 200 Living Donor Kidney Transplantations Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: Mean 5-year follow-up

Pittsburgh/UNITED STATES OF AMERICA

O30.02 565 Living Donor Kidney Transplants Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 7 year Experience

Pittsburgh/UNITED STATES OF AMERICA

O30.03 Defining Long Term Renal Allograft Survival Following Early Corticosteroid Withdrawal and Risk Factor Assessment

Cincinnati/UNITED STATES OF AMERICA

O30.04 Outcomes as a Function of Donor:Recipient Characteristics from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT)

1San Francisco/UNITED STATES OF AMERICA, 2Barcelona/SPAIN, 3Paris/FRANCE, 4São Paulo/BRAZIL, 5Toulouse/FRANCE, 6Hopewell/UNITED STATES OF AMERICA, 7Leuven/BELGIUM, 8Princeton/UNITED STATES OF AMERICA, 9Atlanta/UNITED STATES OF AMERICA

O30.05 Multivariate Analyses of Acute Rejection in Renal Transplant Recipients Receiving Early Corticosteroid Withdrawal

Cincinnati/UNITED STATES OF AMERICA

O30.06 Subclinical Acute Rejection is Associated with Inferior Graft Survival in Kidney Transplant Recipients on Rapid Steroid Withdrawal

Phoenix/UNITED STATES OF AMERICA
O30.07 CNI-free protocol in renal transplantation: Evaluation of long term post-transplant humoral
aloimmune response through protocol biopsies with analysis of C4d deposition and determination of HLA
antibodies by Luminex assay

L.S. Re, J. Petroni, M.C. Rial, O.E. Guardia, T. Galdo, J. Goldberg, D. Casadei
Buenos Aires/ARGENTINA

O30.08 Simvastatin started with donor and recipient preconditioning protects kidney allografts from
chronic rejection

N. Malmström, J. Savikko, J. Rintala, P. Koskinen
Helsinki/FINLAND

O30.09 Eculizumab Prevents Recurrence of Antiphospholipid Antibody Syndrome (APS) in Renal
Allografts

B.E. Lonze¹, N.N. Dagher¹, C.E. Simpkins¹, D.L. Segev¹, A.L. Singer¹, S. Cohney², N. Alachkar¹, R.A.
Montgomery¹
¹Baltimore/UNITED STATES OF AMERICA, ²Parkville/ AUSTRALIA

Session O31 Cell Therapy and Stem Cells

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 212 - 214

Moderators: Hans-Dieter . Volk, Alan . Colman

O31.01 Modulating Inflammation and Stimulating β-Cell Regeneration in Diabetic NOD Mice by a DPP-IV
Inhibitor

Minneapolis/UNITED STATES OF AMERICA

O31.02 Correction of Diabetes Following Transplantation of an Insulin-secreting Human Liver Cell Line:
Melligen Cells

A.M. Simpson, C. Tao, B. Ren, M.A. Swan, B.A. O'Brien, P. Williams
Sydney/ AUSTRALIA

O31.03 Repopulation of hepatocytes simultaneously transplanted into the liver graft in the rat liver
transplantation
TTS 2010 SCIENTIFIC PROGRAM

Kyoto/JAPAN

O31.04 Liver Tissue Engineering Using HGF-Transduced Hepatocytes Provides Therapeutic Effects on Lethal Liver Failure in Mice

K. Ohashi1, K.-I. Kosai2, T. Okano1
1Tokyo Womens Medical University/JAPAN, 2Kagoshima University Faculty Of Medicine/JAPAN

O31.05 MRI enables monitoring of transplanted hepatocytes in a preclinical large animal model

N. Raschzok1, N. Billecke1, A. Zielinski1, K. Steinz1, N.N. Kammer1, S. Schmeisser1, M.H. Morgul2, M.K. Adonopoulou1, J. Pinkernelle1, L. Morawietz1, B. Hiebl1, W. Rüdinger3, U. Teichgräber1, P. Neuhaus1, I.M. Sauer1
1Berlin/GERMANY, 2Leipzig/GERMANY, 3Weinheim/GERMANY

O31.06 Cell therapy using MSCs and BMDCs in rat kidney transplantation

M. Franquesa1, M. Flaquer1, J.M. Cruzado2, J. Torras2, J. Grinyo2, I. Herrero-Fresneda1
1L'Hospitalet De Llobregat/SPAIN, 2Hospitalet De Llobregat/SPAIN

O31.07 Eosinophils in acute rejection of myofibers expressing donor-derived proteins following allotransplantation of myogenic cells: a study in nonhuman primates.

D. Skuk, M. Goulet, J.P. Tremblay
Québec/CANADA

O31.08 First evidence of the mechanism of myofiber death due to acute rejection in muscles transplanted with myogenic cells.

D. Skuk, M. Goulet, J.P. Tremblay
Québec/CANADA

O31.09 Use of amniotic membrane, amniotic fluid, and placental dressing in advanced burn patients

N. Bhattacharya
Calcutta/INDIA

Session O32 Late Breaking II

Tuesday, August 17, 2010 10:30 AM - 12:00 PM
Room: MR 121 - 122
O32.01 Facilitating Cell Enriched Stem Cell Infusion Results in Durable Chimerism, Donor Specific Tolerance, and Allows For Immunosuppressive Drug Withdrawal in Recipients of HLA Disparate Living Donor Kidney Allografts

J.R. LEVENTHAL¹, L. Gallon¹, J. Miller¹, M. Abecassis¹, K. Ravindra², E. Reed², S.T. Ildstad²
¹Chicago/UNITED STATES OF AMERICA, ²Louisville/UNITED STATES OF AMERICA

O32.02 Evidence that Treatment with DHRS9+ Regulatory Macrophages Induced by FcyRIII Ligation and IFN-γ Stimulation Promotes Renal Allograft Tolerance in Patients

J.A. Hutchinson¹, P. Riquelme¹, D.P. Brown¹, B. Sawitzki², M. Rehli¹, S. Tomiuk³, J. Schröder¹, A. Sotnikova⁴, P. Miqueu⁵, M. Zuhayra⁶, H.H. Oberg¹, A. Pascher⁷, U. Lützen⁸, U. Janßen³, F. Thaiss⁵, E. Scheuermann⁷, E. Henze⁴, L. Chatenoud⁶, H.-D. Volk², R.I. Lechler⁹, K.J. Wood¹⁰, D. Kabelitz³, H.J. Schlitt¹, F. Fändrich⁴, E.K. Geissler¹
¹Regensburg/GERMANY, ²Berlin/GERMANY, ³Bergisch Gladbach/GERMANY, ⁴Kiel/GERMANY, ⁵Nantes/FRANCE, ⁶Hamburg/GERMANY, ⁷Frankfurt/GERMANY, ⁸Paris/FRANCE, ⁹London/UNITED KINGDOM, ¹⁰Oxford/UNITED KINGDOM

O32.03 Cross-platform biomarker signature to identify renal transplant tolerance in humans.

E. Perucha¹, P. Sagoo¹, B. Sawitzki², S. Tomiuk³, D.A. Stephens⁴, S. Brouard⁵, I. Rebollo-Mesa¹, R. Hilton¹, K. Bourcier⁶, M. Goldman⁷, K.J. Wood⁸, K. Newell⁶, A. Warrens¹, U. Janssen³, H.-D. Volk², J.-P. Souillou⁵, R.I. Lechler¹, M.P. Hernandez-Fuentes¹
¹London/UNITED KINGDOM, ²Berlin/GERMANY, ³Bergisch Gladbach/GERMANY, ⁴Montreal/CANADA, ⁵Nantes Cedex 1/FRANCE, ⁶San Francisco/UNITED STATES OF AMERICA, ⁷Charleroi/BELGIUM, ⁸Oxford/UNITED KINGDOM

O32.04 ABO Incompatible renal transplantation with Conventional Immunosuppression alone: No antibody removal, No splenectomy or Rituximab: clinical and histological outcomes- 12 months and beyond

Parkville/AUSTRALIA

O32.05 Islet Cell Transplants Fail Due to Donor Specific Antibodies

L. Piemonti¹, P.I. Terasaki², M.J. Everly², P. Maffi¹, S. Mario³, A. Secchi¹, C. Massimo³, M. Ozawa²
¹Milano/ITALY, ²Los Angeles/UNITED STATES OF AMERICA, ³Milan/ITALY

O32.06 CMV Valganciclovir Prophylaxis Versus Preemptive Therapy After Renal Transplantation: One Year Results of a Randomized Clinical Trial
TTS 2010 SCIENTIFIC PROGRAM

O. Witzke¹, M. Nitschke², M. Bartels³, U. Ott⁴, I.A. Hauser⁵
¹Essen/GERMANY, ²Lübeck/GERMANY, ³Leipzig/GERMANY, ⁴Jena/GERMANY, ⁵Frankfurt/M/GERMANY

O32.07 Successful Cross-Organ Classification of Fibrosis based on Microarray Metaanalysis applying a Classifier Model of Renal Transplant IF/TA

S. Rödder¹, A. Scherer², M. Körner¹, H.-P. Marti¹
¹Bern/SWITZERLAND, ²Kontiolahti/FINLAND

O32.08 Genomic Meta-analysis of the Integrin Pathway in Chronic Allograft Nephropathy

A. Dosanjh, D.R. Salomon, S. Kurian
La Jolla/UNITED STATES OF AMERICA

O32.09 UK Registry of Antibody Incompatible Kidney Transplantation 2001-2010

R. Higgins¹, A.J. Hudson², R.J. Johnson², S.V. Fuggle², J. Galliford³, D. Taube³, N. Mamode³, S. Ball⁴, R. Ravanan², N. Torpey⁵, R. Thuraisingham⁵, A. Gupta⁵, C. Newstead⁶, J.A. Bradley⁵
¹Coventry/UNITED KINGDOM, ²Bristol/UNITED KINGDOM, ³London/UNITED KINGDOM, ⁴Birmingham/UNITED KINGDOM, ⁵Cambridge/UNITED KINGDOM, ⁶Leeds/UNITED KINGDOM

12:15 – 13:15 MINI ORAL SESSIONS

Session MO08 Immune Regulation and Tolerance II

Tuesday, August 17, 2010 12:15 PM - 01:15 PM
Room: MR 202 - 204

Moderators: Alvaro . Pacheco-Silva, Willem . Weimar

MO08.01 Bcl-2 inhibition: a new concept to prevent solid allograft rejection

P.E. Cippa¹, A.K. Kraus¹, S. Segerer¹, J. Chen¹, P.D. Bardwell², T. Fehr¹
¹Zürich/SWITZERLAND, ²Worcester/UNITED STATES OF AMERICA

MO08.02 A novel pan-TLR inhibitor promotes permanent acceptance of skin allografts in mice

T.W. He, P. Zhou, B.C. Xue, Y. Liu, C. Li, Z.K. Chen
Wuhan/CHINA

MO08.03 Prevention of skin graft rejection by specific induction of apoptosis of host APC presenting graft-derived antigens
MO08.04 The presence of increased peripheral Th17 lymphocytes in highly sensitized renal transplant patients: implications for immune modulation.

T. Kandeva, S. Liu, J. Tchervenkov
Montreal/CANADA

MO08.05 A novel immunosuppressive agent, DTCM-glutarimide markedly prolongs cardiac allograft survival in mouse when combined with Donor specific transfusion

Y. Tsunetoshi¹, K. Yamashita¹, S. Shibasaki¹, R. Goto¹, K. Wakayama¹, H. Gentaro¹, M. Zaitsu¹, R. Igarashi¹, M. Ozaki¹, K. Umezawa², S. Todo¹
¹Sapporo/JAPAN, ²Yokohama/JAPAN

MO08.06 FGL2 expression induces graft survival in the absence of immunosuppression

Toronto/CANADA

MO08.07 A Quantitative Proteomics Approach For Identification of Potential Biomarkers In Transplant Tolerance

Toronto/CANADA

MO08.08 DAP12 Controls STAT3 Activation in 'Tolerogenic ' Liver Dendritic Cells

T.L. Sumpter, H. Turnquist, A.W. Thomson
Pittsburgh/UNITED STATES OF AMERICA

MO08.09 Immunomodulatory interactions between mesenchymal stem cells and regulatory T cells after kidney transplantation

A. Grohnert, C.C. Baan, P. Koumoutsakos, A. Peeters, W. Weimar, M.J. Hoogduijn
Rotterdam/NETHERLANDS

MO08.10 The Role of Mesenchymal Stem Cells in Stabilizing Pancreatic Islet Cell Transplant in Mice

C. Tan-Tam, V. Nguyen, P. Stock, Q. Tang
San Francisco/UNITED STATES OF AMERICA
MO08.11 The source of Human Mesenchymal Stromal Cells influences their TLR profile as well as their functional properties

Nevessignsky, L. Lagneaux
Brusseles/BELGIUM

MO08.12 Synergistic Immunomodulation by Immunosuppressive agents and Human Mesenchymal Stem Cells on T-cell proliferation and Dendritic cell maturation

T. Searcy, R. Krishnan
Adelaide/AUSTRALIA

Session MO09 International Trends in Organ Donation

Tuesday, August 17, 2010 12:15 PM - 01:15 PM
Room: MR 109 - 110

Moderators: Helen. Pilmore, Maher. Ramzy

MO09.01 Excellent Long-term Outcomes of Kidney Transplantation Using Kidneys from Deceased Donors with Acute Kidney Injury

N. Techawathanawanna, R. Kunprakan, P. Lertsithichai, K. Pipatpannawong, N. Naitook, V. Mavichak, S. Jirasiritham
Bangkok/THAILAND

MO09.02 Liver transplantation with donor aged 70 or above: is it justified?

Hamburg/GERMANY

MO09.03 Validation of the Kidney Donor Risk Index (KDRI) Score in a UK Single Centre DCD Cohort

J.K. Pine, P.J. Goldsmith, D.M. Ridgway, K. Brady, S. Pollard, M. Attia, N. Ahmad, K.V. Menon
Leeds/UNITED KINGDOM

MO09.04 Changes in practice and its effect on the coordination of the organ donation process in Québec: an analysis of the current situation

S. Lavigne¹, M. Carrier², C. lebeau¹, I. sourdif²
¹Québec/CANADA, ²Montréal/CANADA
**TTS 2010 SCIENTIFIC PROGRAM**

**MO09.05** Donor age related conversion rates in 5 European countries: Donor Action® evidence based data demonstrating an unexploited potential

L. Roels¹, J. Smits², B. Cohen¹
¹Linden/BELGIUM, ²Leiden/NETHERLANDS

**MO09.06** Trends in organ donation in the UK

R.J. Johnson¹, C. Counter¹, J.A. Bradley², C.J.E. Watson², C. Rudge³, J. Neuberger¹
¹Bristol/UNITED KINGDOM, ²Cambridge/UNITED KINGDOM, ³London/UNITED KINGDOM

**MO09.07** The possibilities of improving procurement activity in Slovakia (Five years analyses of deaths in region with 865000 people)

J. Miklušiča, Ľudovít. Laca, B. Grandtnerova, B. Palkóc, Ľubomír. Strelka
Martin/SLOVAK REPUBLIC

**MO09.08** Professional experience of Critical Care staff impacting on comfort levels with donation related tasks.

L. Roels¹, J. Smits², B. Cohen¹
¹Linden/BELGIUM, ²Leiden/NETHERLANDS

**MO09.09** Extended Pancreas Donor Program - The EXPAND Study

S.A. Farkas¹, A.A. Schnitzbauer¹, T. Boerner¹, B. Banas¹, H. Arbogast², R. Viebahn³, H.J. Schlitt¹
¹Regensburg/GERMANY, ²Munich/GERMANY, ³Bochum/GERMANY

**MO09.10** Lifetime Probabilities of Needing an Organ Transplant versus Donating an Organ after Death

L. Hornby¹, J. Chandler², J. Burkell³, S.D. Shemie¹
¹Montreal/CANADA, ²Ottawa/CANADA, ³London/CANADA

---

**Session MO10 New Immunosuppressive Agents**

**Tuesday, August 17, 2010 12:15 PM - 01:15 PM**
**Room: MR 211**

Moderators: Barry . Kahan, Mark . Pescovitz

**MO10.01** Safety Profile Of Tasocitinib (CP-690,550)-Based CNI-Free Regimens In De Novo Kidney Transplant Patients In A Dose/Exposure-Finding Phase 2B Study: Results Of A 6-Month Interim Analysis
TTS 2010 SCIENTIFIC PROGRAM

1Sao Paulo/BRAZIL, 2Barcelona/SPAIN, 3St. Louis/UNITED STATES OF AMERICA, 4Dallas/UNITED STATES OF AMERICA, 5Oslo/NORWAY, 6New Haven/UNITED STATES OF AMERICA, 7San Francisco/UNITED STATES OF AMERICA, 8San Diego/UNITED STATES OF AMERICA, 9Bologna/ITALY, 10New London/UNITED STATES OF AMERICA

MO10.02 Correlation Of Tasocitinib (CP-690,550) And MPA Pharmacokinetics With Clinical Events In De Novo Kidney Transplant Patients: Preliminary Results From A Phase 2B Study

1Westmead/AUSTRALIA, 2Rotterdam/NETHERLANDS, 3Los Angeles/UNITED STATES OF AMERICA, 4Chicago/UNITED STATES OF AMERICA, 5Rome/ITALY, 6Seoul/KOREA, 7Porto Alegre/BRAZIL, 8New London/UNITED STATES OF AMERICA

MO10.03 CP-690,550 Inhibits Interleukin2-Mediated STAT5 Activation In CD4+ T Cells OF Adult Kidney Recipients

R. Silva1, K. Piard-Ruster1, S.M. Krams1, O.M. Martinez1, S. Busque2
1Stanford/UNITED STATES OF AMERICA, 2Palo Alto/UNITED STATES OF AMERICA

MO10.04 Protecting Renal Grafts from Immune Rejection in Kidney Transplantation through siRNAi


MO10.05 Comparative Efficacy of Proteasome Inhibitor-Based Antihumoral Therapy for Early Versus Late Post-Transplant Antibody Mediated Rejection in Kidney Transplant

Cincinnati/UNITED STATES OF AMERICA

MO10.06 Proteasome Inhibitor Therapy for Antibody Mediated Rejection: Initial Report from A Multicenter Collaborative

E.S. Woodle1, J. Light2, J. Thielke3, M. Rubin4, W.R. Morrow5, W. Mahle6, C. Franklin7, S. Gabardi8, J. Gill8, I. Roberti9, R. Shapiro10, P. Eckman11, R. Lewis12, G.E. Wall1, R.C. Walsh1, M. Zand13, R.R. Alloway1
1Cincinnati/UNITED STATES OF AMERICA, 2Washington Dc/UNITED STATES OF AMERICA, 3Chicago/UNITED STATES OF AMERICA, 4Boston/UNITED STATES OF AMERICA, 5Little Rock/UNITED STATES OF AMERICA, 6Atlanta/UNITED STATES OF AMERICA, 7Des Moines/UNITED STATES OF AMERICA, 8Vancouver/CANADA, 9West Orange/UNITED STATES OF AMERICA, 10Pittsburgh/UNITED STATES OF AMERICA, 11Minneapolis/UNITED STATES OF AMERICA, 12Austin/UNITED STATES OF AMERICA, 13Rochester/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

MO10.07 The Role of Proteasome Inhibition with Bortezomib in the Treatment of Antibody Mediated Rejection (AMR) after Renal Transplantation

S.M. Flechner, R. Fatica, M. Askar, B. Stephany, E. Poggio, A. Koo, T. Srinivas
Cleveland/UNITED STATES OF AMERICA

MO10.08 Sotrastaurin mediated inhibition of proteinkinase C ameliorates severe posttransplant preservation injury

L. Chaykovska, U. Hoff, A. Kusch, R. Catar, J. Pützer, F. Fuller, D. Dragun
Berlin/GERMANY

MO10.09 Development of Cyclin Kinase Inhibitor as a Potent Immunosuppressive Drug

A.K. Khanna
Baltimore/UNITED STATES OF AMERICA

MO10.10 Clonal deletion with bortezomib permits renal transplant with low-dose corticosteroids alone

H.L. Trivedi¹, P.I. Terasaki², A.V. Vaniker¹, V.B. Trivedi¹, S. Khemchandani¹, S.D. Dave¹, V. Shankar¹, P.R. Modi¹, H. Kaneku², A. Idica³, M.J. Everly³
¹Ahmedabad/INDIA, ²Los Angeles/UNITED STATES OF AMERICA, ³Canoga Park/UNITED STATES OF AMERICA

MO10.11 Reduced C0-levels and increased dose-requirements in renal allograft recipients converted from the standard twice-daily to the novel once-daily prolonged release tacrolimus formulation

Y. Vanrenterghem, H. de Jonge, K. Verbeke, D.R. Kuypers
Leuven/BELGIUM

MO10.12 Renal function is maintained following conversion to Tacrolimus QD (Advagraf) from ciclosporin: primary results from CONCERTO

L. Rostaing¹, A. Sánchez-Fructuoso², M. Glyda³
¹Toulouse/FRANCE, ²Madrid/SPAIN, ³Poznan/POLAND

Session MO11 Societal Issues and Public Policy

Tuesday, August 17, 2010 12:15 PM - 01:15 PM
Room: MR 205 - 207

Moderators: Félix . Cantarovich, Haibo . Wang
MO11.01 Changes in Health-Related Quality of Life Across Three Post-Heart Transplant Stages: Clinical Trial Plan Group vs. non-CTP Group in Taiwan

P.-H. Tseng, S.-S. Wang, F.-J. Shih
Taipei/TAIWAN

MO11.03 Prospective Psychiatric Follow-Up Of Renal Transplant Recipients And Donors: Impact of Procedure And Impact of Follow-Up

I. Yatkin¹, C. Cerit¹, G. Tellioglu¹, M. Kara¹, N. Yilmaz², I. Berber¹, B. Yigit¹, P. Ata Eren¹, M. Caliskan¹, I.M. Titiz¹
¹Istanbul/TURKEY, ²Mugla/TURKEY

MO11.04 Projecting patient outcomes at 20 years based on graft function from randomized trials of immunosuppressants among renal transplant recipients in the United States

A. Levy¹, A. Briggs², K. Johnston³, M.A. Schnitzler⁴, G.J. L'Italien⁵, Y. Yuan⁵, B. Kasiske⁶
¹Halifax, Ns/CANADA, ²Glasgow/UNITED KINGDOM, ³Vancouver/CANADA, ⁴St Louis/UNITED STATES OF AMERICA, ⁵Princeton/UNITED STATES OF AMERICA, ⁶Minneapolis/UNITED STATES OF AMERICA

MO11.05 Attitude towards Kidney donation among Primary care patients in developing country.

S. Joshi¹, R.P. Bhandari²
¹Kathmandu/NEPAL, ²Ktm/NEPAL

MO11.06 Screening tests for coronary artery disease in potential kidney transplant recipients: a systematic review of diagnostic test accuracy

L.W. Wang¹, P. Macaskill¹, M.A. Fahim², J.C. Craig¹, R. Mitchell¹, A. Hayen¹, L. Baines³, S. Lord³, A. Webster¹
¹Sydney/AUSTRALIA, ²Brisbane/AUSTRALIA, ³Newcastle Upon Tyne/UNITED KINGDOM

MO11.07 Struggle for the historic unanimous passage of transplant law in Pakistan

S.A.H. Rizvi¹, S.A.A. Naqvi¹, M.N. Zafar¹, F. Moazam¹, F. Delmonico², L. Noel³
¹Karachi/PAKISTAN, ²Newton/UNITED STATES OF AMERICA, ³Geneva/SWITZERLAND

MO11.08 Are religious communities useful in promoting the organ donation debate? Lessons from the United Kingdom

G. randhawa
Luton/UNITED KINGDOM
TTS 2010 SCIENTIFIC PROGRAM

MO11.09 The paradox of prohibition and how potential adverse consequences of the Istanbul Declaration may be controlled

F. Ambagtsheer, W. Weimar
Rotterdam/NETHERLANDS

MO11.10 Challenging Issues of Overseas Transplantation in Mainland China: Taiwan Organ Transplant Health Professionals’ Perspective

F.-J. Shih¹, Y.-W. Fan¹, H.-M. Chen², C.-M. Chiu³, F.-J. Shih², S.-S. Wang²
¹Taoyuan/TAIWAN, ²Taipei/TAIWAN, ³Kaohsiung/TAIWAN

MO11.11 The long-term consequences of kidney donation in the victims of trafficking in human beings (VTHBs) for the purpose of organ removal

I. Codreanu¹, N. Codreanu¹, F. Delmonico²
¹Chisinau/MOLDOVA, ²Newton/UNITED STATES OF AMERICA

Session MO12 Immunosuppression in Liver Transplantation

Tuesday, August 17, 2010 12:15 PM - 01:15 PM
Room: MR 217 - 219

Moderators: Marcus . Bahra, Goran . Klintmalm

MO12.01 Safety of conversion from twice-daily tacrolimus (Prograf®) to once-daily prolonged-release tacrolimus (Advagraf®) in stable liver transplantation recipients

C. Comuzzi¹, D. Lorenzin¹, A. Rossetto¹, M. Faraci², D. Nicolini², P. Garelli², C. Musolino¹, V. Bresadola¹, G.L. Adani¹, P. Toniutto¹, G. Svegliati Baroni², A. Risaliti², U. Baccarani¹
¹Udine/ITALY, ²Ancona/ITALY

MO12.02 Long-term follow-up of tacrolimus once-daily prolonged release in liver transplant recipients demonstrates good efficacy and renal function

P. Trunečka¹, O. Boillot², U. Neumann³
¹Prague/CZECH REPUBLIC, ²Lyon/FRANCE, ³Berlin/GERMANY

MO12.03 Cost-effectiveness of Mycophenolate Mofetil and Tacrolimus compared to Azathioprine and Tacrolimus following Orthotopic liver transplantation (OLT)
MO12.04 In vivo induction of bona fide CD4+CD25+ regulatory T cells after liver transplantation – the potential influence of polyclonal antithymocyte globulin

D. Stauch¹, A. Yahyazadeh¹, S. Olek¹, U. Baron¹, J. Pratschke², K. Kotsch¹, K. Kunert¹
¹Berlin/Germany, ²Innsbruck/Austria

MO12.05 The Safety of Late Conversions to Sirolimus in Liver Transplantation

Dallas/United States of America

MO12.06 Generic substitution of tacrolimus appears to be safe in the short term in clinically stable liver and kidney transplant patients, but monitoring of tacrolimus blood concentrations in individual patients is essential.

J. Momper, P. Fontes, M.E. DeVera, A. Humar, R. Shapiro, R. Venkataramanan
Pittsburgh/United States of America

MO12.07 17 to 20 Years Longitudinal Follow-up of 1000 Consecutive Primary Liver Transplant under Tacrolimus

A. Jain¹, P. Fontes², G. Mazariagos², M.E. DeVera², K. Soltys², T. Caccarelli², A. Goyal¹, A. Humar², J.W. Marsh²
¹Philadelphia/United States of America, ²Pittsburgh/United States of America

MO12.08 Early versus Late Conversion to mTOR-Inhibitors in Liver Transplant Recipients with Impaired Renal Function at the Time of Transplantation

C. Schleicher, D. Palmes, M. Utech, E. Bonrath, N. Senninger, H. Schmidt, H. Wolters
Muenster/Germany

MO12.09 Beneficial Effect of Induction Therapy for Liver Transplant Recipients with Renal Dysfunction: an Analysis of OPTN/UNOS data

T. Shah, Y. Qazi, T.-L. Fong, Y. Genyk, L. Sher, I.V. Hutchinson, Y.W. Cho
Los Angeles/United States of America

MO12.10 Acute Phase Liver Graft Injury Significantly Mobilized Circulating Endothelial Progenitor Cells, Myeloid-Derived Suppressor Cells and Regulatory T Cells through TLR4 signaling
TTS 2010 SCIENTIFIC PROGRAM

C. Ling\textsuperscript{1}, C.M. Lo\textsuperscript{2}, X. Liu\textsuperscript{1}, K.T. Ng\textsuperscript{1}, Y. Shao\textsuperscript{1}, C. Li\textsuperscript{1}, S.T. Fan\textsuperscript{1}, R.T.P. Poon\textsuperscript{1}, K. Man\textsuperscript{1}
\textsuperscript{1}Hong Kong/HONG KONG, \textsuperscript{2}Pok Fu Lam/HONG KONG

Session MO13 Clinical Strategies and Outcomes in Kidney Transplantation

Tuesday, August 17, 2010 12:15 PM - 01:15 PM
Room: MR 220 - 222

Moderators: Stuart . Flechner, Franco . Citterio

MO13.01 Donor and recipient age are independent determinants for acute rejection rates and transplant outcome

S.G. Tullius, H. Tran, I. Guleria, S.K. Malek, N.L. Tilney, E. Milford
Boston/UNITED STATES OF AMERICA

MO13.02 Effect of Deceased-Donor Age on Median Kidney Recipient and Graft Survival: A Target for Intervention

A.B. Leichtman, K.P. McCullough, R. Wiggins, R. Wolfe
Ann Arbor/UNITED STATES OF AMERICA

MO13.03 Impact Of The Strict Glycemic Control In The Post-Operative Period Of Transplantation With ECD Kidneys. Preliminary Results Of A Prospective And Randomized Trial

L.S. Re, R. Pilotti, J. Petroni, D. Yagupski, J. Goldberg, D. Casadei
Buenos Aires/ARGENTINA

MO13.04 Post Transplant Diabetes Mellitus (PTDM) - Analysis of risk factors, effects on biochemical parameters, graft function - at 5 years of renal transplantation

D. Madhav, R. Ram, K.V. Dakshinamurty
Hyderabad/INDIA

MO13.05 A comparison of effects of short-term maintenance dose exposure of Advagraf\textsuperscript{®} and Neoral\textsuperscript{®} on renal perfusion and function in healthy volunteers.

J.S. Zaltzman
Toronto/CANADA

MO13.06 A randomized placebo controlled trial for deceased kidney donor pretreatment with corticosteroids to prevent acute renal failure
A. Kainz\textsuperscript{1}, J. Wilflingseder\textsuperscript{1}, C. Mitterbauer\textsuperscript{1}, M. Haller\textsuperscript{2}, C. Burghuber\textsuperscript{1}, P. Perco\textsuperscript{2}, R.M. Langer\textsuperscript{3}, G. Heinze\textsuperscript{1}, R. Oberbauer\textsuperscript{1}  
\textsuperscript{1}Vienna/AUSTRIA, \textsuperscript{2}Linz/AUSTRIA, \textsuperscript{3}Budapest/HUNGARY

MO13.07 An Appraisal on the Convenience of Early Everolimus Introduction and Calcineurin Inhibitor Withdrawal in Kidney Recipients: The ERIC Study

J.C. Ruiz\textsuperscript{1}, A. Sánchez Fructuoso\textsuperscript{2}, D. Hernández\textsuperscript{3}, J. Sánchez Plumed\textsuperscript{4}, A. Fernández\textsuperscript{2}, A. Pastor Rodríguez\textsuperscript{5}, J. Paul\textsuperscript{6}, A. Alarcón\textsuperscript{7}  
\textsuperscript{1}Santander/SPAIN, \textsuperscript{2}Madrid/SPAIN, \textsuperscript{3}Málaga/SPAIN, \textsuperscript{4}Valencia/SPAIN, \textsuperscript{5}Tenerife/SPAIN, \textsuperscript{6}Zaragoza/SPAIN, \textsuperscript{7}Mallorca/SPAIN

MO13.08 Utilization of compatible pairs to significantly expand kidney paired donation

A. Bingaman, F. Wright, M. Kapturczak, C. Murphey  
San Antonio/UNITED STATES OF AMERICA

MO13.09 A model based on donor factors for predicting long term survival of living related renal transplants

M.N. Zafar, S.A.A. Naqvi, S.A.H. Rizvi  
Karachi/PAKISTAN

MO13.10 Should we transplant all kidneys from expanded criteria donors – analysis of exclusion criteria.

M. Wszola, P. Domagała, A. Kwiatkowski, A. Perkowska-Ptasinska, M. Majkowska, L. Paczek, A. Chmura  
Warsaw/POLAND

MO13.11 Outcome of high volume live related renal transplants in a developing country

Karachi/PAKISTAN

Session MO14 Islet and Pancreas Transplantation II

Tuesday, August 17, 2010 12:15 PM - 01:15 PM  
Room: MR 212 - 214


MO14.01 Quality of Life after Simultaneous Pancreas and Kidney Transplantation from Living Donors. – Evaluation both for the donors and the recipients using a Short-Form 36 v2 –
MO14.02 Factors Influencing the Acceptance of Donor Solid-Organ Pancreata for Transplantation. An Australian Single Centre Review.

L. Lan¹, W.R. Mulley¹, P. Chaal¹, V. Marion², H. Opdam², A. Saunders¹, J. Kanellis¹
¹Clayton/AUSTRALIA, ²Carlton/AUSTRALIA

MO14.03 Long-Term Survival of Pancreas Allografts Is Similar in Pancreas-After-Kidney and Simultaneous Pancreas-Kidney Transplant Recipients

R.S. Perkins, M.A. Marquez, M. Selzner, A. Norgate, F. Bazerbachi, J. Schiff, A. Ghanekar, I.D. McGilvray, D.R. Grant, P.D. Greig, M.S. Cattral
Toronto/CANADA

MO14.04 Long-term survival of allogeneic islets in a biohybrid device by locally delivered immunosuppression

Miami/UNITED STATES OF AMERICA

MO14.05 Correlation of C peptide levels with Age, Race, and BMI, but not Pancreas Transplant Outcomes.

J.A. Light, M.J. Tucker
Washington DC/UNITED STATES OF AMERICA

MO14.06 Pancreas Transplantation: Transplanting Sensitised Patients in the UK

A.J. Hudson¹, L.L. Mumford¹, S.V. Fuggle¹, C.J.E. Watson²
¹Bristol/UNITED KINGDOM, ²Cambridge/UNITED KINGDOM

MO14.07 Intestinal Complications of Pancreas Transplantation

F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti, U. Boggi
Pisa/ITALY

MO14.08 Oxygen Persufflation Increases Pancreatic ATP Levels and Viable Islet Yield Following 24 Hours Preservation Compared with the Two-Layer Method (TLM)

W.E. Scott III¹, E.S. Avgoustiniatos¹, J. Ferrer-Fabrega¹, B.P. Weegman¹, V.A. Kirkner¹, T. Anazawa², M.D. Rizzari¹, L.S. Kidder¹, S.A. Stein¹, S. Matsumoto¹, J.J. Stone¹, T.M. Suszynski¹, T.C. Aasheim¹, B.E.
TTS 2010 SCIENTIFIC PROGRAM

Hammer\textsuperscript{1}, A.N. Balamurugan\textsuperscript{1}, T.D. O'Brien\textsuperscript{3}, M.P. Murtaugh\textsuperscript{3}, L.A. Tempelman\textsuperscript{4}, D.E. Sutherland\textsuperscript{1}, B.J. Hering\textsuperscript{1}, K.K. Papas\textsuperscript{1}
\textsuperscript{1}Minneapolis/UNITED STATES OF AMERICA, \textsuperscript{2}Fukushima/JAPAN, \textsuperscript{3}St. Paul/UNITED STATES OF AMERICA, \textsuperscript{4}Newton/UNITED STATES OF AMERICA

MO14.09 Successful islet transplantation from a single-donor based on CD40-CD154 costimulation blockade plus NF-\kappa B inhibition

Y. Koshizuka\textsuperscript{1}, K. Yamashita\textsuperscript{1}, M. Watanabe\textsuperscript{1}, D. Kuraya\textsuperscript{1}, M. Ogura\textsuperscript{1}, T. Yoshida\textsuperscript{1}, H. Kamachi\textsuperscript{1}, M. Matsushita\textsuperscript{1}, K. Umezawa\textsuperscript{2}, M. Ozaki\textsuperscript{1}, S. Todo\textsuperscript{1}
\textsuperscript{1}Sapporo/JAPAN, \textsuperscript{2}Yokohama/JAPAN

MO14.10 Improved Pancreatic Islet Yield and Function with a Chloride Channel Blocker during Collagenase Digestion

Fukushima/JAPAN

MO14.11 Engineering Alternative Islet Implant Sites in a Nonhuman Primate Model

Miami/UNITED STATES OF AMERICA


D.M. Rojas, R. Krishnan, P.T. Coates
Adelaide/AUSTRALIA
TTS 2010 SCIENTIFIC PROGRAM

13:00 – 15:00 STATE OF THE ART SYMPOSIA

Session SOTA08 Principles and practice of living donor exchange

Tuesday, August 17, 2010 01:30 PM - 03:00 PM
Room: MR 109 - 110

Moderators: John . Gill, Lloyd . Ratner

SOTA08.1 Living donor exchange for sensitized patients
D.L. Segev
Baltimore/UNITED STATES OF AMERICA

SOTA08.2 The National Living Donor Exchange Programme in The Netherlands.
M. Klerk de
Rotterdam/NETHERLANDS

SOTA08.3 How to organize a national living donor exchange program
E. Cole
Toronto/CANADA

SOTA08 - DISCUSSION

Session SOTA09 Biology and therapeutic potential of regulatory cells

Tuesday, August 17, 2010 01:30 PM - 03:00 PM
Room: MR 212 - 214

Moderators: Shuiping . Jiang, Angus . Thomson

SOTA09.1 Signaling pathways in regulatory cells
M. Levings
Vancouuer/CANADA

SOTA09.2 T-regulatory cells: phenotype and function
TTS 2010 SCIENTIFIC PROGRAM

A. Rudensky
New York/UNITED STATES OF AMERICA

SOTA09.3 Regulatory B cells

T. Tedder
Durham/UNITED STATES OF AMERICA

SOTA09 - DISCUSSION

Session SOTA10 Maintenance immunosuppression

Tuesday, August 17, 2010 01:30 PM - 03:00 PM
Room: Ballroom A/B

Moderators: Anthony Benedict, Cosimi, Bernard Charpentier

SOTA10.1 Novel approaches to inhibit intracellular signals

B. Kahan
Houston/UNITED STATES OF AMERICA

SOTA10.2 Concentration-controlled immunosuppression

T. van Gelder
Rotterdam/NETHERLANDS

SOTA10.3 Translational research and maintenance immunosuppression

A. Kirk
Atlanta/UNITED STATES OF AMERICA

SOTA10.4 Strategies in transplant patients with chronic kidney disease

M. Cantarovich
Montreal/CANADA

SOTA10 - DISCUSSION
Session SOTA11 Genome BC Symposium: Transplant genomics and biomarkers of injury

Tuesday, August 17, 2010 01:30 PM - 03:00 PM  
Room: MR 211

Moderators: John Andrew Bradley, Roslyn Mannon

SOTA11.1 Transplantomics: report of the first international meeting

M. Sarwal  
Stanford/UNITED STATES OF AMERICA

SOTA11.2 Integrative genomics in organ transplantation

D.R. Salomon  
La Jolla/UNITED STATES OF AMERICA

SOTA11.3 Genetic and molecular mechanisms in chronic allograft injury

P. Halloran  
Edmonton/CANADA

SOTA11 - DISCUSSION

Session SOTA12 Biological function and clinical relevance of antibodies to transplantation antigens

Tuesday, August 17, 2010 01:30 PM - 03:00 PM  
Room: Ballroom C

Moderators: Paul Terasaki, Howard Gebel

SOTA12.1 Determinants of biological function of anti-donor antibodies

E.F. Reed  
Los Angeles/UNITED STATES OF AMERICA

SOTA12.2 Comparative clinical importance of class I and class II antibodies
TTS 2010 SCIENTIFIC PROGRAM

S. Fidler
Perth/AUSTRALIA

SOTA12.3 Clinical relevance of antibodies to non-HLA antigens

D. Dragun
Berlin/GERMANY

SOTA12.4 The role and future of the flow and cytotoxic crossmatch

R.H. Kerman
Houston/UNITED STATES OF AMERICA

SOTA12 - DISCUSSION

Session SOTA13 Liver Transplantation for Hepatocellular Cancer

Tuesday, August 17, 2010 01:30 PM - 03:00 PM
Room: MR 118 - 120

Moderators: Federico . Villamil, William . Wall

SOTA13.1 Tumor selection criteria -a new approach

N.M. Kneteman
Edmonton/CANADA

SOTA13.2 Locoregional therapy pre-transplant

F. Yao
San Francisco/UNITED STATES OF AMERICA

SOTA13.3 Priority of HCC candidates on the waiting list

R. Wiesner
Rochester/UNITED STATES OF AMERICA

SOTA13 - DISCUSSION
Session SOTA14 Islet cell replacement: outcomes and allocation

Tuesday, August 17, 2010 01:30 PM - 03:00 PM
Room: MR 220 - 222

Moderators: Anthony . Monaco, Phil . O’Connell

SOTA14.1 Results of Pancreas Transplantation in 2010. The case for prioritized allocation to whole pancreas.

J. Shapiro
Edmonton/CANADA

SOTA14.2 Results of Islet Transplantation in 2010. The case for prioritized allocation to islet transplantation.

S.T. Bartlett
Baltimore/UNITED STATES OF AMERICA

SOTA14.3 Impact of Pancreas and Islet Transplantation on Secondary Complications

A. Secchi
Milano/ITALY

SOTA14.4 Synthesizing the data. Synthesizing the evidence: a strategy for allocation to pancreas and islet transplantation.

P.R. Johnson
Oxford/UNITED KINGDOM

SOTA14 - DISCUSSION

15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA

Session O33 Cellular Mechanisms of Immune Regulation

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
TTS 2010 SCIENTIFIC PROGRAM

Room: MR 220 - 222

Moderators: Alice . Mui, Shane . Grey

O33.01 Allograft Tolerance in Mice with MGMT Chimeric Bone Marrow Engraftment

M. Hu¹, B. Kramer¹, B. Howden², G. Zhang¹, Y.M. Wang¹, G. McCowage¹, I. Alexander¹, P. Gunning¹, S.I. Alexander¹
¹Westmead/AUSTRALIA, ²Blackburn/AUSTRALIA

O33.02 Effects of pretransplantation microchimerism on allograft survival in HLA-haploidentical family donor renal transplantation

S.Y. Joo, M.H. Park, E.Y. Song, Y. Shin, J. Ha, S.J. Kim
Seoul/KOREA

O33.03 Donor Specific Immunoregulation in HLA-Identical Renal Transplant Recipients Given Alemtuzimab and Donor Stem Cells

J. Miller, J. Leventhal, L. Gallon, J. Friedewald, J. Levitsky, A. Tambur, X. Huang, J.M. Mathew
Chicago/UNITED STATES OF AMERICA

O33.04 The Pitfalls of Myeloid-only Mixed-Chimerism: Lack of T cell chimerism correlates with transplant rejection after immunosuppression withdrawal in a novel, MHC-defined primate model.

Atlanta/UNITED STATES OF AMERICA

O33.05 Acquisition of intact alloantigen by recipient DCs provokes cytotoxic CD8 T cell and alloantibody responses.

Cambridge/UNITED KINGDOM

O33.06 A single infusion of the ex-vivo generated immuno-regulatory dendritic cells under a novel agent, NK026680 markedly prolongs cardiac allograft survival

S. Shibasaki¹, K. Yamashita¹, Y. Yanagawa², K. Wakayama¹, H. Gentaro¹, Y. Tsunetoshi¹, M. Zaitsu¹, R. Igarashi¹, S. Haga¹, M. Ozaki¹, S. Todo¹
¹Sapporo/JAPAN, ²Tobetsu/JAPAN

O33.07 Role of maternally derived stem cells in non-inherited maternal antigen-specific tolerance
TTS 2010 SCIENTIFIC PROGRAM

P. Dutta, S.M. Schumacher, W.J. Burlingham
Madison/UNITED STATES OF AMERICA

O33.08 Kidney-derived mesenchymal stem cells modulate dendritic and T cell function to inhibit alloimmune responses and prolong allograft survival

Y. Huang1, C.B. Zhang1, G.-J. Ko1, P. Fiorina2, M.J. Ansari2, R. Abdi2, H. Rabb1, K.L. Womer1
1Baltimore/UNITED STATES OF AMERICA, 2Boston/UNITED STATES OF AMERICA

O33.09 In Vivo Evidence: the Role of Complement Component 3 (C3) in Induction of Myeloid-Derived Suppressor Cells (MDSC)

Cleveland/UNITED STATES OF AMERICA

Session O34 Cellular Assays of the Graft Response

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 217 - 219

Moderators: Ronald . Gill, Hideki . Ohdan

O34.01 Detailed kinetics of T-cells with direct allospecificity after liver transplantation: a novel assay

O. Tapirdamaz1, S. Mancham1, L.V.D. Laan1, G. Kazemier1, K. Thielemans2, H.J. Metselaar1, J. Kweekeboom1
1Rotterdam/NETHERLANDS, 2Brussel/BELGIUM

O34.02 FOXP3 Regulatory T Cells And Not Th17 Cells Are Involved In Ischemia Reperfusion Injury Of Human Donor Kidneys

C. Baan, A. Peeters, S. Korevaar, J.N. IJzermans, W. Weimar
Rotterdam/NETHERLANDS

O34.03 Effects of Donor Specific Bone Marrow Cells Infusion on Living Unrelated Kidney Transplantation

1Ahvaz/IRAN, 2Ulm/GERMANY, 3Seattle/UNITED STATES OF AMERICA, 4Tehran/IRAN

O34.04 Peripheral Blood CD8+KIR2D+ T Cell Repertoires In Liver Transplant Recipients
TTS 2010 SCIENTIFIC PROGRAM

M.R. López-Álvarez1, G. Salgado1, I. Legaz1, L. Gimeno1, J. Gil2, J.A. Campillo1, B. Las Heras1, S. Soriano1, A.M. García-Alonso1, M. Salcedo-Plaza2, P. Parrilla1, M. Muro1, M. Miras1, M.R. Álvarez-López1, A. Minguela1
1El Palmar. Murcia/SPAIN, 2Madrid/SPAIN

O34.05 Organ Specificity of Cross-Reactive Allogeneic Responses by Viral Specific Memory T-Cells

L.J. D’Orsogna1, E. van der Meer-Prins1, P. van der Pol1, M. Franke-van Dijk1, Y. Zoet1, M. Eikmans1, J. Anholts1, A. Mulder1, C. van Kooten1, J. Rossjohn2, J. McCluskey2, D. Roelen1, I. Doxiadis1, F. Claas1
1Leiden/NETHERLANDS, 2Melbourne/AUSTRALIA

O34.06 Do cross-reactive anti-viral T cells mediate allograft rejection in lung transplant recipients?

N. Mifsud, T. Nguyen, T. Kotsimbos
Melbourne/AUSTRALIA

O34.07 Longevity of Direct and Indirect CD4 T cell alloimmune responses

Cambridge/UNITED KINGDOM

O34.08 Increased IL-12p70 release by RAPA-conditioned human monocyte-derived DC promotes pro-inflammatory NK cell-IFN-gama help early during allo-specific CD4+ T cell priming

C. Macedo, M. Castillo-Rama, H. Turnquist, A.W. Thomson, D. Metes
Pittsburgh/UNITED STATES OF AMERICA

O34.09 Killer Immunoglobulin like Receptors incompatibility between HLA-matched Allogeneic HCT donor and recipients is associated with Acute Graft versus host disease

F.M. Khan, S. Wang, J. Doulla, J. Storek, N. Berka
Calgary/CANADA

Session O35 Biomarkers in Kidney Transplantation

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 211

Moderators: Peter . Nickerson, Caner . Suesal

O35.01 Discovery and Validation of Peripheral Blood Diagnostic Biomarkers for Acute Kidney Rejection: Report of the TGCG Study.
TTS 2010 SCIENTIFIC PROGRAM

S. Kurian1, A. Williams1, D. Campbell1, T. Mondala1, S. Head1, S. Horvath2, L. Gaber3, W. Lin2, E. Robison1, R. Schaffer1, J. Fisher1, S.M. Flechner4, L. Chan5, A. Wiseman6, H. Shidban2, R. Mendez2, R. Heilman7, C. Marsh1, D.R. Salomon1

1La Jolla/UNITED STATES OF AMERICA, 2Los Angeles/UNITED STATES OF AMERICA, 3Houston/UNITED STATES OF AMERICA, 4Cleveland/UNITED STATES OF AMERICA, 5Aurora/UNITED STATES OF AMERICA, 6Denver/UNITED STATES OF AMERICA, 7Phoenix/UNITED STATES OF AMERICA

O35.02 Differential regulation of positive or negative costimulatory molecules during acute rejection of human renal allografts

C. Afaneh, M. Lubetzky, T. Muthukumar, R. Ding, S. Seshan, C. Snopkowski, V. Sharma, D. Dadhania, M. Suthanthiran
New York/UNITED STATES OF AMERICA

O35.03 Single Nucleotide Polymorphism associated with Severity of Acute Rejection on Kidney Allograft Biopsies

A. Israni, R. Leduc, P. Jacobson, D. Schladt, W. Guan, W. Oetting, A. Matas, . For DeKAF Investigators Minneapolis/UNITED STATES OF AMERICA

O35.04 Refinement of genomic classifiers for early acute renal allograft rejection

O.P. Gunther, V. Chen, D. Lin, R. Ng, R. Balshaw, Z. Hollander, R. McMaster, B. McManus, P. Keown
Vancouver/CANADA

O35.05 Classification of acute renal rejection with proteogenomic ensemble classifiers

O.P. Gunther1, R. Ng1, R. Balshaw1, D. Lin1, A. Scherer2, V. Chen1, G. Cohen-Freue1, M. Takhar1, Z. Hollander1, R. McMaster1, B. McManus1, P. Keown1

1Vancouver/CANADA, 2Kontiolahti/FINLAND

O35.06 CYP3A5 *1 allele in Tacrolimus-based Immunosuppression: Impacts on Early Acute Cellular Rejection and 12-month Graft Function in Renal Transplantation

S.I. Min, Y.J. Park, S.H. Ahn, I.M. Jung, S.-K. Min, S.J. Kim, J.W. Ha
Seoul/KOREA

O35.07 A longitudinal study of the mRNA transcriptional evaluation in human kidney allograft dysfunction.

Porto Alegre/BRAZIL
TTS 2010 SCIENTIFIC PROGRAM

O35.08 Clinical factors and single nucleotide polymorphisms associated with Chronic Allograft Dysfunction post-kidney transplant

A. Israni, R. Leduc, P. Jacobson, D. Schladt, W. Guan, W. Oetting, A. Matas, . For DeKAF Investigators
Minneapolis/UNITED STATES OF AMERICA

O35.09 Exploratory and Inferential Statistics for the Discovery of Proteomic Biomarkers of Acute Kidney Allograft Rejection

Vancouver/CANADA

Session O36 Ethics, Public Policy and Economics

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 109 - 110

Moderators: Mark . Schnitzler, Zoltan . Kalo

O36.01 Extending Human Subject Research Protections: A Proposed Ban on Publication of Transplantation Research and Use of Data Involving Executed Prisoners

M. Valapour, A. Bodin
Minneapolis/UNITED STATES OF AMERICA

O36.02 Ending abuse of organ transplantation in China

D. Matas
Winnipeg/CANADA

O36.03 Fair Trade Kidney?

M. Moniruzzaman
East Lansing/UNITED STATES OF AMERICA

O36.04 A Center Coordinated, Pre-transplant Evaluation Eliminates Barriers to Kidney Transplantation and Establishes Parity Across All Socio-economic Groups

F. Barrantes1, A. Arvelakis1, W. Asch2, S. Coca2, R. Kalyesubula1, M. Bia2, R.N. Formica1, S. Kulkarni1
1New Haven/UNITED STATES OF AMERICA, 206520/UNITED STATES OF AMERICA
O36.05 The Development of Liver Transplant Registry in China

H. Wang, S. Fan
Hong Kong/HONG KONG

O36.06 European Living Donation and Public Health. EULID project

M. Manyalich¹, A. Ricart¹, C. Ballesté¹, D. Paredes¹, I. Fehrman-Eckholm², C. Hiesse³, L. Dias⁴, P.-D. Line⁵, A. Maxwell⁶, R. Turcu⁷, D. Avsec⁸, G. Kyriakides⁹, A. Nanni Costa¹⁰, J. Walaszewski¹¹
¹Barcelona/SPAIN, ²Göteborg/SWEDE, ³Paris/FRANCE, ⁴Porto/PORTUGAL, ⁵Oslo/NORWAY, ⁶Bristol/UNITED KINGDOM, ⁷Bucharest/ROMANIA, ⁸Ljubljana/SLOVENIA, ⁹Nicosia/CYPRUS, ¹⁰Roma/ITALY, ¹¹Warszaw/A/POLAND

O36.07 Cost-benefit analysis of extended donor coordinator system to increase organ donation rates in Hungary

Z. Kalo¹, J. Marton², S. Mihaly¹, P. Gerendy¹, Z. Kiss¹
¹Budapest/HUNGARY, ²Szeged/HUNGARY

O36.08 A Business Case for Supporting Liver Alone Organ Donors

C. Stoll, J.D. Punch, A. Kowalczyk, L. Fenton, J. Gray, R. Pietroski
Ann Arbor/UNITED STATES OF AMERICA

O36.09 Comparison the economic value of different types of organs in renal transplantation

Z. Kalo
Budapest/HUNGARY

Session O37 Use of mTOR Inhibitors and MPA II

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: Ballroom A/B

Moderators: Stuart . Flechner, Graeme . Russ

O37.01 Comparative pharmacokinetics of a sotrastaurin-everolimus versus a cyclosporine-everolimus regimen in de novo kidney transplant recipients

J.M. Kovarik¹, H. Tedesco-Silva², B. Lien³, L. Toselli⁴, S. Vitko⁵, P. Peeters⁶, M. Soergel¹
¹Basel/SWITZERLAND, ²Sao Paulo/BRAZIL, ³Oslo/NORWAY, ⁴Buenos Aires/ARGENTINA, ⁵Prague/CZECH REPUBLIC, ⁶Ghent/BELGIUM
O37.02 Cyclosporine and Tacrolimus Pharmacokinetics in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients

C. Tan-Tam, L. Frassetto, B. Barin, M. Browne, A. Wolfe, P. Stock, M. Roland, L. Benet
San Francisco/UNITED STATES OF AMERICA

O37.03 Individual Mycophenolat Dosing Based on IMPDH Measurement Significantly Improves Patients Outcomes After Renal Transplantation

D.K. Abendroth¹, M. Raggi¹, S. Siebert¹, M. Stangl²
¹Ulm/GERMANY, ²Munich/GERMANY

O37.04 Population pharmacokinetics of mycophenolic acid and its metabolites in combination with free or reduced doses of calcineurin inhibitors in renal transplant patients: The Symphony sub-study.

H. Colom¹, A.M. Caldes², F. Oppenheimer¹, J. Sánchez Plumed³, M.A. Gentil⁴, D.M. Kuypers⁵, M. Brunet¹, H. Ekberg⁶, J.M. Grinyó¹
¹Barcelona/SPAIN, ²L'Hospitalet De Llobregat/SPAIN, ³Valencia/SPAIN, ⁴Sevilla/SPAIN, ⁵Leuven/BELGIUM, ⁶Malmo/SWEDEN

O37.05 Pharmacokinetics of Mycophenolate Mofetil and enteric-coated Mycophenolate Sodium in Calcineurininhibitor-free treated renal transplantat patients

J. Gossmann¹, J. Graff¹, I. Dragutinovic¹, G. Brandhorst², E. Scheuermann¹, M. Oellerich²
¹Frankfurt/GERMANY, ²Goettingen/GERMANY

O37.06 Improved Renal Function Achieved With Everolimus Plus Cyclosporine Elimination Compared With Cyclosporine Minimization in Renal Transplant Recipients

J.M. Grinyó¹, J. Paul², P. Novoa³, P. Errasti⁴, A. Franco⁵, G. Aldana⁶, J. Pefaur⁷, F. Oppenheimer¹
¹Barcelona/SPAIN, ²Zaragoza/SPAIN, ³Córdoba/ARGENTINA, ⁴Pamplona/SPAIN, ⁵Alicante/SPAIN, ⁶Bogotá/COLOMBIA, ⁷Santiago/CHILE

O37.07 EC-MPS is associated with superior efficacy outcomes compared with MMF in de novo renal transplant recipients (RTxR) : a pooled analysis

M. Salvadori¹, E. Bertoni¹, K. Budde², H. Holzer³, G. Civati⁴, B. Lien⁵, W. Arns⁶
¹Florence/ITALY, ²Berlin/GERMANY, ³Graz/AUSTRIA, ⁴Milano/ITALY, ⁵Oslo/NORWAY, ⁶Koln/GERMANY

O37.08 Concentration Controlled Mycophenolate Dosing in Renal Transplantation in India

Vellore/INDIA
TTS 2010 SCIENTIFIC PROGRAM

O37.09 Lower Incidence of Cytomegalovirus and BK Virus with Everolimus versus Mycophenolate in De Novo Renal Transplant Patients: Results from a Multicenter, Prospective Study

¹Seoul/KOREA, ²Sao Paulo/BRAZIL, ³Lexington/UNITED STATES OF AMERICA, ⁴Taipei/TAIWAN, ⁵Shreveport/UNITED STATES OF AMERICA, ⁶Melbourne/AUSTRALIA, ⁷East Hanover/UNITED STATES OF AMERICA, ⁸Ann Arbor/UNITED STATES OF AMERICA

Session O38 Malignancy After Transplantation

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 202 - 204


O38.01 Risk Stratified Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Defining a New Standard of Care: Results From a Prospective International Multicenter Trial

R.U. Trappe¹, S. Choquet², V. Leblond², D. Dierickx³, P. Mollee⁴, J.M. Zaucha⁵, M. Sender⁶, T. Ekman⁶, P. Reinke¹, R. Neuhaus¹, H. Lehmkuhl¹, M.H. Dreyling¹, U. Dührsen⁷, G. Salles⁸, F. Morschhauser⁹, A. Jaccard¹⁰, T. Lamy¹¹, I. Anagnostopoulos¹, M. Raphael¹², H. Riess¹
¹Berlin/GERMANY, ²Paris/FRANCE, ³Leuven/BELGIUM, ⁴Brisbane/AUSTRALIA, ⁵Gdynia/POLAND, ⁶Gothenburg/SWEDEN, ⁷Essen/GERMANY, ⁸Pierre-Benite/FRANCE, ⁹Lille/FRANCE, ¹⁰Limoges/FRANCE, ¹¹Rennes/FRANCE, ¹²Le Kremlin-Bicetre/FRANCE

O38.02 IL-6 and TNF alpha plasma levels but not IL-10 plasma levels correlate with response to treatment in patients with PTLD: a longitudinal analysis form the German PTLD registry D 2006-2012

Berlin/GERMANY

O38.03 Colorectal Cancer and Advanced Colorectal Neoplasia in Kidney Transplant Recipients: a prospective screening study comparing Faecal Immunochemical Testing for occult blood with Colonoscopy

Adelaide/AUSTRALIA
O38.04 Impact of malignancy on patient survival after renal transplantation: a case control population based cohort study

J. van de Wetering¹, J.I. Roodnat¹, A.C. Hemke², A.J. Hoitsma², W. Weimar¹
¹Rotterdam/NETHERLANDS, ²Leiden/NETHERLANDS

O38.05 Modulation of Cellular MicroRNA by Latent Membrane Protein 1 of Epstein Barr Virus in B Cell Lymphomas

A. Harris, P.J. Lund, S.L. Lambert, S.M. Krams, O.M. Martinez
Stanford/UNITED STATES OF AMERICA

O38.06 Immunosoppressive therapy and risk of post-transplant malignancies in renal transplants: Italian multicentric study.

G. Segoloni¹, P. Rigotti², S. Sandrini², G. Busnach⁴, S. Stefoni⁵, D. Donati⁶, F. Citterio⁷, G. Piredda⁸, P.G. Messa⁴, P. Veroux⁹, P. Piselli⁷, D. Serraino¹⁰
¹Turin/ITALY, ²Padova/ITALY, ³Brescia/ITALY, ⁴Milan/ITALY, ⁵Bologna/ITALY, ⁶Varese/ITALY, ⁷Rome/ITALY, ⁸Cagliari/ITALY, ⁹Catania/ITALY, ¹⁰Aviano (pn)/ITALY

Session O39 Biologic and Therapeutic Advances in Heart Transplantation II

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 205 - 207

Moderators: Mario . Deng, Debra . Isaac

O39.01 Targeted Whole Blood Genomic Diagnostic Biomarker Discovery of Acute Heart Rejection

Vancouver/CANADA

O39.02 Successful reduction of immunosuppression with a novel tolerance protocol in aged, but not in young mice transplanted with cardiac allografts

Q. Liu, Y. Dai, W.J. Shufesky, A.E. Morelli, Z. Wang, Y. Toyoda
Pittsburgh/UNITED STATES OF AMERICA

O39.03 Total Spinal Blockade With Intrathecal Bupivicaine Preserves Cardiac Contractility in a Large Animal Model of Brainstem Death
O39.04 Cardiac Allograft Rejection: Expression and Regulation of the Chemokine Deocy Receptor D6

G. O’Boyle, S. Ali, H. Robertson, J.A. Kirby
Newcastle Upon Tyne/UNITED KINGDOM

O39.05 Cardiac rejection is a Th1 mediated response controlled by donor specific regulatory T cells: No role for Th17 cells

C. Baan, A. Peeters, A.H.M.M. Balk, E. Dijke, W. Weimar
Rotterdam/NETHERLANDS

O39.06 Cardiac allograft rejection correlates with increased expressions of TLR-2, TLR-4 and AIF-1.

Jackson/UNITED STATES OF AMERICA

O39.07 Homocysteine, anti-cardiolipin antibodies and soluble CD40 ligand in heart transplant recipients.

O.V. Orlova, A.O. Shevchenko, E.N. Kazakov, A.J. Kormer, O.P. Shevchenko
Moscow/ RUSSIAN FEDERATION

O39.08 Effect of VEGF Inhibition on Luminal Narrowing and the Pro-Angiogenic Properties of Bone Marrow-Derived Cells

S. Chatur, B. Wong, S. Williams, S. Boroomand, J. Carthy, B. McManus
Vancouver/ CANADA

O39.09 Positive Flow Cytometry Crossmatches and Donor-Specific HLA Antibodies May Not Be Contraindications to Heart Transplantation

Houston/UNITED STATES OF AMERICA

Session O40 HCC and Living Donor Transplantation

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 118 - 120
O40.01 Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma

C. Toso¹, S. Merani², D. Bigam², J. Shapiro², N. Kneteman²
¹Geneva/SWITZERLAND, ²Edmonton/CANADA

O40.02 Liver Transplantation for Hepatocellular Carcinoma in China

H. Wang¹, Y. HUANG², W. Li², W. JIANG², S. Fan¹
¹Hong Kong/HONG KONG, ²Shenzhen/CHINA

O40.03 A pilot study: Sorafenib in patients with post liver transplant recurrence of HCC.

M. Lu, Y. Chen, C. Cai, X. Yi
Guangzhou/CHINA

O40.04 Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation

G. Otto, M. Hoppe-Lotichius, F. Bittinger, M. Pitton, M. Schuchmann
Mainz/GERMANY

O40.05 Changing the landscape of adult to adult living donor liver transplantation: The role of the small for size grafts.

J.F. Botha¹, A.N. Langnas¹, C.E. Freise², W.J. Grant¹, N. Ascher², D.F. Mercer¹, J.P. Roberts²
¹Omaha/UNITED STATES OF AMERICA, ²San Francisco/UNITED STATES OF AMERICA

O40.06 The significance of acute-phase small-for-size liver graft injury in mobilization of circulating EPCs/MDSCs/Tregs after LDLT for HCC patients

K. Man, Y. Shao, K.T. Ng, N. Wong, X. Liu, C. Li, S. Fan, C.-M. Lo
Hong Kong/HONG KONG

O40.07 291 Dual Living-Donor Liver Transplantation at the Single Center

Seoul/KOREA

O40.08 Living donor liver transplantation for adult patients using left liver graft
O40.09 The potential role of early-phase graft injury in induction of late-phase chemoresistance after liver transplantation

Hong Kong/HONG KONG

Session O41 Transplantation in ABO Mismatched and Sensitized Recipients

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: Ballroom C

Moderators: Gunnar . Tyden, James . Gloor

O41.01 Results from an Australian National ABO Incompatible (ABOI) Renal Transplant Collaborative Group

1Sydney/AUSTRALIA, 2Brisbane/AUSTRALIA, 3Adelaide/AUSTRALIA, 4Perth/AUSTRALIA, 5Clayton/AUSTRALIA, 6Newcastle/AUSTRALIA, 7Heidelberg/AUSTRALIA

O41.02 Evolution of Immunosuppressive Regimen in 417 Cases of ABO-incompatible Kidney Transplantation in Single Center.

S. Teraoka, I. Koyama, T. Murakami, I. Nakajima, S. Fuchinoue, H. Ishida, K. Tanabe
Tokyo/JAPAN

O41.03 Desensitization protocol with antibody-specific immunoabsorption strongly interferes with complement activation in ABO-incompatible kidney transplantation

Uppsala/SWEDEN

O41.04 Acute Rejection in Living Donor ABO-incompatible kidney transplantation

D. Polanska-Tamborek, G. Nordén, M. Gäbel, L. Mjörnstedt, I. Fehrman-Ekholm
Göteborg/SWEDEN

O41.05 Unmasking Donor Specific Antibodies in Patients with Antibody Mediated Rejection
O41.06 The significance of IgG subclasses in HLA antibody incompatible kidney transplantation.

D. Lowe¹, R. Higgins², D. Zehnder², M. Hathaway¹, R. Hamer², N. Krishnan², D. Briggs¹
¹Birmingham/UNITED KINGDOM, ²Coventry/UNITED KINGDOM

O41.07 Clinical significance of de novo production of HLA donor-specific antibodies in kidney transplantation.

A. Piazza, E. Poggi, G. Ozzella, D. Caputo, R. Cremona, G. Iaria, G. Tisone, D. Adorno
Rome/ITALY

O41.08 Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation

Tokyo/JAPAN

O41.09 Low levels of donor-specific HLA antibody at transplantation are associated with an early resynthesis response

R. Higgins¹, D. Lowe², D. Zehnder¹, M. Hathaway², N. Krishnan¹, R. Hamer¹, H. Kashi¹, F.T. Lam¹, L.C. Tan¹, C. Imray¹, D. Briggs²
¹Coventry/UNITED KINGDOM, ²Birmingham/UNITED KINGDOM

Session O42 Clinical Pancreas Transplantation I

Tuesday, August 17, 2010 03:30 PM - 05:00 PM
Room: MR 212 - 214

Moderators: John. Najarian, Mark. Meloche

O42.01 Simultaneous Pancreas and Kidney Transplantation from ABO-incompatible Living Donors. – Outcome of Six Consecutive Clinical Trials in a Single Institution–

T. Kenmochi¹, T. Asano¹, K. Saigo¹, M. Maruyama², N. Akutsu², C. Iwashita², K. Otsuki², T. Ito², A. Suzuki¹
¹Chiba City/JAPAN, ²Chiba/JAPAN
O42.02 Risk factors for technical failure after Pancreas (px) Transplant (tx) - single center analysis of over 1000 tx in a decade

Minneapolis/UNITED STATES OF AMERICA

O42.03 Improvement of Patient and Graft Survival in Pancreas Transplants Alone (PTA)

A.C. Gruessner, D.E.R. Sutherland, R.W.G. Gruessner
Tucson/UNITED STATES OF AMERICA

O42.04 Enteroscopic biopsy as a new tool for immunological monitoring after pancreas transplantation

C. Margreiter\(^1\), T. Resch\(^1\), A.-K. Berenji\(^1\), R. Oberhuber\(^1\), C. Boesmueller\(^1\), H. Bonatti\(^2\), R. Margreiter\(^1\), J. Pratschke\(^1\), W. Mark\(^1\)
\(^1\)Innsbruck/AUSTRIA, \(^2\)Charlottesville/UNITED STATES OF AMERICA

O42.05 Portal Venous Drainage of Pancreas Grafts: Impact on Long-Term Results

F. Bazerbachi, M. Selzner, M. Marquez, A. Norgate, I.D. McGilvray, J. Schiff, M.S. Cattral
Toronto/CANADA

O42.06 Cross sectional report of first year clinical outcomes in a cohort of simultaneous pancreas kidney transplant recipients with an immunosuppressive regimen containing everolimus

L. Reniero, G. Illanes, D. Casadei
Buenos Aires/ARGENTINA

O42.07 Pancreas Transplant Alone in Type 1 Diabetic Recipients with Overt Diabetic Nephropathy: Renal Function Outcome

U. Boggi, F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti
Pisa/ITALY

O42.08 Significant Interaction Between Donor and Recipient Age in Patients Undergoing Simultaneous Kidney/Pancreas Transplantation

P. Garzon\(^1\), V. Krishnamurthi\(^2\), J. Sokolich\(^1\), L.K. Kayler\(^1\), J.D. Schold\(^2\), J.F. Magliocca\(^1\)
\(^1\)Gainesville/UNITED STATES OF AMERICA, \(^2\)Cleveland/UNITED STATES OF AMERICA

O42.09 Portal Venous Drainage of Pancreas Allografts Offers No Survival Benefit to Patients Undergoing SPK and May Result in Higher Early Rejection Rates
TTS 2010 SCIENTIFIC PROGRAM

J. Sokolich\textsuperscript{1}, V. Krishnamurthi\textsuperscript{2}, P. Garzon\textsuperscript{1}, L.K. Kayler\textsuperscript{1}, J.D. Schold\textsuperscript{2}, J.F. Magliocca\textsuperscript{1}

\textsuperscript{1}Gainesville/UNITED STATES OF AMERICA, \textsuperscript{2}Cleveland/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

WEDNESDAY, AUGUST 18

07:00 – 08:15 SUNRISE SYMPOSIA

Session SUN12 TTS/IPTA Symposium on Pediatric Transplantation: Overcoming barriers to successful organ transplantation in children

Wednesday, August 18, 2010 07:00 AM - 08:15 AM
Room: MR 212 - 214

Moderators: Anne . Dipchand, Richard . Fine

SUN12.1 Obstacles to generating evidence for pediatric practice: the need for randomized controlled trials in children
T. Klassen
Edmonton/CANADA

SUN12.2 Drug approval in children and the CTOT-C program
B. Harmon

SUN12.3 Ethical issues related to organ donation and transplantation in children: a global perspective
S.V. McDiarmid
Los Angeles/UNITED STATES OF AMERICA

SUN12 - DISCUSSION

Session SUN13 Xenotransplantation: From the lab to the clinic

Wednesday, August 18, 2010 07:00 AM - 08:15 AM
Room: MR 202 - 204


SUN13.1 Current status of xenotransplantation and prospects for clinical application
TTS 2010 SCIENTIFIC PROGRAM

R.N. Pierson III
Baltimore/UNITED STATES OF AMERICA

SUN13.2 Update on clinical trials in xenotransplantation
B. Elliott

SUN13.3 Regulatory issues in the transition to clinical therapy
K. Wonnacott
Rockville/UNITED STATES OF AMERICA

SUN13 - DISCUSSION

Session SUN14 Complications of transplantation

Wednesday, August 18, 2010 07:00 AM - 08:15 AM
Room: MR 205 - 207

Moderators: Alan Jardine, Domingo Casadei

SUN14.1 Biology and biomarkers of accelerated cardiovascular disease in transplantation
B. Fellstrom
Uppsala/SWEDEN

SUN14.2 Prediction and prevention of the metabolic syndrome in transplantation
B. Kasiske
Minneapolis/UNITED STATES OF AMERICA

SUN14.3 Incidence and epidemiology of disease recurrence after transplantation
C. Legendre
Paris/FRANCE

SUN14 - DISCUSSION
Session SUN15 Detection and monitoring of antibodies prior to transplantation

Wednesday, August 18, 2010 07:00 AM - 08:15 AM
Room: MR 217 - 219

Moderators: Phil . Dyer, Maria . Gerbase-DeLima

SUN15.1 Antibody monitoring for patients on the routine waiting list

P.A. Dyer
Edinburgh/UNITED KINGDOM

SUN15.2 Determination and use of the calculated PRA

M.S. Leffell
Baltimore/UNITED STATES OF AMERICA

SUN15.3 The immunology laboratory in clinical desensitization

A.A. Zachary
Baltimore/UNITED STATES OF AMERICA

SUN15.4 The virtual crossmatch and its implications

N. Reinsmoen
Los Angeles/UNITED STATES OF AMERICA

SUN15 - DISCUSSION

Session SUN16 The Biology of Patient Care

Wednesday, August 18, 2010 07:00 AM - 08:15 AM
Room: MR 211

Moderators: Chris . Shay, Norine . Heywood

SUN16.1 Defining the sensitized patient: How to identify what you hope not to find.
TTS 2010 SCIENTIFIC PROGRAM

L.G. Hidalgo
Edmonton/CANADA

SUN16 - DISCUSSION

SUN16.2 Future Directions - Genetic markers of rejection

P.A. Keown
Vancouver/CANADA

SUN16 - DISCUSSION

08:30 – 10:00 PLENARY SESSION

Session PL03 Stem Cells and Regeneration

Wednesday, August 18, 2010 08:30 AM - 10:00 AM
Room: Ballroom A/B

Moderators: Kathryn . Wood, Lee Anne . Tibbles

PL03.1 Generation, Programming and Applications of Induced Pluripotent Stem Cells

H.R. Schoeler
Muenster/GERMANY

PL03.2 Advances in Regenerative Biology and Organ Biogenesis

D. Taylor
City/UNITED STATES OF AMERICA

PL03.3 Lung Repair, Regeneration and Transplantation

S. Keshavjee
Toronto/CANADA
TTS 2010 SCIENTIFIC PROGRAM

08:30 – 10:00 PLENARY SESSION

Session PRS President’s Plenary Symposium

Wednesday, August 18, 2010 10:00 AM - 12:00 PM
Room: Ballroom A/B

Moderators: Jeremy. Chapman, Nicholas. Tilney

PRS.1 Presidential Address

J.R. Chapman
Westmead/AUSTRALIA

PRS.2 Opportunities and Obstacles in Translational Medicine

C. Stiller
London/CANADA

PRS.3 The Science and Technology of Cell Identity

S. Brenner
UNITED STATES OF AMERICA

12:15 – 13:15 MINI ORAL SESSIONS

Session MO15 Immunological Monitoring

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 202 - 204

Moderators: Manikkam. Suthanthiran, Pekka. Hayry

MO15.01 Flow Cytometry Crossmatches Are Influenced by Levels of HLA Expression on Donor Lymphocytes

San Francisco/UNITED STATES OF AMERICA
**TTS 2010 SCIENTIFIC PROGRAM**

MO15.02 Sequential analysis by immunoprecipitation-MALDI-TOF mass spectrometry for detection and identification of alloantibody specificities

A. Heinold, B. Kuehl, G. Brenner-Weiss, G. Opelz, T.H. Tran

1Heidelberg/GERMANY, 2Eggenstein-Leopoldshafen/GERMANY

MO15.03 Post-Transplant HLA antibodies Detected by Luminex Donor-Specific Crossmatch Correlate with Poor Liver Graft Outcome


Sao Paulo/BRAZIL

MO15.04 Phosphospecific Flow Cytometry demonstrates CNI based Inhibition of P38 MAP Kinase in Renal Allograft Patients

R. Vafadari, M. Quaedackers, W.M. Mol, W. Weimar, C.C. Baan

Rotterdam/NETHERLANDS

MO15.05 The Differential Effects of Tacrolimus and Sirolimus in the Human ”Treg-MLR”

J. Levitsky, L. Gallon, J. Miller, J. Leventhal, A. Tambur, X. Huang, C. Flaa, E. Wang, J.M. Mathew

Chicago/UNITED STATES OF AMERICA

MO15.06 Increased pretransplant plasma Kynurenine levels do not protect from but predict acute kidney allograft rejection

I. LAHDOU

Heidelberg/GERMANY

MO15.07 Graft Inflammation And Histological Indicators of Kidney Chronic Allograft Failure: Genetic predisposition to Low Expressing Interleukin-10 Genotypes is significantly correlated

F.M. Khan, A. Sar, I.I. Gonul, J. Doulla, S. Yilmaz, N. Berka

Calgary/CANADA

MO15.08 Genetic analysis of human B lymphocyte repertoire specific to ABO blood group antigens

X. Fan, R. Yin, G. Wong, D. Cheung, Q. Wu, R. Satkunasivam, L.J. West

Edmonton/CANADA

MO15.09 More than thousand successful deceased donor renal transplants without current serum pre-transplant crossmatch.
S. Vaidya
Galveston, UNITED STATES OF AMERICA

MO15.10 Testing for donor-specific anti-endothelial antibodies using the XM-One assay
Chicago, UNITED STATES OF AMERICA

MO15.11 Correlation of B cell positive flow crossmatch and donor specific class II HLA antibody detected by Luminex
J. Downing, P. Dunn
Auckland, NEW ZEALAND

Session MO16 Organ Donation, Preservation and Allocation

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 109 - 110

Moderators: Axel . Rahmel, Paul . Robertson

MO16.01 Bayesian Modeling of the United States Renal Data System Pre-Transplant Variables Accurately Predicts Graft Survival
K.A. Stevens1, S. Phinney2, C. Graybill2, S. Gillern2, M. Salifu2, R. Jindal2, T. Brown1, E. Elster1
1Silver Spring, UNITED STATES OF AMERICA, 2Dc, UNITED STATES OF AMERICA

MO16.02 Expanded criteria donor kidneys for younger recipients- Acceptable Outcomes
K.R. Goplani, P.R. Shah, A.V. Vanikar, P.R. Modi, M.R. Gumber, H.V. Patel, H.L. Trivedi
Ahmedabad, INDIA

MO16.03 Heavy water containing organ preservation solution, Dsol, ameliorates graft survival and function of the rat hearts after extended cold preservation
K. Wakayama1, M. Fukai1, K. Yamashita1, D. Fukumori1, S. Shibasaki1, H. Gentaro1, M. Zaitsu1, Y. Tsunetoshi1, M. Sugawara1, M. Taniguchi1, T. Suzuki1, T. Shimamura1, H. Furukawa2, M. Ozaki1, S. Todo1
1Sapporo, JAPAN, 2Asahikawa, JAPAN

MO16.04 Renal Transplantation Following Donation after Cardiac Death (DCD): Impact of Duration From Withdrawal to Asystole
TTS 2010 SCIENTIFIC PROGRAM

Leeds/UNITED KINGDOM

MO16.05 Sequential transplant of paired kidneys following donation after cardiac death (DCD): Impact of Longer Cold Ischaemia time on the second kidney on graft and patient outcome.

Leeds/UNITED KINGDOM

MO16.06 Impact of Donor Age on Outcome of Kidney Transplantation from Controlled Donation after Cardiac Death

T.A.K. Rana, E. Fitzgerald, J.A. Akoh
Plymouth/UNITED KINGDOM

MO16.07 Extracorporeal normothermic abdominal perfusion “in situ” by leukocytes-free oxygenated blood as resuscitation practice for kidneys from uncontrolled donors with one-hour warm ischemic time

O. Reznik¹, A. Ananyev¹, I. Loginov¹, A. Skvortcov¹, S. Bagnenko¹, Y. Mousyuk²
¹Saint-Petersburg/ RUSSIAN FEDERATION, ²Moscow/ RUSSIAN FEDERATION

MO16.08 Outcomes Following Renal Transplantation after Multi-Organ Retrieval versus Kidney Only Retrieval in Donation after Cardiac Death Donors

Leeds/UNITED KINGDOM

MO16.09 Exploding the myths: the real potential for lung transplantation from Donation-after-Cardiac-Death (DCD) donor lungs

G.I. Snell, B. Levvey, A. Griffiths, S. Graham, D. Pilcher
Melbourne/AUSTRALIA

MO16.10 Machine Measured Renal Resistance (MMRR) is the most sensitive tool for prediction of early renal allograft survival.

New York/UNITED STATES OF AMERICA

MO16.12 Important characteristics of heavy water (D2O) containing cold preservation solution
TTS 2010 SCIENTIFIC PROGRAM
M. Fukai¹, K. Wakayama¹, K. Yamashita¹, D. Fukumori¹, M. Sugawara¹, S. Haga¹, H. Furukawa², M. Ozaki¹, S. Todo¹
¹Sapporo/JAPAN, ²Asahikawa/JAPAN

Session MO17 CNI Minimization Strategies

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 211

Moderators: Yvon . Lebranchu, Daniel . Seron

MO17.01 Sirolimus-based calcineurin inhibitor-free immunosuppressive therapy in renal allograft recipients receiving kidneys from older donors – a randomised study conducted in Sweden and Norway

O. Øyen¹, G. Tufveson², B. Izay³, E. Ingman³, L. Wramner⁴
¹Oslo/NORWAY, ²Uppsala/SWEDEN, ³Solna/SWEDEN, ⁴Gothenburg/SWEDEN

MO17.02 Calcineurin-Free Immunosuppression In Non-Heart-Beating Donor Kidney Transplant Recipients

F. Oppenheimer, V. De la Fuente, N. Esforzado, I. Revuelta, F. Cofan, V. Torregrosa, M.J. Ricart, J.M. Campistol
Barcelona/SPAIN

MO17.03 Full Dose Mycophenolate Mofetil (CellCept®) With Low Dose Tacrolimus Optimizes Renal Function in Long Term Renal Transplant Patients; Results Of The TranCept STAY Study

U. Heemann¹, V. Kliem², A. Hamza³, K. Budde⁴, F. Juarez de la Cruz⁵, W. Arns⁶, C. Gahlemann⁷, J.S. Juergensen⁸, H. Haller⁸
¹Muenchen/GERMANY, ²Hann. Münden/GERMANY, ³Halle/Saale/GERMANY, ⁴Berlin/GERMANY, ⁵TorreÓN/MEXICO, ⁶Koeln-Merheim/GERMANY, ⁷Basel/SWITZERLAND, ⁸Hannover/GERMANY

MO17.04 Impact of early conversion at 3 months from Cyclosporine (CsA) to Sirolimus (SRL) in association with Mycophenolate Mofetil (MMF) on renal function

Y. LEBRANCHU¹, O. TOUPANCE¹, G. TOUCHARD¹, E. THERVET¹, I. ETIENNE¹, P. WESTEEL¹, B. HURAULT DE LIGNY¹, B. MOULIN¹, J. REROLLE¹, T. FOURGET¹, L. SAADA², M. BUCHLER¹
¹Tours/FRANCE, ²Neuilly Sur Seine/FRANCE

MO17.05 Conversion from tacrolimus to sirolimus-based immunosuppressive regimen in kidney transplant recipients. Preliminary results
MO17.06 Conversion To Low Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplant: A Prospective, Protocol Biopsy Guided Study

Buffalo/UNITED STATES OF AMERICA

MO17.07 De novo Everolimus With Early Elimination of Cyclosporine Provides Better Renal Function at Month 12 in Renal Transplant Patients With Higher Month 3 Renal Function and Graft Survival

J.M. Grinyó¹, J. Paul², P. Novoa³, P. Errasti⁴, A. Franco⁵, G. Aldana⁶, J. Pefaur⁷, F. Oppenheimer¹
¹Barcelona/SPAIN, ²Zaragoza/SPAIN, ³Córdoba/ARGENTINA, ⁴Pamplona/SPAIN, ⁵Alicante/SPAIN, ⁶Bogotá/COLOMBIA, ⁷Santiago/CHILE

MO17.08 Better Renal Allograft Function with Everolimus Facilitated CNI Reduction - Graft Type, Donor Criteria and Gender Analysis

L. Chan¹, H. Riad², G. Tufveson³, D.M. Cibrik⁴, H. Tedesco-Silva⁵, H. Schwende⁶, Z. Wang⁷, G. Junge⁶
¹Aurora/UNITED STATES OF AMERICA, ²Manchester/UNITED KINGDOM, ³Uppsala/SWEDEN, ⁴Ann Arbor/UNITED STATES OF AMERICA, ⁵Sao Paulo/BRAZIL, ⁶Basel/SWITZERLAND, ⁷East Hanover/UNITED STATES OF AMERICA

MO17.09 Cyclosporine (CyA) very low dose with Everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS

E. Bertoni, G. Rosso, A. Larti, L. Di Maria, M. Zanazzi, M. Salvadori
Florence/ITALY

MO17.10 60% Reduction in Cyclosporine Exposure with Everolimus Over 12 Months in De Novo Renal Transplant Recipients: Results from a Multicenter, Randomized Study

¹Banská Bystrica/SLOVAK REPUBLIC, ²Ann Arbor/UNITED STATES OF AMERICA, ³Lexington/UNITED STATES OF AMERICA, ⁴Seoul/KOREA, ⁵Milano/ITALY, ⁶Melbourne/AUSTRALIA, ⁷Shreveport,/UNITED STATES OF AMERICA, ⁸East Hanover/UNITED STATES OF AMERICA, ⁹Sao Paulo/BRAZIL

MO17.11 Conversion to Tacrolimus QD (Advagraf) from ciclosporin reduces ciclosporin-related side effects: results from CONCERTO

E. Ikehara¹, V.D. Garcia², E. David-Neto¹, D.D.B.M. Carvalho³, F.L. Contieri⁴, M. Abbud-Filho⁵, H. Tedesco Silva¹, E. Ikehara¹
¹Sao Paulo/BRAZIL, ²Porto Alegre/BRAZIL, ³Rio De Janeiro/BRAZIL, ⁴Curitiba/BRAZIL, ⁵Sao Jose Do Rio Preto/BRAZIL
TTS 2010 SCIENTIFIC PROGRAM

M. Glyda\textsuperscript{1}, L. Rostaing\textsuperscript{2}, A. Sánchez-Fructuoso\textsuperscript{3}
\textsuperscript{1}Poznan/POLAND, \textsuperscript{2}Toulouse/FRANCE, \textsuperscript{3}Madrid/SPAIN

Session MO18 Innovations in Heart Transplantation I

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 205 - 207

Moderators: Jon . Kobashigawa, Andreas . Zuckermann

MO18.01 Proton Pump Inhibitors Impact Cyclosporine Dose/Exposure Relation in De Novo HTxR Treated with MMF or Everolimus – Emphasis of Therapeutic Drug Monitoring

C. Bara\textsuperscript{1}, G. Laufer\textsuperscript{2}, M.G. Crespo\textsuperscript{3}, T.J. Dengler\textsuperscript{4}, A. Karpov\textsuperscript{5}, L. Potena\textsuperscript{6}, H. Schwende\textsuperscript{5}, S. Varnous\textsuperscript{7}, G. Junge\textsuperscript{3}
\textsuperscript{1}Hannover/GERMANY, \textsuperscript{2}Wien/AUSTRIA, \textsuperscript{3}Coruna/SPAIN, \textsuperscript{4}Heidelberg/GERMANY, \textsuperscript{5}Basel/SWITZERLAND, \textsuperscript{6}Bologna/ITALY, \textsuperscript{7}Paris/FRANCE

MO18.02 IgG immune restoration after intravenous immunoglobulin replacement therapy in heart recipients with post transplant antibody deficiency

Madrid/SPAIN

MO18.03 Hormonal status influences adaptive and maladaptive signaling after mTOR inhibition in female cardiomyocytes

A. Kusch, M. Schmidt, R. Catar, B. Hegner, D. Dragun
Berlin/GERMANY

MO18.04 Angiographic Stanford type B2 lesions indicate post-cardiac transplant microvascular dysfunction as assessed by Doppler flow velocity measurements

N.E. Hiemann\textsuperscript{1}, R. Meyer\textsuperscript{2}, H.B. Lehmkuhl\textsuperscript{1}, C. Knosalla\textsuperscript{1}, R. Hetzer\textsuperscript{1}, E. Wellnhofer\textsuperscript{1}
\textsuperscript{1}Berlin/GERMANY, \textsuperscript{2}Nerlin/GERMANY

MO18.06 Both dopamine and its derivate N-Octanoyl-Dopamine protect cardiomyocytes against cold preservation injury

B. Yard, C. Hepp, C. Vettel, U. Benck, P. Schnuelle, S. Hoeger
Mannheim/GERMANY
MO18.07 T-helper 1 cells play a key role in the fibro-proliferative response in Cardiac Allograft Vasculopathy.

Utrecht/NETHERLANDS

MO18.08 Everolimus prevents clinically silent, biopsy-proven antibody-mediated rejection in cardiac transplant recipients

N.E. Hiemann¹, E. Wellnhofer¹, H.B. Lehmkuhl¹, C. Knosalla¹, R. Hetzer¹, R. Meyer²
¹Berlin/GERMANY, ²Nerlin/GERMANY

MO18.09 Estimation of Cardiovascular Risk in 1007 Heart Transplants Recipients – The Framingham Risk Score

A. Zuckermann¹, C. Bara², H. Eisen³, A. Karpov⁴, J. Kobashigawa⁵, H.B. Lehmkuhl⁶, H. Ross⁷, H. Schwende⁸, G. Junge⁴
¹Vienna/AUSTRIA, ²Hannover/GERMANY, ³Philadelphia/UNITED STATES OF AMERICA, ⁴Basel/SWITZERLAND, ⁵Los Angeles/UNITED STATES OF AMERICA, ⁶Berlin/GERMANY, ⁷Toronto/CANADA

MO18.10 Combined heart and liver transplantation for congenital heart disease and end-stage liver cirrhosis

Pittsburgh/UNITED STATES OF AMERICA

MO18.11 Biomarkers of Chronic Heart Allograft Rejection

Vancouver/CANADA

MO18.12 Efficacy of CPRA and virtual crossmatch is negatively impacted by false positive reactivity resulted from denatured HLA Class I antigens present on Luminex as well as Flow single antigen beads.

S. Vaidya
Galveston,/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 217 - 219

Moderators: Pierre. Clavien, Andrej. Buczkowski

MO19.01 Evolution of Nonalcoholic Steatohepatitis in Liver Transplantation: Frequency and Comparative Outcomes of the SRTR database

M.R. Charlton, J.M. Burns, J. Heimbach, K. Watt, R. Pedersen, R. Dierkhising
Rochester/UNITED STATES OF AMERICA

MO19.02 The Codman classification applied in liver transplantation: a tool for quality control and improvement of outcomes

J. Moon, A. Tzakis, S. Koonce
Miami/UNITED STATES OF AMERICA

MO19.03 The influence of alcohol abuse history on the differential, longitudinal patterns of mental and physical quality of life following liver transplant

Detroit/UNITED STATES OF AMERICA

MO19.04 Predictors of 30 day readmissions; an analysis to identify what the cost of these are and what we might modify to reduces these.

R. Gilroy1, J. Sabah2, S. Govindan2, M. Waldron2, A.T. atav@ksu.edu3, J. Kindscher2
1UNITED STATES OF AMERICA, 2Kansas City/UNITED STATES OF AMERICA, 3Manhattan/UNITED STATES OF AMERICA

MO19.05 Suramin Improves Survival of Steatotic Grafts after Partial Liver Transplantation

S. He, H. Rehman, Z. Zhong
Charleston/UNITED STATES OF AMERICA

MO19.06 HCV infection and HLA-DRB1*11 in liver transplantation: a 15 years marriage

Torino/ITALY

MO19.07 The Use of Hepatitis B Core Antibody Positive Donor Livers Does Not Have a Deleterious Effect on Graft Survival in Liver Transplantation for Hepatitis C
TTS 2010 SCIENTIFIC PROGRAM

Portland/UNITED STATES OF AMERICA

MO19.08 Crucial Role of Post-reperfusion Allograft Biopsy in Evaluation of Follow-up Biopsies after Liver Transplantation

M. Raoufi¹, M. El Atrache¹, K. Brown¹, D. Moonka¹, A. Yoshida¹, D. Kim¹, M. Kazimi¹, S. Sharma², M. Abouljoud¹
¹Detroit/UNITED STATES OF AMERICA, ²Detroit/UNITED STATES OF AMERICA

Session MO20 Xenotransplantation

Wednesday, August 18, 2010 12:15 PM - 01:15 PM
Room: MR 220 - 222

Moderators: Maria . Koummanda, David . White

MO20.01 siRNA-Mediated Tissue Factor Knockdown in Neonatal Porcine Islet Cell Clusters Resulted in Suppression of IBMIR in Vitro

M. Ji, S. Yi, H. Smith-Hurst, P. Phillips, J. Wu, P.J. O’Connell
Sydney/ AUSTRALIA

MO20.02 Auxiliary Transplantation of the chimeric liver graft in mouse and rat combination and evaluation of the long-term survival and proliferative capacity of the transplanted graft in the recipient rat

T. Hata¹, K. Endo¹, K. Jobara¹, J. Iwasaki¹, E. Kobayashi², S. Uemoto¹
¹Kyoto/JAPAN, ²Shimotsuke/JAPAN

MO20.03 Comparison of Survival of GalT-KO Pig Skin to Allogeneic Skin on Baboons: the Role of Graft Bed Depth and of Cyclosporine treatment

Boston/UNITED STATES OF AMERICA

MO20.04 Prolonged ex-vivo pulmonary xenograft function using genetically-modified porcine donor lungs

G. Westall¹, B. Levvey¹, S. Marasco¹, J. Gooi¹, R. McEgan¹, M. Meenan¹, C. Egan¹, F. Rosenfeldt¹, E. Salvaris¹, K. Dwyer¹, M. Nottle², G.I. Snell¹, P. Cowan³
¹Melbourne/ AUSTRALIA, ²Adelaide/ AUSTRALIA
TTS 2010 SCIENTIFIC PROGRAM

MO20.05 High levels of cytotoxic anti-non Gal preformed natural antibody did not induce hyperacute rejection but did cause early graft loss in a GalT-KO pig-to-baboon thymokidney model

Boston/UNITED STATES OF AMERICA

MO20.06 Increased frequency of CD4+CD25Hi Foxp3+ Treg cells in peripheral blood of long term heterotopic cardiac xenograft (Pig to Baboon) recipients

Bethesda/UNITED STATES OF AMERICA

MO20.07 An analysis of pig cytidine monophospho-N-acetylneuraminic acid (CMP-NeuAc) hydroxylase.

Suita/JAPAN

MO20.08 Mid-term Efficacy of Porcine Corneal Xenotransplantation in Non-Human Primates

Seoul/KOREA

MO20.09 Immunogenicity of Islets Isolated from Three and Seven Day-Old Newborn Pigs

H. Arefanian¹, D.C. Mok¹, Q. Ramji¹, I.R. Badell², P.W. Thompson², C. Larsen², R.G. Gill¹, G.S. Korbutt¹, R.V. Rajotte¹, G.R. Rayat¹
¹Edmonton/CANADA, ²Atlanta/UNITED STATES OF AMERICA

MO20.10 Aberrant activation of coagulation is independent of xenoreactive antibody titer and complement activation in ex vivo perfusion of porcine kidneys.

J. Klose, W. Ramackers, S. Bergmann, J. Klempnauer, M. Winkler
Hannover/GERMANY

MO20.11 Generation of Porcine Cardiac Xenografts: AAV2/9-Mediated Gene Transfer into Myocytes using the in situ Langendorff Perfusion Model

L. Burdorfi, J. Postrach¹, E. Thein¹, R. Hinkel¹, M. Schmidt¹, A. Bauer¹, S. Michel¹, P. Brenner¹, B. Reichart¹, C. Kupatt¹, M. Schmoeckel²
¹Munich/GERMANY, ²Hamburg/GERMANY

Session MO21 Late Breaking Mini Oral
**TTS 2010 SCIENTIFIC PROGRAM**

**Wednesday, August 18, 2010 12:15 PM - 01:15 PM**

**Room: MR 212 - 214**

Moderators: *Kareem . Abu-Elmagd*

MO21.01 FOXP3+ T-cells and TH2 immune response shift are induced by local expression of Indoleamine 2,3 dioxygenase in a composite islet graft

R. B. Jalili¹, A. Moeen¹, R. Hartwell¹, G. Warnock¹, B. Larijani², A. Ghahary¹

¹Vancouver/CANADA, ²Tehran/IRAN

MO21.02 Over-expression of B7-H4 in Beta Cells from Transgenic Mice Prolongs Islet Allograft Survival in Transplantation

X. Wang¹, J. Hao¹, D. METZGER¹, A. Mui¹, Z. Ao¹, C.B. Verchere¹, L. Chen², D. Ou¹, G.L. Warnock¹

¹Vancouver/CANADA, ²Baltimore/UNITED STATES OF AMERICA

MO21.03 A New Enzyme Mixture to Consistently Achieve High Human Islet Yield and Improved Allogenic and Autograft Islet Transplantation Outcome

A.N. Balamurugan¹, G. Loganathan¹, M. Bellin¹, J.J. Wilhelm¹, J. Harmon¹, T. anazawa¹, D. Radosevich¹, T. Yuasa¹, M. Tiwari¹, K.K. Papas¹, R.C. McCarthy², D.E. Sutherland¹, B.J. Hering¹

¹Minneapolis/UNITED STATES OF AMERICA, ²Indianapolis/UNITED STATES OF AMERICA

MO21.04 Pancreatic Islet Cell Preservation by Human Endothelial Protein C Receptor Over Expression in a Syngeneic Murine Model of Intraportal Islet Transplantation

E. Lee, L. Murray-Segal, A. d'Apice, P. Cowan, H. Gock

Fitzroy/AUSTRALIA

MO21.05 The Glucagon-Like Peptide-1 Analogue Exenatide Reduces Amyloid-Induced Beta-Cell Toxicity in Cultured Human Islets


Vancouver/CANADA

MO21.06 Impact of Metabolic Demand on Islet Transplant Survival and Tolerance Induction

R.G. Gill¹, M.R. Nicolls², A. Koh³, M. Coulombe¹

¹Aurora/UNITED STATES OF AMERICA, ²Ca/UNITED STATES OF AMERICA, ³Edmonton/CANADA

MO21.07 A health-economic analysis of clinical islet transplantation
TTS 2010 SCIENTIFIC PROGRAM

H.-J. Schuurman¹, J. Beckwith¹, J.A. Nyman¹, B. Flanagan¹, R. Schrover²
¹Minneapolis/UNITED STATES OF AMERICA, ²Wollstonecraft/AUSTRALIA

MO21.08 Induction of Tolerance Via Polymer Modification of Leukocytes

D. Wang, W. Toyofuku, M.D. Scott
Vancouver/CANADA


T. Pont¹, J. Gener¹, E. Oliver², M. Bodi³, M. Badia⁴, J. Mestre⁵, X. Esquirol⁶, S. Quintana⁷, N. Masnou¹, E. Muñoz³, R. Deulofeu¹
¹Barcelona/SPAIN, ²Hospitalet De Llobregat/SPAIN, ³Tarragona/SPAIN, ⁴Lleida/SPAIN, ⁵Sabadell/SPAIN, ⁶Granollers/SPAIN, ⁷Terrassa/SPAIN

MO21.10 Computed Tomographic Angiography and Perfusion in the diagnosis of brain death - Primary Report

R. Bohatyrewicz¹, M. Sawicki¹, A. Walecka¹, J. Walecki², O. Rowinski², Z. Czajkowski¹, A. Krzysztalowski¹, J. Pastuszka¹, M. Zukowski¹
¹Szczecin/POLAND, ²Warsaw/POLAND

MO21.11 An adjuvanted Influenza A H1N1 vaccine (Pandemrix®) does not provide a protective immune response in the majority of renal transplant recipients

S. Brakemeier, B. Schweiger, P. Glander, F. Diekmann, H.H. Neumayer, K. Budde
Berlin/GERMANY

MO21.12 Early Combination of Proteinuria at Low Grade and Impaired Renal Function Predicts Both Patient and Kidney Graft Survival.

D. Hernández¹, G. Perez-Suarez², D. Marrero², J. Gonzalez-Posada², M. Rufino³, P. Delgado Mallén², A. Torres²
¹Malaga/SPAIN, ²Tenerife/SPAIN, ³Ofra S/n. La Laguna/SPAIN

13:30 – 15:00 STATE OF THE ART SYMPOSIA

Session SOTA15 Developing societal and ethical consensus on living donation

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 109 - 110
TTS 2010 SCIENTIFIC PROGRAM


SOTA15.1 The Istanbul declaration and beyond
F. Delmonico
Newton/UNITED STATES OF AMERICA

SOTA15.2 The position of the WHO on living donation
L. Noel
Geneva/SWITZERLAND

SOTA15.3 Aspects of Organ donation in the Muslim Society
S.A.A. Naqvi
Karachi/PAKISTAN

SOTA15.4 Overcoming the problem of commercialism in India
G. Abraham
Chennai/INDIA

SOTA15 - DISCUSSION

Session SOTA16 Innovations in regenerative medicine

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 212 - 214

Moderators: Alan . Colman, Doris . Taylor

SOTA16.1 Stem cells and gene transfer in transplantation and regeneration
H.-D. Volk
Berlin/GERMANY

SOTA16.2 Tissue engineering for transplantation and regenerative medicine
TTS 2010 SCIENTIFIC PROGRAM

M. Sefton
Toronto/CANADA

SOTA16.3 Regenerative medicine and the stem cell: a marriage that is improving with time
A. Colman

SOTA16 - DISCUSSION

Session SOTA17 Prevention and treatment of antibody mediated rejection

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: Ballroom A/B

Moderators: Ulrich . Frei, Joseph . Kim

SOTA17.1 Factors influencing tolerance and outcome in ABO incompatible transplantation
G. Tyden
Stockholm/SWEDEN

SOTA17.2 A critical review of the transplantation response in the pre-sensitized patient
A. Peng
Los Angeles/UNITED STATES OF AMERICA

SOTA17.3 Acute antibody-mediated rejection
M. Samaniego
Ann Arbor/UNITED STATES OF AMERICA

SOTA17.4 Chronic antibody-mediated rejection
M.D. Stegall
Rochester/UNITED STATES OF AMERICA

SOTA17 - DISCUSSION

Session SOTA18 Immune regulation and tolerance
TTS 2010 SCIENTIFIC PROGRAM

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 220 - 222

Moderators: Peter Morris, Anita Chong

SOTA18.1 Mechanisms of immune regulation and tolerance
M. Sayegh
Boston/UNITED STATES OF AMERICA

SOTA18.2 Mixed chimerism and human tolerance
M. Sykes
Boston/UNITED STATES OF AMERICA

SOTA18.3 Molecular signatures of human tolerance
J.-P. Soulillou
Nantes/FRANCE

SOTA18 - DISCUSSION

Session SOTA19 Clinically Relevant Molecular Mechanisms in Lung Transplantation

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 211

Moderators: Shaf Keshavjee, Marty Zamora

SOTA19.1 Recipient and Donor Characteristics Associated with Primary Graft Dysfunction
J. Christie
Philadelphia/UNITED STATES OF AMERICA

SOTA19.2 Fibrosis Rather Than Alloreactivity is the Target in Chronic Lung Allograft Dysfunction
A. Boehler

SOTA19.3 Donor Specific Antibodies Post Lung Transplant - Making Sense of the Data
TTS 2010 SCIENTIFIC PROGRAM

A. Zeevi
Pittsburgh/UNITED STATES OF AMERICA

SOTA19.4 Targeted Therapy for Severe Pumonary Arterial Hypertension in Idiopathic Pulmonary Fibrosis

P. Corris
Newcastle/UNITED KINGDOM

SOTA19 - DISCUSSION

Session SOTA20 Hepatitis C positive patient

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 118 - 120

Moderators: Gary . Levy, Olaf . Guckelberger

SOTA20.1 Risk factors for HCV recurrence

M. Berenguer
Valencia/SPAIN

SOTA20.2 Immunosuppression for the HCV recipient

G.A. Levy
Toronto/CANADA

SOTA20.3 The Treatment of HCV recurrence

M.R. Charlton
Rochester/UNITED STATES OF AMERICA

SOTA20 - DISCUSSION

Session SOTA21 Ischemia - reperfusion injury

Wednesday, August 18, 2010 01:30 PM - 03:00 PM
Room: MR 121 - 122
TTS 2010 SCIENTIFIC PROGRAM

Moderators: Hans Sollinger, Ferdinand Muehlbacher

SOTA21.1 The biology of brain death and organ damage
S.G. Tullius
Boston/UNITED STATES OF AMERICA

SOTA21.2 Tissue Inflammation and Repair
J. Bonventre
Boston/UNITED STATES OF AMERICA

SOTA21.3 Strategies for cytoprotection in ischemic organ injury
P.-A. Clavien
Zurich/SWITZERLAND

SOTA21.4 Current status of organ preservation solutions
T. van Gulik

SOTA21 - DISCUSSION
15:30 – 17:00 AFTERNOON CONCURRENT SYMPOSIA

Session O43 Experimental and Human Tolerance

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 220 - 222

Moderators: Megan . Sykes, Maria . Hernandez-Fuentes

O43.01 Costimulatory blockade does not promote survival of skin component in non-human-primate composite tissue allografts

Baltimore/UNITED STATES OF AMERICA

O43.02 Chronic rejection in a non-human primate model of facial composite tissue allotransplantation: clinical, pathological, and immunohistochemical characterization

Baltimore/UNITED STATES OF AMERICA

O43.03 Tolerance to a Composite Tissue Allografts after the Induction of Mixed Chimerism in a Pre-Clinical Large Animal Model

D.W. Mathes, B. Hwang, T. Miwongtum, S. Graves, R. Storb
Seattle/UNITED STATES OF AMERICA

O43.04 Tolerance of Renal Allografts across HLA barriers: Follow-up on the First Trial and Initial Results of the Second

T. Kawai1, D.H. Sachs1, T. Spitzer1, N. Tolkoff-Rubin1, R.B. Colvin1, S. Saidman1, D.S.C. Ko1, W. Wong1, W. Williams1, M. Sykes1, A.B. Cosimi1, I. T.N.036ST Study Group2
1Boston/UNITED STATES OF AMERICA, 2Bethesda/UNITED STATES OF AMERICA

O43.05 Inducing Tolerance in Clinical Kidney Transplantation

S. Strober, S. Busque, S. Dejbakhsh-Jones, C. Benike, L. Li, J. Shizuru, R. Lowsky, E. Engleman, M. Sarwal, J.D. Scandling
Stanford/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

O43.06 Sixteen Kidney Transplant Patients surviving for almost 2 years with No Maintenance Immunosuppression or Steroids Alone

H.L. Trivedi1, H. Kaneku2, P.I. Terasaki2, M.J. Everly3, A. Feroz1, A.V. Vanikar1, V.B. Trivedi1, P.R. Modi1, S.D. Dave1
1Ahmedabad/INDIA, 2Los Angeles/UNITED STATES OF AMERICA, 3Canoga Park/UNITED STATES OF AMERICA

O43.07 Successful induction of donor-specific tolerance using Super-agonistic CD28 antibody in rat renal allografts

H. Azuma1, H. Nohmi1, N. Ibuki1, T. Inamoto1, Y. Isaka2, S. Takahara2, Y. Katsuoka1
1Takatsuki/JAPAN, 2Suita/JAPAN

O43.08 Proper Tolerance: A More Realistic Approach To Improve Long-Term Outcomes For Pediatric Living-Donor Liver Transplantation

H. Ohe1, T. Koshiba1, Y. Li1, S. Sakaguchi1, K.J. Wood2, S.R. Calne3, S. Uemoto1
1Kyoto/JAPAN, 2Oxford/UNITED KINGDOM, 3Cb2 Zas/UNITED KINGDOM

Session O44 Xenotransplantation I

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 217 - 219

Moderators: Carl Groth, Emanuele Cozzi

O44.01 Over Six Month Survival Of Cardiac Xenograft Is Achievable But Heterotopic Placement Of The Graft May Limit Consistent Prolonged Survival

M.M. Mohiuddin1, P.C. Corcoran1, A.K. Singh1, A.M. Azimzadeh2, R.F. Hoyt1, M.P. Thomas1, M.A. Eckhaus1, D. Ayares3, R.N. Pierson III2, K.A. Horvath1
1Bethesda/UNITED STATES OF AMERICA, 2Baltimore/UNITED STATES OF AMERICA, 3Blacksburg/UNITED STATES OF AMERICA

O44.02 The Worldwide First Model with Heterotopic Thoracic Xenogeneic Heart Transplantation Compared with the Heterotopic Abdominal Technique

P. Brenner1, J. Postrach1, A. Bauer1, M. Thomann1, M. Loewenthal1, S. Blanck1, S. Michel1, B. Wintersperger1, K. Sotlar1, C. Schmitz1, M. Schmoeckel2, B. Reichart1
1Munich/GERMANY, 2Hamburg/GERMANY
**O44.03** Pilot evaluation of anti-GPIb effects on platelet sequestration in an ex vivo xenogeneic pig liver perfusion model

L. Burdorf\(^1\), R.N. Barth\(^1\), T. Zhang\(^1\), E. Rybak\(^1\), I.I. Salles\(^2\), K. Broos\(^2\), E. Welty\(^1\), C.J. Avon\(^1\), A. Laaris\(^1\), B. McCormick\(^1\), D. Ayares\(^3\), H. Deckmyn\(^2\), A.M. Azimzadeh\(^1\), R.N. Pierson III\(^1\)\(^1\)Baltimore/UNITED STATES OF AMERICA, \(^2\)Kortrijk/BELGIUM, \(^3\)Blacksburg/UNITED STATES OF AMERICA

**O44.04** A study of the Prevention of PERV Infection by siRNA on Pig Dolichyl-Phosphate Mannosyltransferase

Suita/JAPAN

**O44.05** Prolonged Xenograft Survival Induced By ICOS-IG Is Associated With Increased Foxp3+ Cells

R. Hodgson\(^1\), A. Ziolkowski\(^2\), D. Christiansen\(^1\), E. Mouhtouris\(^1\), C.J. Simeonovic\(^2\), F. Ierino\(^1\), M.S. Sandrin\(^1\)\(^1\)Heidelberg/AUSTRALIA, \(^2\)Canberra/AUSTRALIA

**O44.06** Normal glucose tolerance and long-term function of microencapsulated porcine, piscine, and human islet xenografts in spontaneously diabetic NOD mice

S. Safley\(^1\), H. Cui\(^2\), S. Cauffiel\(^1\), K. Gordon\(^1\), B.-Y. Xu\(^3\), C. Larsen\(^1\), J.R. Wright\(^3\), C.J. Weber\(^1\)\(^1\)Atlanta/UNITED STATES OF AMERICA, \(^2\)New York/UNITED STATES OF AMERICA, \(^3\)Calgary/CANADA

**O44.07** Xenograft of Microencapsulated Sertoli cells alone cures NOD mice with spontaneous autoimmune diabetes

R. Calafiore, F. Fallarino, M. Calvitti, F. Mancuso, E. Becchetti, P. Puccetti, G. Luca
Perugia/ITALY

**O44.08** Down-regulation of NPI Tissue Factor Expression Alleviates the IBMIR in Islet Transplantation

W. Wang, X. Ma, B. Ye, F. Gao
Changsha/CHINA

---

**Session O45 Molecular Diagnostics and Genomics**

**Wednesday, August 18, 2010 03:30 PM - 05:00 PM**
**Room: MR 211**

Moderators: Phil . Dyer, Andrea . Zachary
O45.01 Transcripts selective for donor specific antibody identify C4d positive and C4d negative antibody mediated rejection

L.G. Hidalgo, P.M. Campbell, P. Halloran
Edmonton/CANADA

O45.02 Immunomonitoring of face and hand grafted patients by comparing mRNA markers in tissues versus blood can help to differentiate rejection versus viral infection episodes.

A. Eljaafari¹, P. Petruzzo¹, J. Kanitakis¹, L. BADET¹, E. Morelon¹, A. Gazarian¹, C. Dagot¹, J.-L. Beziat¹, S. Testelin², B. Devauchelle², X. Martin¹, J.M. Dubernard¹, P. Miossec¹
¹Lyon/FRANCE, ²Amiens/FRANCE

O45.03 Temporal gene expression changes occurring in the kidney graft post-transplantation

Richmond/UNITED STATES OF AMERICA

O45.04 Small Bowel allografts undergoing Rejection show distinct Transcriptome Profiles in formalin-fixed mucosal biopsies

Miami/UNITED STATES OF AMERICA

O45.05 Graft loss is poorly represented in the most inflamed rejection kidney transplant biopsies

L.G. Hidalgo, P. Halloran
Edmonton/CANADA

O45.06 Identification of stable control genes for normalization of blood based biomarker panels

Y. Yang¹, M. Takhar¹, Z. Hollander¹, D. Lin¹, J. Wilson-McManus¹, R.T. Ng¹, P.A. Keown², R.M. McMaster², B. McManus¹, S.J. Tebbutt²
¹Vancouver/CANADA, ²Vancouver/CANADA

O45.07 Nuclear Factor of Activated T-Cells (NFAT) Gene Variations in the Onset of Posttransplant Diabetes Mellitus (PTDM)

Y. Chen, I. Hutchinson
Los Angeles/UNITED STATES OF AMERICA

O45.08 Mycophenolic acid Induced Apoptosis in Human Jurkat Cells via Generation of ROS and Regulation HO-1 Expression
TTS 2010 SCIENTIFIC PROGRAM

Gwangju/KOREA

Session O46 Epidemiology and Clinical Outcomes II

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 109 - 110

Moderators: Angela . Webster, John . Pirsch

O46.01 Long-term compensation of renal function after donor nephrectomy is not affected by donor factors

K.H. Huh\textsuperscript{1}, Y.S. Kim\textsuperscript{1}, M.K. Ju\textsuperscript{1}, M.S. Kim\textsuperscript{1}, S.I. Kim\textsuperscript{1}, K. Park\textsuperscript{2}
\textsuperscript{1}Seoul/KOREA, \textsuperscript{2}Seongnam/KOREA

O46.02 Age Matching of Donors to Recipients Does Not Impact on Outcome in Renal Transplantation Following Donation After Cardiac Death

Leeds/UNITED KINGDOM

O46.03 Kidney Transplantation From Donation after Cardiac Death: a French Academic Hospital Experience

I. ABBOUD, C. LEFAUCHEUR, C. ANTOINE, F. FIEUX, F. GAUDEZ, M.-N. PERALDI, D. GLOTZ
Paris/FRANCE

O46.04 Matched Analysis of Renal Transplants following Donation after Cardiac Death Verses Donation after Brainstem Death

Leeds/UNITED KINGDOM

O46.05 Outcomes of Kidneys Donated after Cardiac Death

D.M. Summers\textsuperscript{1}, J. Allen\textsuperscript{2}, R.J. Johnson\textsuperscript{2}, S.V. Fuggle\textsuperscript{3}, D. Collett\textsuperscript{2}, C.J.E. Watson\textsuperscript{1}, J.A. Bradley\textsuperscript{1}
\textsuperscript{1}Cambridge/UNITED KINGDOM, \textsuperscript{2}Bristol/UNITED KINGDOM, \textsuperscript{3}Oxford/UNITED KINGDOM
TTS 2010 SCIENTIFIC PROGRAM

O46.06 Current long term outcomes of both controlled and uncontrolled Non Heart Beating Donor (NHBD) kidneys – a five year follow up study.

A. Kanwar¹, M.A. Khurram¹, S. Stamp¹, L. El-Asir¹, M. Reddy¹, H. Wyrley-Birch¹, J. Asher¹, M. Gok¹, A. Cunningham², N. Carter², B. Jacques¹, N. Soomro¹, D. Rix¹, D. Manas¹, D. Talbot¹
¹Newcastle Upon Tyne/UNITED KINGDOM, ²Sunderland/UNITED KINGDOM

O46.07 Outcomes of graft kidney according to donor scoring system and renal biopsy in deceased kidney transplantation

K.H. Huh¹, Y.S. Kim¹, M.K. Ju¹, M.S. Kim¹, S.I. Kim¹, K. Park²
¹Seoul/KOREA, ²Seongnam/KOREA

O46.08 Contribution of donor and recipient characteristics to short- and long-term pancreas graft survival

Leiden/NETHERLANDS

O46.09 The Influence of Bilateral Nephrectomy (BN) on Long-term Graft and Patient Survival in Recipients (1968-1985) treated with Azathioprine and Prednisolone only

J.F. Douglas
Belfast N Ireland/UNITED KINGDOM

Session O47 Clinical Trials of Immunosuppression

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: Ballroom A/B


O47.01 The TranCept Trial – Final Study Results Demonstrate Benefits From Introduction of Mycophenolate Mofetil (CellCept®) Several Years After Transplantation.

H.-U. Meier-Kriesche¹, U. Heemann², P. Merville³, H. Tedesco-Silva⁴, J. Ferraris⁵, C. Bernasconi⁶
¹Gainesville/UNITED STATES OF AMERICA, ²Muenchhen/GERMANY, ³Bordeaux/FRANCE, ⁴Sao Paulo/BRAZIL, ⁵Buenos Aires/ARGENTINA, ⁶Basel/SWITZERLAND

O47.02 Impact of maintenance immunosuppressive regimens on the immune response of renal transplant recipients – balance between graft protective suppression of immune functions and a near physiological immune response
O47.02 Application of a Validated Long-term Renal Transplant Graft Survival Prediction Model to Expected Belatacept Phase III Trial Outcomes

M.A. Schnitzler¹, D. Trivedi², G.J. L'Italien³
¹Shiloh/UNITED STATES OF AMERICA, ²Plainsboro/UNITED STATES OF AMERICA, ³Wallingford/UNITED STATES OF AMERICA

O47.03 Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT)

S. Florman¹, A. Durrbach², C. Larsen³, J.M. Pestana⁴, H. de Jonge⁵, F. Vincenti⁶, A. Block⁷, P. Garg⁷, B. Copley⁷, T. Duan⁷, J.M. Grinyó⁸
¹New York/UNITED STATES OF AMERICA, ²Paris/FRANCE, ³Atlanta/UNITED STATES OF AMERICA, ⁴Na/UNITED STATES OF AMERICA, ⁵Leuven/BELGIUM, ⁶San Francisco/UNITED STATES OF AMERICA, ⁷Princeton/UNITED STATES OF AMERICA, ⁸08907/SPAIN

O47.04 Long-term Post Transplantation Switch to an Everolimus-based Therapy with CNI Elimination/Minimization Does Not Overall Impact Graft Function: The Ascertain Study

H. Holdaas
Oslo/NORWAY

O47.05 Calcineurin Inhibitor Sparing in De Novo Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

A. Sharif¹, J. Moore², S. Shabir¹, A. Bentall¹, S. Ball¹, R. Borrows¹
¹Birmingham/UNITED KINGDOM, ²Shrewsbury/UNITED KINGDOM

O47.06 Long Term Outcomes with Early Corticosteroid Withdrawal Regimens in Kidney Transplantation: Comparison to Long Term Corticosteroid Maintenance Therapy


O47.07 Delayed graft function (DGF) affects early tacrolimus disposition in renal allograft recipients: a possible link to posttransplantation diabetes mellitus (PTDM).

H. de Jonge, M. Naesens, K. Verbeke, Y. Vanrenterghem, D.R. Kuypers
Leuven/BELGIUM
TTS 2010 SCIENTIFIC PROGRAM

O47.08 Immunosuppressive drugs change the NADPH oxidase expression pattern in kidney cells

J.G. Kosovski¹, A. Blumert¹, P.C. Baer¹, H. Geiger¹, I.A. Hauser²
¹Frankfurt/GERMANY, ²Frankfurt/M/GERMANY

Session O48 Advances in Surgery and Imaging

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 202 - 204


O48.01 Management of Symptomatic Primary Lymphocele after Kidney Transplantation: A Systematic Review

A. Lucewicz, V.W.T. Lam, W. Hawthorne, R. Allen, H.C.C. Pleass
Sydney/AUSTRALIA

O48.02 Western Australia Program Using Kidney from Urologist Referrals for Renal Transplant

B. He¹, A. Mitchell², W. Lim², L. Delriviere²
¹Perth/AUSTRALIA, ²6009/AUSTRALIA

O48.03 Renal Transplant Protection Using Perfusate-based Carbon Monoxide Releasing Molecules

London/CANADA

O48.04 Performance of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula and Inulin Based Glomerular Filtration Rate Equation (IB-eGFR) Against Iothalamate Plasma Urine Clearance and 24 Hour Urine Creatinine Clearance Measurement in Live Donor Nephrectomy Evaluation

B. Tanriover, M. Ghanta, D.J. Cohen, L. Ratner, T.L. Nicholas
New York/UNITED STATES OF AMERICA

O48.05 Older Live Kidney Donors: Safety on Long-term Follow-up

L.F. Dols, N.F. Kok, K.T. Tran, T. Terkivatan, W. Weimar, J.N. IJzermans
Rotterdam/NETHERLANDS

O48.06 Fluorescent imaging of non-human primate composite tissue allografts demonstrates prolonged graft lymphedema independent of rejection
O48.07 Extra-anatomical hepatic artery reconstruction in living donor liver transplantation: lessons from 352 liver transplants.

H. Uchiyama, K. Shirabe, A. Taketomi, Y. Soejima, T. Yoshizumi, Y. Maehara
Fukuoka/JAPAN

O48.08 Transient elastography and development of a non-invasive multiparameter score for assessment of allograft fibrosis in liver transplant patients

Essen/GERMANY, Kiel/GERMANY

O48.09 Technical aspects of monolateral dual kidney transplantation (DKT) from expanded criteria donors (ECD): experience of 100 patients

B. Ekser, L. Furian, A. Broggiato, C. Silvestre, E.S. Pierobon, C. Longo, A. Soligo, N. Baldan, P. Rigotti
Padova/ITALY

Session O49 Molecular and Clinical Aspects of Lung Transplantation

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 205 - 207

Moderators: Robert Levy, Bronwyn Levvey

O49.01 Intratracheal Delivery of Adenoviral Vector ex vivo Results in Reduced Vector-Associated Inflammation in Lung Pre- and Post- Transplantation

Toronto/CANADA

O49.02 Excellent intermediate clinical outcomes from a National Donation-after-Cardiac Death (DCD) Lung Transplant Collaborative

B. Levvey, M. Harkess, P. Hopkins, D. Chambers, A.R. Glanville, G.I. Snell
Melbourne/AUSTRALIA, Sydney/AUSTRALIA, Brisbane/AUSTRALIA
TTS 2010 SCIENTIFIC PROGRAM

O49.03 Extracorporeal membrane oxygenation in fully awake patients with right heart failure as bridge to transplantation

Hannover/GERMANY

O49.04 Beneficial Effects of Perioperative Low-dose Inhalation of Carbon Monoxide on Pulmonary Allograft Survival in MHC-inbred CLAWN Miniature Swine

Kagoshima/JAPAN

O49.05 Egr1- a novel target for acute allograft rejection in an experimental lung transplant model

N. Waki, M. Yamane, M. Okazaki, S. Sugimoto, S. Yamamoto, O. Yoshida, T. Oto, S. Miyoshi
Okayama/JAPAN

O49.06 Inhaled hydrogen gas therapy for prevention of lung transplant-induced ischemia/reperfusion injury in rats

Pittsburgh/UNITED STATES OF AMERICA

O49.07 Lactate and Lactate/Pyruvate Ratio During Acellular Normothermic Ex Vivo Rejected and Clinical Human Lung Perfusion

Toronto/CANADA

O49.08 An Aggressive Lung Recruitment Protocol Increases the Percentage of Lung Donors with No Increased Adverse Effect in Lung Recipients

D. Lebovitz, K. Reis, J. Yun, L. Herman, K.R. McCurry
Cleveland/UNITED STATES OF AMERICA

O49.09 A World-wide Survey of Antifungal Prophylaxis in Lung Transplant (LTx) Centers

Melbourne/AUSTRALIA

Session O50 Intestine and Multivisceral Transplantation
TTS 2010 SCIENTIFIC PROGRAM

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 118 - 120

Moderators: Satoru Todo, Douglas Farmer

O50.01 Donor Specific Human Leukocyte Antigen (HLA) Antibodies and Visceral Transplantation: Outcome Analysis with Special Reference to the Liver-Contained Allografts

G. Wu, J. Lunz, G. Costa, R. Cruz, G. Mazariegos, K. Soltys, A. Zeevi, K.M. Abu-Elmagd
Pittsburgh/UNITED STATES OF AMERICA

O50.02 Association between elevation of anti-HLA Panel Reactive Antibodies and episodes of acute small bowel rejection after intestinal or multivisceral transplantation

I.M. Gonzalez-Pinto¹, A. Tzakis², H.-L. Tsai³, J.-W. CHANG³, P. Tryphonopoulos², G. Selvaggi², S. Nishida², D. Levi², A. Tekin², J. Moon², E. Island², P. Ruiz²
¹Oviedo/SPAIN, ²Miami/UNITED STATES OF AMERICA, ³Taipei/TAIWAN

O50.03 Anti-donor Specific Antibodies Associated with Acute Rejection in the Early Post-transplant Period of Small Bowel and Multivisceral Allograft Recipients

H. TSAI¹, A. Tzakis², I. Gonzalez-Pinto³, J.-W. CHANG¹, P. Tryphonopoulos², S. Nishida², E. Island², G. Selvaggi², A. Tekin², J. Moon², D. Levi², E.S. Woodle⁴, P. Ruiz²
¹Taipei/TAIWAN, ²Miami/UNITED STATES OF AMERICA, ³Oviedo/SPAIN, ⁴Cincinnati/UNITED STATES OF AMERICA

O50.04 The Toll-like Receptor Pathway Contributes to Small Intestine Allograft Rejection

Stanford/UNITED STATES OF AMERICA

O50.05 Ex vivo resection and autotransplantation for locally invasive tumors involving major vascular pedicles

T. Kato, R. Sandoval, B. Samstein, S. Lobritto, M. Martinez, M. Goldstein, J. Guerrera, S. Caruana, R. Brown, J. Emond
New York/UNITED STATES OF AMERICA

O50.06 Osmotic requirements for a novel intraluminal nutrient preservation solution tailored to the intestine.

Edmonton/CANADA
TTS 2010 SCIENTIFIC PROGRAM

O50.07 Predictors of Survival after Intestinal Transplantation: Analysis of a Large, Single Center Experience

Los Angeles/UNITED STATES OF AMERICA

O50.08 Cambridge- Miami (CaMi) pre-transplant risk score for intestinal and multivisceral transplantation in adults

R. Sivaprakasam¹, S. Nishida², A. Butler¹, M. Takahashi², S. Gabe¹, N. Jamieson¹, A. Tzakis², S. Middleton¹
¹Cambridge/UNITED KINGDOM, ²Miami/UNITED STATES OF AMERICA

O50.09 Assessing US Deceased Donor Intestine Organs: OPTN/SRTR Analysis of Current Practice and Determination of Potentially Underutilized Intestine Donors

G. Mazariegos¹, D. Steffick², S. Horslen³, J. Fryer⁴, D.L. Sudan⁵, J.C. Magee²
¹Pittsburgh/UNITED STATES OF AMERICA, ²Ann Arbor/UNITED STATES OF AMERICA, ³Seattle/UNITED STATES OF AMERICA, ⁴Chicago/UNITED STATES OF AMERICA, ⁵Durham/UNITED STATES OF AMERICA

Session O51 Immunological Monitoring in Kidney Transplantation

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 121 - 122

Moderators: Ferdinand . Muehlbacher, Patricia . Campbell

O51.01 Imbalance of Intragraft Th1/Th2 Transcription Factors is Strongly Correlated with Different Mechanism of Acute Renal Allograft Rejection

Q. Sun, Z. Liu, D. Cheng, M. Zhang, L. Li
Nanjing/CHINA

O51.02 Afectation of apoptotic pathways with the administration of immunosuppressive drugs to donors: the role of TNFa, Bax and Bcl-2.

F. Cicora¹, N. Lausada², P. Gonzalez¹, G. Palti¹, C. Raimondi¹
¹Buenos Aires/ARGENTINA, ²La Plata/ARGENTINA

O51.03 Allospecific CD154+T-Cytotoxic Memory Cells Associate with Acute Cellular Rejection After Renal Transplantation.
C. Ashokkumar, R. Shapiro, H.P. Tan, B. Elinoff, S. Fedorek, C. Morgan, R. Sindhi, A. Humar
Pittsburgh/UNITED STATES OF AMERICA

O51.04 Potential Value of Foxp3 and Regulatory T cell-Related Gene Expression monitoring in Peripheral Blood after Renal Transplantation

H. Iwase1, T. Kobayashi1, K. Iwasaki1, M. Haneda1, A. Katayama1, A. Takeda1, K. Morozumi1, Y. Watarai1, K. Uchida2, Y. Kodera1, A. Nakao1
1Nagoya City/JAPAN, 2Nagoya/JAPAN

O51.05 Post operative monitoring of donor specific T cells response as a prognostic factor in organ transplantation by the assay using the indirect presentation of autologous dendritic cells

Seoul/KOREA

O51.06 Increased frequency of CD4+CD25+FoxP3+ T cells in patients with chronic allograft dysfunction after kidney transplantation

K. Timrott, F.W.R. Vondran, S. Kollrich, F. Lehner, J. Klempnauer, R. Schwinzer
Hannover/GERMANY

O51.07 B and Plasma Cells, but not C4d, in Renal Biopsies During Acute Rejection are Sensitive Markers of Poor Graft Outcome

Chicago/UNITED STATES OF AMERICA

O51.08 Urine Metabolic Profiling Alterations in Response to Acute Cellular Allograft Rejection after Kidney Transplantation

X. wang, T. zhu, D. zhu, M. xu, R. rong, Y. Guo
Shanghai/CHINA

Session O52 Experimental Islet Transplantation

Wednesday, August 18, 2010 03:30 PM - 05:00 PM
Room: MR 212 - 214

Moderators: Leo . Buhler, Olle . Korsgren
O52.01 Interruption of a cross-talk between the complement and coagulation cascades improves early outcomes after intraportal islet transplantation

K. Tokodai¹, M. Goto¹, A. Inagaki¹, W. Nakanishi¹, N. Okada², H. Okada³, S. Satomi¹
¹Sendai/JAPAN, ²Nagoya/JAPAN, ³Toyohashi/JAPAN

O52.02 Recruitment of T regulatory cells to islet grafts prevents recurrent autoimmune diabetes

L. Bischoff, J. Montane, G. Soukhatcheva, D. Dai, R. Tan, C.B. Verchere
Vancouver/CANADA

O52.03 Development of a New Strategy for Minimizing Islet Cell Mass in Type 1 Diabetic Recipients: Diannexin Reduces Proapoptotic Bid, Promotes Anti-inflammatory Interleukin-10 and Improves Early Graft Function in the Marginal Islet Mass Transplantation Model

E. Cheng, H. Yang, V. Sharma, M. Lagman, D. Leeser, M. Suthanthiran
New York/UNITED STATES OF AMERICA

O52.04 A pathway for Human Islet Protease-Activated Receptors (PARs) in Tissue Factor mediated Immediate Blood Inflammatory Reaction.

H.S. Smith-Hurst, S.P. Stoner, P.M. Phillips, L. Williams, A. Patel, W.J. Hawthorne, P.J. O'Connell
Westmead/AUSTRALIA

O52.05 T regulatory cell mediated protection of allograft in type 1 diabetes

Vancouver/CANADA

O52.06 Pancreatic islets undergo substantial molecular remodelling after islet isolation and transplantation, resulting in heparanase-mediated damage during allograft rejection

C.J. Simeonovic¹, F.J. Choong¹, A. Ziolkowski¹, D. Brown¹, S. Popp¹, C. Freeman¹, H. Irving-Rodgers², R. Rodgers², C. Parish¹
¹Canberra/AUSTRALIA, ²Adelaide/AUSTRALIA

O52.07 In vitro and in vivo over-induction of autophagy in pancreatic islets by rapamycin and impairs islet function

Suita/JAPAN

O52.08 Human Islets Prepared For Clinical Transplantation Exhibit An Altered Glycolytic Profile
OS2.09 Treatment with Anakinra and Tocilizumab reduce the pro-inflammatory response and enhances islet survival and function in human islets during culture: implications for clinical islet transplantation.

A. Sahraoui\textsuperscript{1}, K. Kloster-Jensen\textsuperscript{1}, T. Lund\textsuperscript{1}, O. Korsgren\textsuperscript{2}, A. Foss\textsuperscript{1}, H. Scholz\textsuperscript{1}

\textsuperscript{1}Oslo/NORWAY, \textsuperscript{2}Uppsala/SWEDEN
THURSDAY, AUGUST 19

07:00 – 08:15 SUNRISE SYMPOSIA

Session SUN17 Women in transplantation

Thursday, August 19, 2010 07:00 AM - 08:15 AM
Room: MR 212 - 214

Moderators: Kathryn Wood, Lee Anne Tibbles

SUN17.1 Update on the WIT initiative
K.J. Wood
Oxford/UNITED KINGDOM

SUN17.2 Women in Academic Careers: Progress and Persistent Hurdles
J. Lieberman
Boston/UNITED STATES OF AMERICA

SUN17.3 Career challenges for young women in transplantation sciences
C. Baan
Rotterdam/NETHERLANDS

SUN17.4 Career challenges for women as clinician-scientists in transplantation
S. Moffatt-Bruce
Columbus/UNITED STATES OF AMERICA

Session SUN18 IATDMCT Partner Symposium: Therapeutic monitoring of immunosuppression

Thursday, August 19, 2010 07:00 AM - 08:15 AM
Room: MR 202 - 204

Moderators: Eric Thervet, David Holt

SUN18.1 Evolving strategies for therapeutic drug monitoring
TTS 2010 SCIENTIFIC PROGRAM

D.W. Holt
London/UNITED KINGDOM

SUN18.2 The contribution of pharmacogenomics and pharmacogenetics

D.R. Kuypers
Leuven/BELGIUM

SUN18.3 Biomarkers of pharmacological effect

E.S. Thervet
Paris/FRANCE

SUN18 - DISCUSSION

Session SUN19 Exciting updates in CMV

Thursday, August 19, 2010 07:00 AM - 08:15 AM
Room: MR 205 - 207

Moderators: Roberta . Lattes, Raymund . Razonable

SUN19.1 Biology and Pathogenesis

H.-D. Volk
Berlin/GERMANY

SUN19.2 Summary of TTS Guidelines

C.N. Kotton
Boston/UNITED STATES OF AMERICA

SUN19.3 Immunology and Assays

M. Sester
Homburg/GERMANY

SUN19.4 Optimal Management in Lung Transplant

M. Zamora
Aurora/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

SUN19 - DISCUSSION

Session SUN20 Detection and monitoring of antibodies after transplantation

Thursday, August 19, 2010 07:00 AM - 08:15 AM
Room: MR 211


SUN20.1 Update on desensitization strategies
J.M. Gloor
Rochester/UNITED STATES OF AMERICA

SUN20.2 Determinants of antibody formation and titre after transplantation
R. Bray
Atlanta/UNITED STATES OF AMERICA

SUN20.3 Long-term implications of HLA antibody
C. Suesal

SUN20.4 Monitoring and treatment of antibody-mediated rejection
R.A. Montgomery
Baltimore/UNITED STATES OF AMERICA

SUN20 - DISCUSSION

08:30 – 10:00 PLENARY SYMPOSIA

Session PL04 Innovations in Immune Suppression

Thursday, August 19, 2010 08:30 AM - 10:00 AM
Room: Ballroom A/B

Moderators: Greg . Knoll, Gary . Levy
**TTS 2010 SCIENTIFIC PROGRAM**

PL04.1 miRNA in Immunity and Transplantation

J. Bluestone  
San Francisco/UNITED STATES OF AMERICA

PL04.2 Guidance of Immunosuppression by Biomarkers

P. Reinke  
Berlin/GERMANY

PL04.3 Current Advances in Clinical Immunosuppression

R.B. Mannon  
Birmingham/UNITED STATES OF AMERICA

---

**10:30 – 12:00 MORNING CONCURRENT SYMPOSIA**

**Session O53 Clinical Role of HLA Antibodies**

**Thursday, August 19, 2010 10:30 AM - 12:00 PM**  
**Room: MR 202 - 204**

Moderators: Samantha Fidler, Phil Dyer

OS3.01 Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants

R.J. Duquesnoy, M. Marrari  
Pittsburgh/UNITED STATES OF AMERICA

OS3.02 Anti-HLA Antibody Characteristics Influence Results of Plasma Cell Targeted Therapy For Antibody Mediated Rejection

E.S. Woodle¹, A. Girnita¹, P. Brailey¹, M. Zand², R.C. Walsh¹, R.R. Alloway¹  
¹Cincinnati/UNITED STATES OF AMERICA, ²Rochester/UNITED STATES OF AMERICA

OS3.03 HLA Antibodies Can be Detected in Kidney Allograft Biopsies and Nephrectomy Tissue Even When Not Present in Serum
TTS 2010 SCIENTIFIC PROGRAM

1Los Angeles/UNITED STATES OF AMERICA, 2Ahmedabad/INDIA, 3Boston/UNITED STATES OF AMERICA, 4Canoga Park/UNITED STATES OF AMERICA

O53.04 The Impact of Donor Specific Antibody on Liver Allograft Survival after Living Donor Liver Transplantation

A. Yoshizawa1, H. Egawa2, Y. Ogura1, K. Yurugi1, R. Hishida1, E. Ashihara1, A. Miyagawa-Hayashino1, H. Ohe1, T. Iida1, K. Hata1, M. Nizumoto1, A. Mori1, T. Kaido1, T. Maekawa1, S. Uemoto1
1Kyoto/JAPAN, 2Gifu/JAPAN

O53.05 Are Additional Antibodies Detected by Luminex Single Antigen Testing Clinically Relevant? A Collaborative Transplant Study Report

C. Süsal, K. Mahmoud, J. Ovens, A. Ruhenstroth, B. Döhler, S. Scherer, G. Opelz
Heidelberg/GERMANY

O53.06 Contributions of Flow Cross Match (FXM) Results and Donor Specific Antibody (DSA) Measurements to Antibody Mediated Rejection (AMR) in Donor Sensitized Kidney Transplants

T.B. Dunn1, O. Ozturk2, H. Noreen1, D. Maurer1, R. Bray2, H. Gebel2, A.J. Matas1
1Minneapolis/UNITED STATES OF AMERICA, 2Atlanta/UNITED STATES OF AMERICA

O53.07 Donor Specific Antibody Changes after Nephrectomy

Indianapolis/UNITED STATES OF AMERICA

O53.08 Epitope specificity of HLA DQA1 and DQB1 antibodies detected in sera from renal transplant recipients.

A. Piazza, G. Ozzella, E. Poggi, D. Caputo, R. Cremona, V. Imbroglini, D. Adorno
Rome/ITALY

Session O54 NK Cells in Graft Injury and Acceptance

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 205 - 207

Moderators: M.-J. Hébert, Alice Mui
O54.01 Depletion of NK cells Prevents Spontaneous Acceptance of Liver Allografts

Stanford/UNITED STATES OF AMERICA

O54.02 Depletion of macrophages and/or NK cells in combination with T cell targeting based strategies eliminates the requirement of irradiation for engraftment

H. Xu, J. Yan, Z. Zhu, Y. Huang, Y. Wen, L.D. Bozulic, S.T. Ildstad
Louisville/UNITED STATES OF AMERICA

O54.03 Small Intestine Allograft Survival is Prolonged in the Absence of NKG2D

L.-E. Wai, M. Wang, T. Ito, K. Piard-Ruster, O.M. Martinez, S.M. Krams
Stanford/UNITED STATES OF AMERICA

O54.04 Reciprocal Activation of Natural Killer (NK) Cells and Dendritic Cells with a Distinct Role for NKp46 in NK Cell Activation

L.-E. Wai, S.M. Krams
Stanford/UNITED STATES OF AMERICA

O54.05 The inhibitory receptor FcγRIIb delays chronic but not acute allograft rejection

Cambridge/UNITED KINGDOM

O54.06 NK cell regulation of antigen-driven T cell expansion

M. Braun, K. Weatherly, F. Gaudray, M. Noval Rivas
Gosselies/BELGIUM

O54.07 Alloreactivity of rat NK cells is reduced by the membrane molecule rClrb (RT12) encoded by the Natural killer gene complex (NKC)

D. Poehnert¹, J. Hundrieser¹, M. Koch², J. Klempnauer¹, K. Wonigeit¹
¹Hanover/GERMANY, ²Hamburg/GERMANY

O54.08 Targeting the NK cell cytotoxicity receptor NKp46 delays acute graft rejection in a murine model of heterotopic heart transplantation

C.-T. Le, D. Stauch, K. Göldner, K. Kotsch, K. Kunert
Berlin/GERMANY
O54.09 Rapamycin and Mycophenolic acid, but not Cyclosporin A, impair human NK cell cytolytic activity due to differential effects on the NK cell phenotype in vitro

D.N. Eissens, A. van der Meer, B. van Cranenbroek, F.W.M.B. Preijers, I. Joosten
Nijmegen/NETHERLANDS

Session O55 Molecular and Cellular Pathology of the Kidney Allograft

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 211

Moderators: Kim . Solez

O55.01 Double Stains of p-53 and Cytokeratin-7 with SV-40 Staining Identify Different Phases and Location of Polyoma Virus Infection in Renal Allograft Biopsies

Royal Oak/UNITED STATES OF AMERICA

O55.02 Inflammation in Areas of Tubular Atrophy (iatr) Predicts Kidney Allograft Failure

R.B. Mannon¹, A.J. Matas², R. Leduc², J.M. Cecka³, F. Cosio⁴, R. Gaston¹, S. Gourishankar⁵, P. Halloran⁵, L. Hunsicker⁶, B. Kasiske², J. Grande⁴
¹Birmingham/UNITED STATES OF AMERICA, ²Minneapolis/UNITED STATES OF AMERICA, ³Los Angeles/UNITED STATES OF AMERICA, ⁴Rochester/UNITED STATES OF AMERICA, ⁵Edmonton/CANADA, ⁶Iowa City/UNITED STATES OF AMERICA, ⁷Winnipeg/CANADA

O55.03 C4d (+) and C4d (-) chronic transplant glomerulopathy cases – clinical and histological characteristics

A. Perkowska-Ptas inska¹, M. Ciszek¹, A.L. Urbanowicz¹, A. Chmura¹, S. Nazarewski¹, L. Paczek¹, M. Glyda¹, A. Debska-Slizien³, A. Rydzewski¹, K. Dziewanowski³, M. Durlik¹
¹Warsaw/POLAND, ²Poznan/POLAND, ³Gdansk/POLAND, ⁴Szczecin/POLAND

O55.04 Interstitial fibrosis evolution on early sequential routine renal allograft biopsies using numerical quantification analysis

A. Servais, E.S. Ther vet, V. Meas-Yedid, L.H. Noel, F. Martinez, H. Kreis, J. Zuber, M.O. Timsit, J.C. Olivo Marin, C. Legendre
Paris/FRANCE

O55.05 The Maryland Aggregate Pathology Index (MAPI) is superior to the Kidney Donor Risk Index (KDRI) as a predictor of graft outcome.
TTS 2010 SCIENTIFIC PROGRAM

B. Philosophe, B.P. Neuman, R.N. Barth, E.J. Schweitzer, S.A. Fayek, S.T. Bartlett, M. Cooper, R. Munivenkatappa
Baltimore/UNITED STATES OF AMERICA

O55.06 C4d now and then

P.S. Verghese, T.B. Dunn, K.J. Gillingham, Y. Kim, A.J. Matas
Minneapolis/UNITED STATES OF AMERICA

O55.07 Deficiency in Donor Interleukin 6 Expression Prolongs Renal Allograft Survival

H. Wang1, Z. Lan1, W. Ge1, Q. Guan2, H. Chen3, C.Y. Nguan2, C. Du2
1London/CANADA, 2Vancouver/CANADA, 3Montreal/CANADA

O55.08 Adverse impact of mild hypertension post transplant on 1 year chronic interstitial fibrosis and tubular atrophy scores in kidney allograft biopsy among a cohort on rapid steroid withdrawal protocol.

Phoenix/UNITED STATES OF AMERICA

Session O56 Epidemiology and Clinical Outcomes I

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 109 - 110


O56.01 A prospective cohort study on return to work, functional ability and health-related quality of life after kidney transplantation

M. Korkeila, L.-M. Petersson, B. von zur Mühlens, G. Tufveson, K. Alexanderson, A. Tibell
Stockholm/SWEDEN

O56.02 GFR Slopes Have Significantly Improved Among Renal Transplants in the US

T. Srinivas, D. Goldfarb, E. Poggio, S. Flechner, J.D. Schold
Cleveland/UNITED STATES OF AMERICA

O56.03 The Framingham Risk Score underestimates cardiovascular events in Canadian renal transplant recipients
TTS 2010 SCIENTIFIC PROGRAM

S.A. Silver, M. Huang, M.M. Nash, G.V.R. Prasad
Toronto/CANADA

O56.04 Reduced risk of renal graft loss from recurrent glomerulonephritis in the modern transplant era

P. Clayton¹, S.P. McDonald², S. Chadban¹
¹Sydney/ AUSTRALIA, ²Adelaide/ AUSTRALIA

O56.05 Evolution of Glucose Metabolism Early after Kidney Transplantation using The Latest American Diabetes Association Guideline

F.L. Luan, A.O. Ojo
Ann Arbor/ UNITED STATES OF AMERICA

O56.06 Different etiologies of graft loss and death in Asian kidney transplant recipients: A report from Thai Transplant Registry

Y. Avihingsanon¹, A. Ingsathit¹, N. Premasathian¹, C. Pongskul², S. Jittiganont³, V. Sumethkul¹
¹Bangkok/ THAILAND, ²Khon Kaen/ THAILAND, ³Chiang-Mai/THAILAND

O56.07 Screening for renal cancer in recipients of kidney transplants

G. Wong¹, K. Howard², A. Webster², J.R. Chapman¹, J. Craig¹
¹Westmead/ AUSTRALIA, ²Sydney/ AUSTRALIA

O56.08 Racial Disparity in the Outcome of Simultaneous Pancreas and Kidney Transplantation

F.L. Luan, M. Kommareddi, D.M. Cibrik, M. Samaniego, A.O. Ojo
Ann Arbor/ UNITED STATES OF AMERICA

O56.09 Period Analysis for More Up-to-Date Graft and Patient Survival Estimates in Transplantation: An Evaluation Using United Network for Organ Sharing Data

A. Gondos, H. Brenner
Heidelberg/ GERMANY

Session O57 Pre-Clinical Immunosuppressive Agents

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: Ballroom A/B

Moderators: Randall . Morris, Daniel . Abramowicz
O57.01 Mechanism Analysis of Long Term Graft Survival by Monocarboxylate Transporter-1 (MCT-1) Inhibition

Skokie/UNITED STATES OF AMERICA

O57.02 Protective Immunity Remains Intact following Antibody Removal via Proteasome Inhibition

M.J. Everly1, P.I. Terasaki2, H.L. Trivedi3, J. Hopfield1, H. Kaneko2
1Canoga Park/UNITED STATES OF AMERICA, 2Los Angeles/UNITED STATES OF AMERICA, 3Ahmedabad/INDIA

O57.03 Soluble CD83-Mediated Kidney Allograft Tolerance Associated with Prevalence of Tolerogenic Dendritic Cells and Expression of Indoleamine 2,3-dioxygenase

Z. Lan1, W. Ge1, J. Arp1, J. Jiang1, W. Liu1, D. Healey2, C. Nicolette2, A.M. Jevnikar1, B. Garcia1, H. Wang1
1London/CANADA, 2Durham/UNITED STATES OF AMERICA

O57.04 Suppression of Antidonor Antibody Response by Soluble CD83 Prevents Chronic Renal Allograft Rejection

Z. Lan1, W. Ge1, J. Arp1, W. Liu1, S. Brand2, D. Healey2, C. Nicolette2, B. Garcia1, H. Wang1
1London/CANADA, 2Durham/UNITED STATES OF AMERICA

O57.05 Selective CD28 inhibition prolongs graft survival and attenuates CAV in monkey heart recipients treated with CD154 blockade

T. Zhang1, L. Burdorf1, S. Kelishadi1, T. Stoddard1, C.J. Avon1, A. Laaris1, A. Ward1, X. Cheng1, E. Welty1, J.-P. Soulillou2, B. Vanhove2, A.M. Azimzadeh1, R.N. Pierson III1
1Baltimore/UNITED STATES OF AMERICA, 2Nantes/FRANCE

O57.06 In vivo immunosuppressive effects of intravenous immunoglobulin on innate and adaptive immune cells involved in allograft rejection

A.S. Tjon, T. Tha-In, H.J. Metselaar, L.V.D. Laan, Z.M. Groothuismink, S. Mancham, M.V. Hagen, J. Kwekkeboom
Rotterdam/NETHERLANDS

O57.07 DTGH-glutarimide, a new activator protein-1 (AP-1) inhibitor ameliorates transplant vasculopathy in mice

M. Zaitsu1, K. Yamashita1, S. Shibasaki1, R. Goto1, K. Wakayama1, H. Gentaro1, Y. Tsunetoshi1, R. Igarashi1, M. Ozaki1, K. Umezawa2, S. Todo1
1Sapporo/JAPAN, 2Yokohama/JAPAN
TTS 2010 SCIENTIFIC PROGRAM

O57.08 Treatment of brain dead donors with anti-IL-6R monoclonal antibody attenuates the early and late inflammatory immune response

A. Reutzel-Selke¹, F. Beiglboeck¹, M. Velikova¹, M. Marksteiner¹, D. Polenz¹, S. Lippert¹, P. Neuhaus¹, K. Kotsch¹, J. Pratschke²
¹Berlin/GERMANY, ²Innsbruck/AUSTRIA

O57.09 SHIP Agonist Regulation of the Immune Response

A. Ming-Lum
Vancouver/CANADA

Session O58 Other Viral Infections in Transplantation

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 220 - 222

Moderators: Raymund . Razonable, Dietmar . Abendroth

O58.01 Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients: An Interim Analysis

F. Sanai¹, K.I. Bzeizi¹, K.A. Almeshari², D. Mousa¹, H. ashgar², G. ALshoail¹, A. AlMadani¹, H.A. Aleid²
¹11211/SAUDI ARABIA, ²Riyadh/SAUDI ARABIA

O58.02 Beta Cell Replacement Therapy in Five HIV Infected Patients with Renal Failure Secondary to Type I Diabetes Mellitus

G.R. Roll, A.M. Posselt, C.E. Freise, S.-M. Kang, R. Hirose, G. Szot, S. Feng, P. Stock
San Francisco/UNITED STATES OF AMERICA

O58.03 Dengue Viral Infection in Renal Transplant Recipients in Karachi Pakistan.

S. Baqi, A. Nasim, S. Anis, T. Aziz, S.A.H. Rizvi, S.M. Zeeshan
Karachi/PAKISTAN

O58.04 Adenovirus Infection is a Significant Complication Following Kidney Transplantation: Course of Infection and Outcome in Relation to the Level of Blood Adenovirus DNA and Lymphocyte Reconstitution

Bangkok/THAILAND

154
O58.05 Impaired varicella zoster virus specific memory T-cell responses in kidney transplant patients

N.M. van Besouw, G.M.G.M. Verjans, J.M. Zuijderwijk, A.L. Geel, W. Weimar
Rotterdam/NETHERLANDS

O58.06 Pandemic Influenza A/H1N1 virus infection in solid organ transplant recipients: A multicenter study

A. Smud\textsuperscript{1}, C. Nagel\textsuperscript{1}, E. Madsen\textsuperscript{1}, M.C. Rial\textsuperscript{1}, L. Barcan\textsuperscript{1}, A. Gomez\textsuperscript{2}, M. Bangher\textsuperscript{3}, A. Martinoia\textsuperscript{4}, J. Altclas\textsuperscript{1}, C. Salgueira\textsuperscript{1}, E. Temporiti\textsuperscript{1}, P. Bonvehi\textsuperscript{1}, N. Enriquez\textsuperscript{1}, E. Efron\textsuperscript{1}, J. Bibolini\textsuperscript{1}, R. Lattes\textsuperscript{1}
\textsuperscript{1}Buenos Aires/ARGENTINA, \textsuperscript{2}Santa Fe/ARGENTINA, \textsuperscript{3}Corrientes/ARGENTINA, \textsuperscript{4}La Plata/ARGENTINA, \textsuperscript{5}Formosa/ARGENTINA

O58.07 Adoptive transfer of EBV specific T-cells (EBV-CTL) for treatment of documented EBV lymphoma following allogeneic hematopoietic stem cell (HSCT) or organ transplants (OT): clinical, viral and immunologic correlates.

New York/UNITED STATES OF AMERICA

Session O59 Striving to Harness the Immune System in Pediatric Solid Organ Transplantation

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 217 - 219

Moderators: Richard . Kirk, Helen . Evans

O59.01 Validation of a Transcriptional Profile of Tolerance in Pediatric Liver Transplant Recipients

L.J. Wozniak\textsuperscript{1}, L. Li\textsuperscript{2}, S. Hsieh\textsuperscript{2}, R.S. Venick\textsuperscript{1}, M.E. Ament\textsuperscript{1}, R.W. Busuttil\textsuperscript{1}, M.M. Sarwal\textsuperscript{2}, S.V. McDiarmid\textsuperscript{1}
\textsuperscript{1}Los Angeles/UNITED STATES OF AMERICA, \textsuperscript{2}Stanford/UNITED STATES OF AMERICA

O59.02 Circulating donor-specific anti-HLA antibody may identify rejection-prone pediatric small bowel transplant recipients

C. Ashokkumar, A. Zeevi, C. Bentlejewski, J. Dobberstein, G. Mazariegos, K.M. Abu-Elmagd, R. Sindhi
Pittsburgh/UNITED STATES OF AMERICA

O59.03 High prevalence of B-10 B-cells in human infants: Regulatory impact on immune response following heart transplantation?
TTS 2010 SCIENTIFIC PROGRAM

S. Urschel, I.M. Larsen, I.M. Rebeyka, D.B. Ross, L.J. West
Edmonton/CANADA

O59.04 HLA-G II genotype and low levels of soluble HLA-G post-transplant are associated with first year rejection post pediatric heart transplantation.

A. Zeevi, C. Bentlejewski, B. Feingold, R. Ferrell, J. Lunz, S. Ferrone, S. Webber
Pittsburgh/UNITED STATES OF AMERICA

O59.05 Critical Role of Naive Regulatory T Cells in Operational Tolerance After Pediatric Living-Donor Liver Transplantation

H.A. Nafady Hego, Y. Li, H. Ohe, S. Sakaguchi, S. Uemoto, T. Koshiba
Kyoto/JAPAN

O59.06 A Peripheral Blood 12 Gene-Set for Diagnosis of Pediatric Liver Allograft Tolerance

Stanford/UNITED STATES OF AMERICA

O59.07 Linking innate and adaptive immunity: C3d plasma levels and CD21 expressing B-cells in ABO-incompatible infant heart transplantation

S. Urschel, I.M. Larsen, K. Derkatz, L.J. West
Edmonton/CANADA

O59.08 Epithelial-to-mesenchymal transition gene expression is associated with early tubulointerstitial damage in pediatric renal transplant recipients

M.J. Vitalone1, M. Naesens2, L. Li1, T. Sidgel1, S. Hesih1, M.M. Sarwal1
1Stanford/UNITED STATES OF AMERICA, 2Leuven/BELGIUM

O59.09 Alterations in T Regulatory Cell Levels in Pediatric Liver Transplant Recipients On Calcineurin Inhibitors Or Off Immunosuppression

K. Piard-Ruster, R. Silva, W. Berquist, B. Pham, A. Gallo, S.M. Krams, C. Esquivel, O.M. Martinez
Stanford/UNITED STATES OF AMERICA

Session O60 Outcomes of Liver Transplantation II

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 118 - 120

Moderators: Sigfried . Erb, William . Wall
TTS 2010 SCIENTIFIC PROGRAM

O60.01 Recipient Characteristics Associated with Early Hepatic Artery Thrombosis and Graft Loss after Liver Transplantation

T.M. Schmitt, S.C. Kumer, K. Brayman, C. Argo, P. Northup, T.R. Flohr
Charlottesville/UNITED STATES OF AMERICA

O60.02 Liver transplantation using donation after cardiac death donors: Single-Centre long-term outcome

London/UNITED KINGDOM

O60.03 Can We Expand Liver Donor Pool using Donation after Cardiac Death in the United States?

M. Stapfer, Y.W. Cho, L. Sher, I.V. Hutchinson, Y. Genyk
Los Angeles/UNITED STATES OF AMERICA

O60.04 Urinary ethyl glucuronide testing for detection of alcohol consumption is superior to common alcohol markers in liver transplant candidates and recipients

K. Staufer¹, H. Andresen¹, N. Tobias², B. Nashan¹, M. Sterneck¹
¹Hamburg/GERMANY, ²Bremen/GERMANY

O60.05 Inhibition of Sphingosine Kinase Prevents Failure of Liver Grafts from Non-Heart-Beating Donors after Transplantation

Y. Shi, H. Rehman, C.D. Smith, Z. Zhong
Charleston/UNITED STATES OF AMERICA

O60.06 Obesity as an adverse factor for survival in sick liver transplant recipients (MELD>25)

Dallas/UNITED STATES OF AMERICA

O60.07 The Positive Crossmatch in Liver Transplantation: A Risk Factor for Preservation Injury?

Dallas/UNITED STATES OF AMERICA

O60.08 Liver transplantation in HIV+ versus HIV- patients: a case control study
O60.09 A New Functional Definition of Initial Poor Function after Liver Transplantation

M. Stockmann, J.F. Lock, M. Malinowski, D. Seehofer, P. Neuhaus
Berlin/GERMANY

Session O61 Bone Marrow Transplantation

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: Ballroom C


O61.01 Transient Mixed Chimerism, Lymphocyte Recovery and Evidence for Early Donor-Specific Unresponsiveness in Patients Receiving Combined Kidney and Bone Marrow Transplantation to Induce Tolerance

Boston/UNITED STATES OF AMERICA

O61.02 Administration of polyclonal recipient Tregs leads to mixed chimerism, skin and heart graft tolerance without irradiation

N. Pilat¹, C. Klaus¹, U. Baranyi¹, E. Jaeckel², R. Oberhuber³, G. Brandacher³, B. Zelger², F. Muehlbacher¹, T. Wekerle¹
¹Vienna/AUSTRIA, ²Hannover/GERMANY, ³Innsbruck/AUSTRIA

O61.03 Increased Frequency of Regulatory T cells in Patients Receiving HLA Haploidentical Combined Kidney and Bone Marrow Transplantation to Induce Tolerance

Boston/UNITED STATES OF AMERICA

O61.04 Immune-based Conditioning to Establish Chimerism Induces Tolerance to Composite Tissue Allotransplants

158
TTS 2010 SCIENTIFIC PROGRAM

Louisville/UNITED STATES OF AMERICA

O61.05 Bone Marrow Component of Hind Limb Allograft Promotes Marrow-Derived Hematopoietic Stem Cell Engraftment, Chimerism and Tolerance

Pittsburgh/UNITED STATES OF AMERICA

O61.06 GVHD-associated immune suppression is the result of an intrinsic defect in MHC class II antigen presentation within donor DC

Brisbane/AUSTRALIA

O61.07 Stem cell mobilization with G-CSF induces Th17 differentiation and promotes scleroderma.

G.R. Hill¹, S.D. Olver¹, R.D. Kuns¹, A. Varelias², N.C. Raffelt¹, A. Don¹, K.A. Markey¹, Y.A. Wilson¹, M.J. Smyth³, Y. Iwakura⁴, J. Tocker⁵, A. Clouston¹, K.P.A. MacDonald¹
¹Brisbane/AUSTRALIA, ²Herston/AUSTRALIA, ³Melbourne/AUSTRALIA, ⁴Tokyo/JAPAN, ⁵Seattle/UNITED STATES OF AMERICA

Session O62 Clinical Pancreas Transplantation II

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 212 - 214

Moderators: James . Shapiro, Steven . Paraskevas

O62.01 Thymoglobulin vs Basiliximab as Induction Therapy for Combined Kidney-Pancreas Transplantation- Impact on Graft Rejection, Function, and Infectious Complications

F. Bazerbach, M. Selzner, M. Marquez, A. Norgate, I.D. McGilvray, J. Schiff, M.S. Catrall
Toronto/CANADA

O62.02 Occurrence and significance of de novo anti-HLA antibodies after pancreas transplantation

Nantes/FRANCE

O62.03 Outcome of Pancreas Transplantation with 5 Years Follow-up or More
TTS 2010 SCIENTIFIC PROGRAM

F. Vistoli, C. Croce, S. Signori, C. Moretto, M. Del Chiaro, G. Amorese, M. Barsotti, P. Marchetti, U. Boggi
Pisa/ITALY

O62.04 Pancreas Transplantation: A UK and US Comparison

A.J. Hudson¹, L.L. Mumford¹, R.J. Johnson¹, S.V. Fuggle¹, C.J.E. Watson²
¹Bristol/UNITED KINGDOM, ²Cambridge/UNITED KINGDOM

O62.05 Import(IMP) vs Local(LOC) pancreas (px) - is there an increased risk?

Minneapolis/UNITED STATES OF AMERICA

O62.06 Long-term results of pancreas transplantation in patients older than 50 years

P. Schenker¹, T. Klein², O. Vonend³, A. Wunsch¹, B. Krämer², R. Viebahn¹
¹Bochum/GERMANY, ²Herne/GERMANY, ³Düsseldorf/GERMANY

O62.07 Antibody Mediated Rejection in Pancreas Allograft Recipients: Experience with Bortezomib-Based Therapy

Cincinnati/UNITED STATES OF AMERICA

O62.08 Dichotomy between DSA and C4d Deposition in Pancreas Allograft Rejection

A. Govil, A. Tevar, R.R. Alloway, G. Mogilishetty, P. Brailey, E.S. Woodle, P. Roy-Chaudhury
Cincinnati/UNITED STATES OF AMERICA

O62.09 Sirolimus does not prolong wound healing in simultaneous pancreas and kidney recipients: a retrospective single center analysis

P. Girman, L. Pektorova, R. Koznarova, K. Lipar, P. Boucek, M. Adamec, F. Saudek
Prague/CZECH REPUBLIC

Session O63 Xenotransplantation II

Thursday, August 19, 2010 10:30 AM - 12:00 PM
Room: MR 121 - 122

O63.01 Introduction of Human soluble TNFRI-Fc into porcine endothelial cells suppressed activation of porcine endothelial cells

B. CHO¹, S. Hurh¹, N.-I. Byeon¹, H. Lee², M.-G. Kim¹, J. Yang¹, B.C. Lee¹, C. Ahn¹
¹Seoul/KOREA, ²Daejeon/KOREA

O63.02 Specific Humoral Non-responsiveness to Swine Antigens and Engraftment Following Administration of GaIT-KO Porcine Bone Marrow to Baboons.

F. Liang¹, A. Griesemer², J.R. Scalea¹, I. Wamala¹, A. Tena¹, S. Moran¹, K. Yamada¹, C.A. Huang¹, D.H. Sachs¹
¹Boston/UNITED STATES OF AMERICA, ²New York/UNITED STATES OF AMERICA

O63.03 Anti-GPIb Fab reduces activation and sequestration of human platelets in a xenogeneic pig lung perfusion model

L. Burdorf¹, T. Zhang¹, E. Rybak¹, I.I. Salles², K. Broos², E. Welty¹, C.J. Avon¹, A. Laaris¹, X. Cheng¹, D. Ayares³, H. Deckmyn², R.N. Pierson III¹, A.M. Azimzadeh¹
¹Baltimore/UNITED STATES OF AMERICA, ²Kortrijk/BELGIUM, ³Blacksburg/UNITED STATES OF AMERICA

O63.04 Quantification of Baboon Thymopoiesis In Porcine Thymokidney Xenografts by a Signal Joining TCR Excision Circle (sjTREC) Assay

A. Tena¹, P. Vallabhajousula², R.J. Hawley¹, A. Griesemer³, K. Yamada¹, D.H. Sachs¹
¹Boston/UNITED STATES OF AMERICA, ²Philadelphia/UNITED STATES OF AMERICA, ³New York/UNITED STATES OF AMERICA

O63.05 Optimal T cell depletion is essential for successful thymokidney transplants in GaIT-KO pig to baboon model

Boston/UNITED STATES OF AMERICA

O63.06 Ex vivo expanded non-human primate regulatory T cells suppress effector cell response to xeno antigen.

Minneapolis/UNITED STATES OF AMERICA

O63.07 Humanized NOD-SCID IL-2rgamma/- mice - A novel animal model to study human CD4+CD25+ regulatory T cell-mediated suppression in xenotransplantation
TTS 2010 SCIENTIFIC PROGRAM

S. Yi, M. Ji, J. Wu, W. Hawthorne, L. Williams, P.J. O'Connell
Sydney/AUSTRALIA

O63.08 Hepatocyte Growth Factor regimen in a life supporting xenoegeneic islet transplantation CLAWN miniature swine - to - cynomologous monkey model

K. Yamada¹, H. Nishimura¹, H. Sahara¹, T. Okitsu², K. Setoyama¹, M. Oku¹, M. Tasaki¹, O. Wunimenghe¹, A. Griesemer³, H. Tsubouchi¹, A. Shimizu¹
¹Kagoshima/JAPAN, ²Kyoto/JAPAN, ³New York/UNITED STATES OF AMERICA

O63.09 Human CD47 expression prevents macrophage-mediated rejection of porcine cells in mice that express SIRPa capable of binding to human CD47

C. Wang¹, H. Wang¹, K. Ide², Y. Wang¹, H. Ohdan², Y.-G. Yang¹
¹Boston/UNITED STATES OF AMERICA, ²Hiroshima/JAPAN

12:15 – 13:15 MINI ORAL SESSIONS

Session MO22 Immunopharmacology

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 202 - 204

Moderators: Dirk . Kuypers, Mario . Abbud-Filho

MO22.01 Relationship Between Belatacept Exposure and Clinical Endpoints in Renal Transplant Patients

S. Zhou¹, A. Roy¹, J. Shen¹, S. Kaul¹, M. Pfister²
¹Princeton/UNITED STATES OF AMERICA, ²Plainsboro/UNITED STATES OF AMERICA

MO22.02 Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Renal Transplant Patients

Princeton/UNITED STATES OF AMERICA

MO22.03 Cyclosporin pharmacokinetics in Asian population and the impact of early AUC in predicting long term outcomes

Karachi/PAKISTAN
MO22.04 Multiple Regression Derived Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Australian Adult Kidney Transplant Recipients

Brisbane/AUSTRALIA

MO22.05 Evaluation of Limited Sampling Strategies for Simultaneous Estimation of Tacrolimus, Mycophenolic Acid and Prednisolone Exposure in Adult Kidney Transplant Recipients

Brisbane/AUSTRALIA

MO22.06 Pharmacogenetic Factors affecting Mycophenolate Mofetil (MMF) Pharmacokinetic and Pharmacodynamic Variability in the Opticept Kidney Transplant Study: Preliminary Analysis

M.C. Milone1, A. Israni2, W. Fan1, D. McGain1, N. Riccio1, R. Bloom1, U. Meier-Kriesche3, D.M. Cibrik4, B. Kaplan5, S. Mulgaonkar6, D. Patel7, L.M. Shaw1
1Philadelphia/UNITED STATES OF AMERICA, 2Minneapolis/UNITED STATES OF AMERICA, 3Gainesville/UNITED STATES OF AMERICA, 4Ann Arbor/UNITED STATES OF AMERICA, 5Tucson/UNITED STATES OF AMERICA, 6Livingston/UNITED STATES OF AMERICA, 7East Hanover/UNITED STATES OF AMERICA

MO22.07 Early Mycophenolic Acid (MPA) Dose Modifications are Associated with Compromised Graft Outcomes: Rationale for Dose Changes and Analysis of Effects in the Mycophenolic Acid Observational Renal Transplant (MORE) Registry

F. Shihab1, R. Stratta2, A. Olyaei3, R. Carson4, O. Pankewycz5, A. Wiland6, P. Lake6
1Salt Lake City/UNITED STATES OF AMERICA, 2Winston-Salem/UNITED STATES OF AMERICA, 3Portland/UNITED STATES OF AMERICA, 4Spokane/UNITED STATES OF AMERICA, 5Buffalo/UNITED STATES OF AMERICA, 6E Hanover/UNITED STATES OF AMERICA

MO22.08 Initial intensified dosing of Enteric-Coated Mycophenolate Sodium (EC-MPS) versus Standard Dosing Improves Rejection Prophylaxis in De Novo Renal Transplant Recipients

1Leuven/BELGIUM, 2Sao Paulo/BRAZIL, 3Cologne/GERMANY, 4Saskatoon/CANADA, 5Córdoba/SPAIN, 6Bari/ITALY, 7Halifax/CANADA, 8Melbourne/AUSTRALIA, 9Basel/SWITZERLAND, 10Berlin/GERMANY

MO22.09 12-Month, Single-Center Evaluation of GI Complications in Renal Transplant Recipients Initiated on Mycophenolic Acid (MPA) Therapy
TTS 2010 SCIENTIFIC PROGRAM

M. Cooper, F. Rasetto, B. Philosophe, S. Bartlett, J. Nogueira
Baltimore/UNITED STATES OF AMERICA

MO22.10 Early Outcome Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry: Initial Comparisons of EC-MPS (Myfortic®) and MMF (CellCept®).

A. Olyaei¹, L. Chan², K. Ueda³, B. Nibhanupudy⁴, L. Ratner⁵, E. Greer¹, P. Lake⁶, A. Wiland⁷
¹Portland/UNITED STATES OF AMERICA, ²Denver/UNITED STATES OF AMERICA, ³San Francisco/UNITED STATES OF AMERICA, ⁴Orlando/UNITED STATES OF AMERICA, ⁵New York/UNITED STATES OF AMERICA, ⁶E Hanover/UNITED STATES OF AMERICA, ⁷East Hanover/UNITED STATES OF AMERICA

MO22.11 Everolimus(E) Vs Enteric Coated Mycophenolate Sodium (EC-MPS): Proteomic and Pathologic Aspects in a 1-Year Prospective Randomized Study

M. Salvadori¹, E. Bertoni¹, G. Ghiggeri², M. Prunotto², G. Candiano², L. Santucci², M. Bruschi², A. Pedretto², S. Moll³, A. Larti¹
¹Florence/ITALY, ²Genova/ITALY, ³Geneva/SWITZERLAND

MO22.12 Maintenance immunosuppression with CNI and Everolimus after ABO incompatible living related kidney transplantation.

Hamburg/GERMANY

Session MO23 Pediatric Organ Transplantation

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 109 - 110

Moderators: Richard . Thistlewaite, Oscar . Salvatierra

MO23.01 Immune Cell Function Assay in Pediatric Heart Transplant Recipients

M. -S. Wong¹, M. Kemna², L. Iwasaki², J. Rutledge², R. Boucek², Y.M. Law²
¹Brisbane/AUSTRALIA, ²Seattle/UNITED STATES OF AMERICA

MO23.02 Long-term Outcomes in Pediatric Intestinal Retransplantation

Pittsburgh/UNITED STATES OF AMERICA
TTS 2010 SCIENTIFIC PROGRAM

MO23.03 Plasma Proteomic Biomarker Candidates that Predict Acute Rejection in Pediatric Renal Transplantation

E.W. Tsai, J. LeBlanc, D.W. Gjertson, R.B. Ettenger, E.F. Reed
Los Angeles/UNITED STATES OF AMERICA

MO23.04 BK Virus infection/replication prevalence in pediatric liver transplant recipients and its relation to long term renal function loss

G. VARELA-FASCINETTO, B. RUSSEK-PORTALES, M. MEDEIROS-DOMINGO, J.A. HERNANDEZ-PLATA, P. GARCIA-ROCA
Mexico City/MEXICO

MO23.05 Inefficiency and ethical problems due to a pediatric priority allocation policy for deceased donor kidney in Quebec

J.-L. Wolff¹, N. Philippe²
¹Sherbrooke/CANADA, ²Montreal/CANADA

MO23.06 Pre-Transplant Treg Frequency Correlates with Rejection in Pediatric Renal Transplantation

J. Tong, S.-M. Kang, Q. Tang, P. Stock
San Francisco/UNITED STATES OF AMERICA

MO23.07 Pediatric Liver Transplant Patients Exhibit Increases in Natural Killer Cell Activation Receptor Expression Post-Transplant

B. Pham, R. Silva, K. Piard-Ruster, A. Gallo, C.O. Esquivel, O.M. Martinez, S.M. Krams
Stanford/UNITED STATES OF AMERICA

MO23.08 Prognosis and new advances in early portal vein thrombosis after pediatric liver transplantation. No-touch hilum technique

J. Bueno, C. Venturi, M. Perez Lafuente, A. Segara, I. Bilbao, R. Charco
Barcelona/SPAIN

MO23.09 Outcome of liver retransplantation in children – impact of early and late retransplantation

U. Herden, R. Ganschow, B. Nashan, L. Fischer
Hamburg/GERMANY

MO23.10 Outcome of focal segmental glomerulosclerosis after renal transplantation with/without podocine gene mutations in Turkish children

Birmingham/UNITED KINGDOM

Session MO24 Cardiac and Metabolic Complications of Transplantation

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 211

Moderators: Bertram . Kasiske, Josep . Grinyo

MO24.01 A retrospective audit of cardiac workup and outcomes in patients considered for renal transplantation at Auckland City Hospital

E. Curry, M. Webster, P. Mullins, H. Pilmore
Auckland/NEW ZEALAND

MO24.02 Reticulated Platelets and Platelet Reactivity in Renal Transplant Recipients on anti Platelet Therapy

Florence/ITALY

MO24.03 Similar Risk of Renal Graft Loss Due to Thrombosis for Everolimus Versus MPA-based Regimens

B. Stevens1, S. Flechner2, L.J. Wei3, G. Friedman4, M. Vergara4, H. Jiang4, H. Tedesco-Silva5, D. Cibrik6
1Omaha/UNITED STATES OF AMERICA, 2Cleveland/UNITED STATES OF AMERICA, 3Boston/UNITED STATES OF AMERICA, 4East Hanover/UNITED STATES OF AMERICA, 5Sao Paulo/BRAZIL, 6Ann Arbor/UNITED STATES OF AMERICA

MO24.04 Increased thrombogenicity associated with mTOR inhibition

M.C. Baas, V.E.A. Gerdes, J.C. Meijers, I.J.M. ten Berge, F.J. Bemelman
Amsterdam/NETHERLANDS
MO24.05 Predictors of Cardiovascular Events in Adult Renal Transplant Recipients

D. Arlen¹, E. Cole², D. Holland³, A.M. Jevnikar⁴, S.J. Kim², G. Knoll⁵, H. Ross², J.S. Zaltzman²
¹Hamilton/CANADA, ²Toronto/CANADA, ³Kingston/CANADA, ⁴London/CANADA, ⁵Ottawa/CANADA

MO24.06 Anti-phospholipid antibody syndrome in end stage renal disease patients: low probability but high consequence outcome.

S. Vaidya
Galveston,/UNITED STATES OF AMERICA

MO24.07 Reduction of Immunosuppression-Associated Diarrhea by Probiotics Following Renal Transplantation

W.H. Marks¹, T.Y. Spinelli¹, S.F. Olmstead²
¹Seattle/UNITED STATES OF AMERICA, ²Reno/UNITED STATES OF AMERICA

MO24.08 Predicting Impending Hyperglycaemia in Normoglycaemic Renal Transplant Recipients

A. Sharif¹, V. Ravindran², G. Dunseath³, S. Luzio³, D. Owens³, K. Baboolal²
¹Birmingham/UNITED KINGDOM, ²Cardiff/UNITED KINGDOM, ³Penarth/UNITED KINGDOM

MO24.09 Glucose intolerance in renal transplant recipients is associated with increased albuminuria

Osaka/JAPAN

MO24.10 LIM-0705 is an Investigational New Drug to Prevent and/or Treat Tacrolimus-Induced Toxicities

M.P. Chang¹, R. Elfont¹, Y. Zhao¹, D.C. Brennan², V.J. Lee¹, W.R. Robbins¹
¹South San Francisco/UNITED STATES OF AMERICA, ²St. Louis/UNITED STATES OF AMERICA

MO24.11 Effects of Everolimus With Very low Tacrolimus Exposure on the Incidence of NODM After Renal Transplantation in the ASSET Study

J. Pascual¹, R. Hené², S. Vitko³, M. Christiaans⁴, H. Tedesco Silva⁵, K. Ciechanowski⁶, L. Rostaing⁷, J. Dominguez⁸, A. Wiecek⁹, A. Gurkan¹⁰, R.M. Langer¹¹
¹Barcelona/SPAIN, ²Utrecht/NETHERLANDS, ³Prague/CZECH REPUBLIC, ⁴Maastricht/NETHERLANDS, ⁵Sao Paolo/BRAZIL, ⁶Szczecin/POLAND, ⁷Toulouse/FRANCE, ⁸Santiago/CHILE, ⁹Francuska/POLAND, ¹⁰Adana/TURKEY, ¹¹Budapest/HUNGARY
TTS 2010 SCIENTIFIC PROGRAM
Session MO25 Innovations in Heart Transplantation II

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 205 - 207

Moderators: Abbas . Khani-Hanjani, Stephan . Schueler

MO25.01 Gender does matter – gender specific outcome analysis of 1000 heart transplants at a single centre
I. Kaczmarek, S. Eifert, P. Ueberfuhr, B. Meiser, B. Reichart
Munich/GERMANY

MO25.02 New Onset Graft Dysfunction after Heart Transplantation – Incidence and Mechanism-Related In-Hospital Outcomes
New York/UNITED STATES OF AMERICA

MO25.03 Novel supercoolant, kaempferol 7-O-beta-D-glucopyranoside (KF7G), enabled 30-hour donor heart preservation at -2°C in a rat heart transplantation model.
S. Shimada¹, N. Motomura¹, O. Kinoshita¹, A. Murakami¹, M. Ono¹, S. Fujikawa²
¹Tokyo/JAPAN, ²Sapporo/JAPAN

MO25.04 Characterization of Pericardial and Pleural Effusions in De Novo Heart Transplant Recipients Treated with Everolimus
A. Zuckermann¹, J.M. Arizon², G. Dong³, H. Eisen⁴, J. Kobashigawa⁵, H.B. Lehmkuhl⁶, C. Pellegrini⁷, H. Ross⁸, M.J. Barten⁹
¹Vienna/AUSTRIA, ²Cordoba/SPAIN, ³East Hanover/UNITED STATES OF AMERICA, ⁴Philadelphia/UNITED STATES OF AMERICA, ⁵Los Angeles/UNITED STATES OF AMERICA, ⁶Berlin/GERMANY, ⁷Pavia/ITALY, ⁸Toronto/CANADA, ⁹Leipzig/GERMANY

MO25.05 Impact of Anti-CD25 Monoclonal Antibody as Part of a Calcineurin Inhibitor-Free Immunosuppression Regimen on Th17 cells in Heart Transplantation Recipients
S. Kalyanasundaram, M.-T.J.-P. Nguyen, S. Liu, S. Goldstein, M. Cantarovich, J. Tchervenkov
Montreal/Canada

MO25.06 Blood pressure control in orthotopic heart transplant and kidney allograft recipients is far from satisfactory
MO25.07 Placenta growth factor is associated with cardiac allograft vasculopathy.

O.P. Shevchenko, O.V. Orlova, E.N. Kazakov, A.J. Kormer, A.O. Shevchenko
Moscow/RUSSIAN FEDERATION

MO25.09 The Morphologic Grading of Acute Rejections after Heart Transplantation Does not Always Reflect the Severity of Alteration in Myocardial Function

M. Dandel, H.B. Lehmkuhl, D. Kemper, C. Knosalla, R. Hetzer
Berlin/GERMANY

MO25.10 Comparison of high-dose and low-dose therapy with everolimus in heart transplant recipients with chronic renal failure

U. Fuchs¹, A. Zittermann², B. Schulze², W. Deyerling², K. Hakim-Meibodi², U. Schulz², J. Gummert²
¹BAd Oeynhausen/GERMANY, ²Bad Oeynhausen/GERMANY

MO25.11 Clinical results of immunsuppressive therapy in heart transplant receipients receiving Tacrolimus and Everolimus compared to the combination of Ciclosporin A and Everolimus

U. Fuchs, A. zittermann, B. schulze, W. deyerling, K. Hakim-Meibodi, U. Schulz, J. Gummert
BAd Oeynhausen/GERMANY

MO25.12 Immunoadsorption Therapy in Heart Transplant Candidates With Idiopathic Dilated Cardiomyopathy who Tested Positive for Antibodies Against Beta-1 Adrenoceptors can Delay Listing for Transplantation

M. Dandel, G. Wallukat, A. Englert, H.B. Lehmkuhl, R. Hetzer
Berlin/GERMANY

Session MO26 Interventions and Outcomes in Liver Transplantation II

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 217 - 219

Moderators: Ian Alwayn, Stephen Lynch

MO26.01 Risk assessment of liver donation for patients with familial amyloid polyneuropathy in domino liver transplantation: 100 cases from a single center
MO26.02 Impact of graft type on the regeneration pattern of remnant liver: Right hepatectomy versus Extended right hepatectomy
M.K. Ju, K.H. Huh, S.I. Kim, J.S. Choi, D.J. Joo, M.S. Kim
Seoul/KOREA

MO26.03 Outcome, alcohol recidivism and quality of life after liver transplantation in patients with alcohol-toxic liver cirrhosis: a single-center-experience
Regensburg/GERMANY

MO26.04 Lessons Learned from 140 Consecutive Living Donor Liver Transplantations for Biliary Atresia in a Single Center
C.-L. Chen1, A.M. Concejero1, C.-C. Wang1, S.-H. Wang1, C.-C. Lin1, Y.-W. Liu1, C.-C. Yong1, T.-S. Lin1, Y.-C. Chiang1, Y.-F. Cheng2, B. Jawan1, H.-L. Eng1
1Kaohsiung/TAIWAN, 2Kaohsiung Hsien/TAIWAN

MO26.05 Lobster - Liver observational study to assess the effect of CellCept therapy on clinical outcomes in liver transplant patients: Interim results after 6 months
1Regensburg/GERMANY, 2Hannover/GERMANY, 3Frankfurt/GERMANY, 4Jena/GERMANY, 5Heidelberg/GERMANY, 6Leipzig/GERMANY, 7Ancona/ITALY, 8Bologna/ITALY, 9Essen/GERMANY

MO26.06 Primary liver team or local team for liver procurement: Can this impact graft outcome?
R. Kashyap1, P. Abt2, S. Safadjou1, S. Agarwal1, S. Ramalingam1, B. Maliakkal1, G. Ramaraju1, C. Marroquin1, C. Barry1, M. Orloff1
1Rochester/UNITED STATES OF AMERICA, 2Philadelphia/UNITED STATES OF AMERICA

MO26.07 Clinical Outcome of Patients who had been waiting for Combined Liver and Kidney Transplants during post-MELD Era
Y.A. Qazi, Y.W. Cho, T.-L. Fong, I.V. Hutchinson, T. Shah
Los Angeles/UNITED STATES OF AMERICA
MO26.08 A MELD-score based liver allocation system has a negative impact on waiting list mortality and is associated with lower post-transplant survival in a country with a unique, large geographic organ procurement area

A.G. Villamil, J.C. Bandi, O.A. Galdame, S. Marciano, P.C. Casciato, E. de Santibañes, A.C. Gadano
Buenos Aires/ARGENTINA

MO26.09 Major neurologic, renal and cardiac complications post liver transplant in recipients over 65 yrs of age – Single center experience

Rochester/UNITED STATES OF AMERICA

Session MO27 Experimental and Clinical Lung Transplantation

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 220 - 222

Moderators: Annette . Boehler, Martin . Strueber

MO27.01 Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response And Experimental Obliterative Airway Disease

R. Krebs¹, J. Tikkanen¹, M. Hollmén¹, Y. Wu², B. Pytowski², P. Koskinen¹, K. Lemström¹
¹Helsinki/FINLAND, ²New York/UNITED STATES OF AMERICA

MO27.02 Alloantigen Requirements for the Induction and the Maintenance of Peripheral Tolerance following Porcine Lung Transplantation

Hannover/GERMANY

MO27.03 Inhaled hydrogen gas therapy for donors mitigates ventilator-induced lung graft injury

Pittsburgh/UNITED STATES OF AMERICA

MO27.04 Anti-High-Mobility Group Box-1 Antibodies Reduce Pulmonary Ischemia-Reperfusion Injury in Miniature Swine
MO27.05 Historic and Current Preformed HLA Donor-Specific Antibodies Are Associated With Increased Acute Allograft Rejection in Lung Transplantation

M. Askar, J.D. Schold, M. Budev, L. Klingman, S.C. Murthy, D.P. Mason, J. Yun, G. Pettersson, K.R. McCurry
Cleveland/UNITED STATES OF AMERICA

MO27.06 Prediction of Short-Term Course of Right Heart Failure in Patients with Pulmonary Arterial Hypertension Referred for Transplantation

M. Dandel, H.B. Lehmkuhl, D. Kemper, C. Knosalla, R. Hetzer
Berlin/GERMANY

MO27.07 Intermediate-term outcomes of the living donor lobar lung transplantation following hematopoietic stem cell transplantation from the same donor

Kyoto/JAPAN

MO27.08 Bortezomib in Lung Transplantation: A Promising Start

M.J. Everly¹, J. Neumann², S. Schio², H. Tarrascon², A. Bortolotto², C. Costa², T. Machuca², S. Camargo², L. Sanchez², T. Michelon², R. Canabarro², H. Sporleder², S. Fernandes², J. Camargo², F. Perin², J. Felicetti²
¹Canoga Park/UNITED STATES OF AMERICA, ²Porto Alegre/BRAZIL

MO27.09 The peculiar mechanisms and graft recovery through anti-inflammatory response after lung transplantation from non-heart-beating donors

Okayama/JAPAN

MO27.10 Mitochondrial Injury in Pulmonary Ischmia-Reperfusion Injury

Würzburg/GERMANY

MO27.11 Systemic nicotine treatment reduces macrophage infiltration in rat lung allografts.
MO27.12 The variety activations of mitogen-activated protein kinases (MAPKs) and regulations of their down-stream molecules after rat lung transplantation from non-heart-beating donors (NHBDs)

Okayama/JAPAN

Session MO28 Stem Cells and Cellular Transplantation

Thursday, August 19, 2010 12:15 PM - 01:15 PM
Room: MR 212 - 214

Moderators: Igor . Sauer, Clyde . Barker

MO28.01 Immunogenicity of human Mesenchymal Stem Cells; susceptibility for CD8+ T cell and NK cell mediated lysis

M.J. Hoogduijn, M.J. Crop, S.S. Korevaar, R. de Kuiper, N.M. van Besouw, J.N. IJzermans, C. Baan, W. Weimar
Rotterdam/NETHERLANDS

MO28.02 Function of human Mesenchymal Stem Cells under Inflammatory conditions

M.J. Hoogduijn¹, M.J. Crop¹, S.S. Korevaar¹, J.N. IJzermans¹, M. Pescatori¹, A.P. Stubbs¹, W.F. van IJcken¹, E. Eggenhofer², M.H. Dahlke², W. Weimar¹, C. Baan¹
¹Rotterdam/NETHERLANDS, ²Regensburg/GERMANY


Stanford/UNITED STATES OF AMERICA

MO28.04 Experimental Study of Bone Mesenchymal Stem Cells’ Differentiation into Cardiac Cells Induced by BMP-2

S. zhenya, D. Yiguo
Suzhou/CHINA
MO28.05 The Experimental Research on Cardiac Function Recovery Using Autologous BM-MSCs Transplantation with Anti-inflammation Treatment in the Acute Period of MI

S. zhenya, L. Weijie, H. Yanqiu
Suzhou/CHINA

MO28.06 Use of ‘facilitator cells’ to enhance fetal hepatocyte engraftment

M.G. Joshi1, P.B. Patil1, N. Hernandez1, D. Hallberg1, Z. He2, J. Holgersson1, M. Olausson1, S. Holgersson1
1Gothenburg/SWEDEN, 2Florida/UNITED STATES OF AMERICA

MO28.07 In vitro engineering of a functional human liver tissue for transplantation

J. Bierwolf1, M. Luetgethetmann1, S. Cohen2, O. Kryukov2, S. Deichmann1, P.-J. Erbes1, B. Nashan1, J. Pollok1
1Hamburg/GERMANY, 2Beer-Sheva/ISRAEL

MO28.08 Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Allografts by Donor Stem Cell Infusion

J. Leventhal1, L. Gallon1, J. Miller1, M. Abecassis1, K. Ravindra2, E. Reed2, S.T. Ildstad2
1Chicago/UNITED STATES OF AMERICA, 2Louisville/UNITED STATES OF AMERICA

MO28.09 NKG2D Ligands alleles affect Clinical Outcomes following Sibling Stem Cell Transplantation

Birmingham/UNITED KINGDOM

MO28.10 Clinical Use Of Amniotic Fluid In Osteoarthritis : A Source Of Cell Therapy

N. Bhattacharya
Calcutta/INDIA

MO28.11 The Combination of Autologous Mesenchymal Stem Cells, Acellular Dermal Matrix and Growth Factors for Cartilage Regeneration in Experimental Cartilage Defect Model in Nonhuman Primates

L. Jiang, A. Ma, L. Song, Y. Hu, H. Dun, P. Daloze, M. Zafarullah, H. Chen
Montreal/CANADA

MO28.12 Outstanding Survival and Regeneration Process by the Use of Intelligent Acellular Dermal Matrices and Mesenchymal Stem Cells in a Burn Pig Model.

E. Mansilla1, G. Marin1, G. Larsen2, G. Roque1, K.E. Martire1, J.C. Raimondi1, V. Diaz Aquino1, L. Nuñez2, J.M. Tau1, H. Drago4, F. Sturla4, R. Lamonega1, C. Gardiner1, R. Spretz2, N. Lausada1, J. Cordone1, N.
TTS 2010 SCIENTIFIC PROGRAM

Biassi¹, A. Maceira¹
¹La Plata/ARGENTINA, ²Nebraska/UNITED STATES OF AMERICA, ³Chicago/UNITED STATES OF AMERICA,
⁴Buenos Aires/ARGENTINA

13:30 – 15:00 STATE OF THE ART SYMPOSIA

Session SOTA22 Planning for donation after cardiac death

Thursday, August 19, 2010 01:30 PM - 03:00 PM
Room: MR 109 - 110

Moderators: Ron . Shapiro, Sam . Shemie

SOTA22.1 Uncontrolled Donation after Cardiac Death

J. Nunez
Madrid/SPAIN

SOTA22.2 Donation after cardiac death in the US

H.M. Nathan
Philadelphia/UNITED STATES OF AMERICA

SOTA22.3 Development of UK DCD program from legal and medical perspectives

C. Rudge
London/UNITED KINGDOM

SOTA22.4 Optimal preservation of NHB-donor grafts

R. Ploeg

SOTA22 - DISCUSSION

Session SOTA23 Tissue transplantation and reconstruction

Thursday, August 19, 2010 01:30 PM - 03:00 PM
TTS 2010 SCIENTIFIC PROGRAM

Room: MR 212 - 214

Moderators: Stefan . Tullius, Mark . Hardy

SOTA23.1 Adapting the Banff Scoring System to the Biology of Vacularized Composite Allografts

L. Cendales
Atlanta/UNITED STATES OF AMERICA

SOTA23.2 Mixed tissue transplantation for facial reconstruction

M. Siemionow
Cleveland/UNITED STATES OF AMERICA

SOTA23.3 Mixed tissue transplantation for limb replacement

J.M. Dubernard
Lyon/FRANCE

SOTA23 - DISCUSSION

Session SOTA24 Immunosuppression and post-transplant malignancy

Thursday, August 19, 2010 01:30 PM - 03:00 PM
Room: Ballroom A/B

Moderators: Angela . Webster, Edward . Geissler

SOTA24.1 Molecular signals, viral infection and immune suppression in post-transplant malignancy

E.K. Geissler
Regensburg/GERMANY

SOTA24.2 Epidemiology of malignancy after transplantation

G. Opelz
Heidelberg/GERMANY

SOTA24.3 Immunosuppressive strategies in patients with post-transplant malignancy
TTS 2010 SCIENTIFIC PROGRAM

R. Hirose  
San Francisco/UNITED STATES OF AMERICA

SOTA24.4 Innovations in therapy of cancer in transplant recipients

J. Connor  
Vancouver/CANADA

SOTA24 - DISCUSSION

Session SOTA25 Injury, repair and remodeling

Thursday, August 19, 2010 01:30 PM - 03:00 PM  
Room: Ballroom C

Moderators: Bruce . McManus, Jerzy . Kupiec-Weglinski

SOTA25.1 Innate and adaptive immunity in ischemia-reperfusion injury

J.W. Kupiec-Weglinski  
Los Angeles/UNITED STATES OF AMERICA

SOTA25.2 Biomarkers of injury and response in transplanted patients

B. McManus  
Vancouver/CANADA

SOTA25.3 Genomic fingerprints of tissue injury and remodeling / Role of the endothelium

M.J. Hébert  
Montreal/CANADA

SOTA25 - DISCUSSION

Session SOTA26 Cellular xenotransplantation

Thursday, August 19, 2010 01:30 PM - 03:00 PM
TTS 2010 SCIENTIFIC PROGRAM

Room: MR 211


SOTA26.1 Anti-gal and non-gal antibodies in xenotransplantation

M. Breimer
Gothenburg/SWEDEN

SOTA26.2 Developments in cellular xenotransplantation

E. Cozzi
Padua/ITALY

SOTA26.3 Islet xenotransplantation: Advances towards the clinic

B.J. Hering
Minneapolis/UNITED STATES OF AMERICA

SOTA26 - DISCUSSION

Session SOTA27 Graft Injury in Liver Transplantation

Thursday, August 19, 2010 01:30 PM - 03:00 PM
Room: MR 118 - 120

Moderators: Stephen . Lynch, Rui . Maio

SOTA27.1 Clinical prevention of ischemia-reperfusion injury

R.W. Busuttil
Los Angeles/UNITED STATES OF AMERICA

SOTA27.2 DCD grafts

N. Heaton
London/UNITED KINGDOM

SOTA27.3 Steatotic grafts
TTS 2010 SCIENTIFIC PROGRAM

P. Friend
Oxford/UNITED KINGDOM

SOTA27 - DISCUSSION

Session SOTA28 Intestinal transplantation

Thursday, August 19, 2010 01:30 PM - 03:00 PM
Room: MR 220 - 222

Moderators: Andreas Tzakis, David Grant

SOTA28.1 Basic Science of intestinal transplantation
M. Zasloff

SOTA28.2 Intestine Rehabilitation Options
L. Pironi
Bologna/ITALY

SOTA28.3 ITR and SRTR Clinical Outcomes
G. Mazariegos
Pittsburgh/UNITED STATES OF AMERICA

SOTA28 - DISCUSSION

16:00 – 17:00 CLOSING CEREMONY

Session PL05 Closing Ceremony - What's Hot and What's not?

Thursday, August 19, 2010 04:00 PM - 05:00 PM
Room: Ballroom A/B

Moderators: Peter Neuhaus, Gerhard Opelz

PL05.1 Advances in Clinical Transplantation
G.A. Levy
Toronto/CANADA

PL05.2 Advances in Basic Science

D.H. Sachs
Boston/UNITED STATES OF AMERICA

PL05.3 TTS 2012 - See you in Berlin, Germany

P. Neuhaus
Berlin/GERMANY